6	DUAVEE.xml:S1:4:1	O
ADVERSE	DUAVEE.xml:S1:6:7	O
REACTIONS	DUAVEE.xml:S1:14:9	O

The	DUAVEE.xml:S1:27:3	O
following	DUAVEE.xml:S1:31:9	O
adverse	DUAVEE.xml:S1:41:7	O
reactions	DUAVEE.xml:S1:49:9	O
are	DUAVEE.xml:S1:59:3	O
discussed	DUAVEE.xml:S1:63:9	O
in	DUAVEE.xml:S1:73:2	O
greater	DUAVEE.xml:S1:76:7	O
detail	DUAVEE.xml:S1:84:6	O
in	DUAVEE.xml:S1:91:2	O
other	DUAVEE.xml:S1:94:5	O
sections	DUAVEE.xml:S1:100:8	O
of	DUAVEE.xml:S1:109:2	O
the	DUAVEE.xml:S1:112:3	O
label	DUAVEE.xml:S1:116:5	O
:	DUAVEE.xml:S1:121:1	O

Cardiovascular	DUAVEE.xml:S1:130:14	B-AdverseReaction
Disorders	DUAVEE.xml:S1:145:9	I-AdverseReaction
[	DUAVEE.xml:S1:155:1	O
see	DUAVEE.xml:S1:156:3	O
Warnings	DUAVEE.xml:S1:161:8	O
and	DUAVEE.xml:S1:170:3	O
Precautions	DUAVEE.xml:S1:174:11	O
(	DUAVEE.xml:S1:186:1	O
5.2	DUAVEE.xml:S1:187:3	O
)	DUAVEE.xml:S1:190:1	O
]	DUAVEE.xml:S1:193:1	O

Malignant	DUAVEE.xml:S1:201:9	B-AdverseReaction
Neoplasms	DUAVEE.xml:S1:211:9	I-AdverseReaction
[	DUAVEE.xml:S1:221:1	O
see	DUAVEE.xml:S1:222:3	O
Warnings	DUAVEE.xml:S1:227:8	O
and	DUAVEE.xml:S1:236:3	O
Precautions	DUAVEE.xml:S1:240:11	O
(	DUAVEE.xml:S1:252:1	O
5.3	DUAVEE.xml:S1:253:3	O
)	DUAVEE.xml:S1:256:1	O
]	DUAVEE.xml:S1:259:1	O

Gallbladder	DUAVEE.xml:S1:267:11	B-AdverseReaction
Disease	DUAVEE.xml:S1:279:7	I-AdverseReaction
[	DUAVEE.xml:S1:287:1	O
see	DUAVEE.xml:S1:288:3	O
Warnings	DUAVEE.xml:S1:293:8	O
and	DUAVEE.xml:S1:302:3	O
Precautions	DUAVEE.xml:S1:306:11	O
(	DUAVEE.xml:S1:318:1	O
5.5	DUAVEE.xml:S1:319:3	O
)	DUAVEE.xml:S1:322:1	O
]	DUAVEE.xml:S1:325:1	O

Hypertriglyceridemia	DUAVEE.xml:S1:333:20	B-AdverseReaction
[	DUAVEE.xml:S1:354:1	O
see	DUAVEE.xml:S1:355:3	O
Warnings	DUAVEE.xml:S1:360:8	O
and	DUAVEE.xml:S1:369:3	O
Precautions	DUAVEE.xml:S1:373:11	O
(	DUAVEE.xml:S1:385:1	O
5.8	DUAVEE.xml:S1:386:3	O
)	DUAVEE.xml:S1:389:1	O
]	DUAVEE.xml:S1:392:1	O

EXCERPT	DUAVEE.xml:S1:402:7	O
:	DUAVEE.xml:S1:409:1	O
In	DUAVEE.xml:S1:413:2	O
four	DUAVEE.xml:S1:416:4	O
prospective	DUAVEE.xml:S1:421:11	O
,	DUAVEE.xml:S1:432:1	O
randomized	DUAVEE.xml:S1:434:10	O
,	DUAVEE.xml:S1:444:1	O
placebo	DUAVEE.xml:S1:446:7	O
-	DUAVEE.xml:S1:453:1	O
controlled	DUAVEE.xml:S1:454:10	O
trials	DUAVEE.xml:S1:465:6	O
the	DUAVEE.xml:S1:472:3	O
common	DUAVEE.xml:S1:476:6	O
adverse	DUAVEE.xml:S1:483:7	O
reactions	DUAVEE.xml:S1:491:9	O
(	DUAVEE.xml:S1:501:1	O
incidence	DUAVEE.xml:S1:502:9	O
5%	DUAVEE.xml:S1:515:2	O
)	DUAVEE.xml:S1:517:1	O
were	DUAVEE.xml:S1:519:4	O
muscle	DUAVEE.xml:S1:524:6	B-AdverseReaction
spasms	DUAVEE.xml:S1:531:6	I-AdverseReaction
,	DUAVEE.xml:S1:537:1	O
nausea	DUAVEE.xml:S1:539:6	B-AdverseReaction
,	DUAVEE.xml:S1:545:1	O
diarrhea	DUAVEE.xml:S1:547:8	B-AdverseReaction
,	DUAVEE.xml:S1:555:1	O
dyspepsia	DUAVEE.xml:S1:557:9	B-AdverseReaction
,	DUAVEE.xml:S1:566:1	O
abdominal	DUAVEE.xml:S1:568:9	B-AdverseReaction
pain	DUAVEE.xml:S1:578:4	I-AdverseReaction
upper	DUAVEE.xml:S1:583:5	I-AdverseReaction
,	DUAVEE.xml:S1:588:1	O
oropharyngeal	DUAVEE.xml:S1:590:13	B-AdverseReaction
pain	DUAVEE.xml:S1:604:4	I-AdverseReaction
,	DUAVEE.xml:S1:608:1	O
dizziness	DUAVEE.xml:S1:610:9	B-AdverseReaction
,	DUAVEE.xml:S1:619:1	O
and	DUAVEE.xml:S1:621:3	O
neck	DUAVEE.xml:S1:625:4	B-AdverseReaction
pain	DUAVEE.xml:S1:630:4	I-AdverseReaction
(	DUAVEE.xml:S1:635:1	O
6.1	DUAVEE.xml:S1:638:3	O
)	DUAVEE.xml:S1:643:1	O

To	DUAVEE.xml:S1:651:2	O

report	DUAVEE.xml:S1:654:6	O
SUSPECTED	DUAVEE.xml:S1:661:9	O
ADVERSE	DUAVEE.xml:S1:671:7	O
REACTIONS	DUAVEE.xml:S1:679:9	O
,	DUAVEE.xml:S1:688:1	O
contact	DUAVEE.xml:S1:690:7	O
Pfizer	DUAVEE.xml:S1:698:6	O
Inc	DUAVEE.xml:S1:705:3	O
.	DUAVEE.xml:S1:708:1	O

at	DUAVEE.xml:S1:710:2	O
1	DUAVEE.xml:S1:713:1	O
-	DUAVEE.xml:S1:714:1	O
800	DUAVEE.xml:S1:715:3	O
-	DUAVEE.xml:S1:718:1	O
438	DUAVEE.xml:S1:719:3	O
-	DUAVEE.xml:S1:722:1	O
1985	DUAVEE.xml:S1:723:4	O
or	DUAVEE.xml:S1:728:2	O
FDA	DUAVEE.xml:S1:731:3	O
at	DUAVEE.xml:S1:735:2	O
1	DUAVEE.xml:S1:738:1	O
-	DUAVEE.xml:S1:739:1	O
800	DUAVEE.xml:S1:740:3	O
-	DUAVEE.xml:S1:743:1	O
FDA	DUAVEE.xml:S1:744:3	O
-	DUAVEE.xml:S1:747:1	O
1088	DUAVEE.xml:S1:748:4	O
or	DUAVEE.xml:S1:753:2	O
www	DUAVEE.xml:S1:756:3	O
.	DUAVEE.xml:S1:759:1	O
fda	DUAVEE.xml:S1:760:3	O
.	DUAVEE.xml:S1:763:1	O
gov	DUAVEE.xml:S1:764:3	O
medwatch	DUAVEE.xml:S1:768:8	O
.	DUAVEE.xml:S1:776:1	O

6.1	DUAVEE.xml:S1:788:3	O

Clinical	DUAVEE.xml:S1:792:8	O
Trials	DUAVEE.xml:S1:801:6	O
Experience	DUAVEE.xml:S1:808:10	O

Because	DUAVEE.xml:S1:822:7	O
clinical	DUAVEE.xml:S1:830:8	O
trials	DUAVEE.xml:S1:839:6	O
are	DUAVEE.xml:S1:846:3	O
conducted	DUAVEE.xml:S1:850:9	O
under	DUAVEE.xml:S1:860:5	O
widely	DUAVEE.xml:S1:866:6	O
varying	DUAVEE.xml:S1:873:7	O
conditions	DUAVEE.xml:S1:881:10	O
,	DUAVEE.xml:S1:891:1	O
adverse	DUAVEE.xml:S1:893:7	O
reaction	DUAVEE.xml:S1:901:8	O
rates	DUAVEE.xml:S1:910:5	O
observed	DUAVEE.xml:S1:916:8	O
in	DUAVEE.xml:S1:925:2	O
the	DUAVEE.xml:S1:928:3	O
clinical	DUAVEE.xml:S1:932:8	O
trials	DUAVEE.xml:S1:941:6	O
of	DUAVEE.xml:S1:948:2	O
a	DUAVEE.xml:S1:951:1	O
drug	DUAVEE.xml:S1:953:4	O
cannot	DUAVEE.xml:S1:958:6	O
be	DUAVEE.xml:S1:965:2	O
directly	DUAVEE.xml:S1:968:8	O
compared	DUAVEE.xml:S1:977:8	O
to	DUAVEE.xml:S1:986:2	O
rates	DUAVEE.xml:S1:989:5	O
in	DUAVEE.xml:S1:995:2	O
the	DUAVEE.xml:S1:998:3	O
clinical	DUAVEE.xml:S1:1002:8	O
trials	DUAVEE.xml:S1:1011:6	O
of	DUAVEE.xml:S1:1018:2	O
another	DUAVEE.xml:S1:1021:7	O
drug	DUAVEE.xml:S1:1029:4	O
and	DUAVEE.xml:S1:1034:3	O
may	DUAVEE.xml:S1:1038:3	O
not	DUAVEE.xml:S1:1042:3	O
reflect	DUAVEE.xml:S1:1046:7	O
the	DUAVEE.xml:S1:1054:3	O
rates	DUAVEE.xml:S1:1058:5	O
observed	DUAVEE.xml:S1:1064:8	O
in	DUAVEE.xml:S1:1073:2	O
clinical	DUAVEE.xml:S1:1076:8	O
practice	DUAVEE.xml:S1:1085:8	O
.	DUAVEE.xml:S1:1093:1	O

The	DUAVEE.xml:S1:1099:3	O
safety	DUAVEE.xml:S1:1103:6	O
of	DUAVEE.xml:S1:1110:2	O
conjugated	DUAVEE.xml:S1:1113:10	O
estrogens	DUAVEE.xml:S1:1124:9	O
bazedoxifene	DUAVEE.xml:S1:1134:12	O
was	DUAVEE.xml:S1:1147:3	O
evaluated	DUAVEE.xml:S1:1151:9	O
in	DUAVEE.xml:S1:1161:2	O
four	DUAVEE.xml:S1:1164:4	O
Phase	DUAVEE.xml:S1:1169:5	O
3	DUAVEE.xml:S1:1175:1	O
clinical	DUAVEE.xml:S1:1177:8	O
trials	DUAVEE.xml:S1:1186:6	O
ranging	DUAVEE.xml:S1:1193:7	O
from	DUAVEE.xml:S1:1201:4	O
12	DUAVEE.xml:S1:1206:2	O
weeks	DUAVEE.xml:S1:1209:5	O
to	DUAVEE.xml:S1:1215:2	O
24	DUAVEE.xml:S1:1218:2	O
months	DUAVEE.xml:S1:1221:6	O
in	DUAVEE.xml:S1:1228:2	O
duration	DUAVEE.xml:S1:1231:8	O
and	DUAVEE.xml:S1:1240:3	O
enrolling	DUAVEE.xml:S1:1244:9	O
6	DUAVEE.xml:S1:1254:1	O
,	DUAVEE.xml:S1:1255:1	O
210	DUAVEE.xml:S1:1256:3	O
postmenopausal	DUAVEE.xml:S1:1260:14	O
women	DUAVEE.xml:S1:1275:5	O
age	DUAVEE.xml:S1:1281:3	O
40	DUAVEE.xml:S1:1285:2	O
to	DUAVEE.xml:S1:1288:2	O
75	DUAVEE.xml:S1:1291:2	O
years	DUAVEE.xml:S1:1294:5	O
(	DUAVEE.xml:S1:1300:1	O
mean	DUAVEE.xml:S1:1301:4	O
age	DUAVEE.xml:S1:1306:3	O
55	DUAVEE.xml:S1:1310:2	O
years	DUAVEE.xml:S1:1313:5	O
)	DUAVEE.xml:S1:1318:1	O
.	DUAVEE.xml:S1:1319:1	O

A	DUAVEE.xml:S1:1321:1	O
total	DUAVEE.xml:S1:1323:5	O
of	DUAVEE.xml:S1:1329:2	O
1	DUAVEE.xml:S1:1332:1	O
,	DUAVEE.xml:S1:1333:1	O
224	DUAVEE.xml:S1:1334:3	O
patients	DUAVEE.xml:S1:1338:8	O
were	DUAVEE.xml:S1:1347:4	O
treated	DUAVEE.xml:S1:1352:7	O
with	DUAVEE.xml:S1:1360:4	O
DUAVEE	DUAVEE.xml:S1:1365:6	O
and	DUAVEE.xml:S1:1372:3	O
1	DUAVEE.xml:S1:1376:1	O
,	DUAVEE.xml:S1:1377:1	O
069	DUAVEE.xml:S1:1378:3	O
patients	DUAVEE.xml:S1:1382:8	O
received	DUAVEE.xml:S1:1391:8	O
placebo	DUAVEE.xml:S1:1400:7	O
.	DUAVEE.xml:S1:1407:1	O

Women	DUAVEE.xml:S1:1409:5	O
enrolled	DUAVEE.xml:S1:1415:8	O
in	DUAVEE.xml:S1:1424:2	O
Studies	DUAVEE.xml:S1:1427:7	O
1	DUAVEE.xml:S1:1435:1	O
and	DUAVEE.xml:S1:1437:3	O
2	DUAVEE.xml:S1:1441:1	O
received	DUAVEE.xml:S1:1443:8	O
calcium	DUAVEE.xml:S1:1452:7	O
(	DUAVEE.xml:S1:1460:1	O
600	DUAVEE.xml:S1:1461:3	O
-	DUAVEE.xml:S1:1464:1	O
1200	DUAVEE.xml:S1:1465:4	O
mg	DUAVEE.xml:S1:1470:2	O
)	DUAVEE.xml:S1:1472:1	O
and	DUAVEE.xml:S1:1474:3	O
vitamin	DUAVEE.xml:S1:1478:7	O
D	DUAVEE.xml:S1:1486:1	O
(	DUAVEE.xml:S1:1488:1	O
200	DUAVEE.xml:S1:1489:3	O
-	DUAVEE.xml:S1:1492:1	O
400	DUAVEE.xml:S1:1493:3	O
IU	DUAVEE.xml:S1:1497:2	O
)	DUAVEE.xml:S1:1499:1	O
daily	DUAVEE.xml:S1:1501:5	O
,	DUAVEE.xml:S1:1506:1	O
while	DUAVEE.xml:S1:1508:5	O
women	DUAVEE.xml:S1:1514:5	O
in	DUAVEE.xml:S1:1520:2	O
Studies	DUAVEE.xml:S1:1523:7	O
3	DUAVEE.xml:S1:1531:1	O
and	DUAVEE.xml:S1:1533:3	O
4	DUAVEE.xml:S1:1537:1	O
received	DUAVEE.xml:S1:1539:8	O
no	DUAVEE.xml:S1:1548:2	O
calcium	DUAVEE.xml:S1:1551:7	O
and	DUAVEE.xml:S1:1559:3	O
vitamin	DUAVEE.xml:S1:1563:7	O
D	DUAVEE.xml:S1:1571:1	O
supplementation	DUAVEE.xml:S1:1573:15	O
as	DUAVEE.xml:S1:1589:2	O
part	DUAVEE.xml:S1:1592:4	O
of	DUAVEE.xml:S1:1597:2	O
the	DUAVEE.xml:S1:1600:3	O
protocol	DUAVEE.xml:S1:1604:8	O
.	DUAVEE.xml:S1:1612:1	O

The	DUAVEE.xml:S1:1618:3	O
incidence	DUAVEE.xml:S1:1622:9	O
of	DUAVEE.xml:S1:1632:2	O
all	DUAVEE.xml:S1:1635:3	O
-	DUAVEE.xml:S1:1638:1	O
cause	DUAVEE.xml:S1:1639:5	O
mortality	DUAVEE.xml:S1:1645:9	B-AdverseReaction
was	DUAVEE.xml:S1:1655:3	O
0.0%	DUAVEE.xml:S1:1659:4	B-Negation
in	DUAVEE.xml:S1:1664:2	O
the	DUAVEE.xml:S1:1667:3	O
DUAVEE	DUAVEE.xml:S1:1671:6	O
group	DUAVEE.xml:S1:1678:5	O
and	DUAVEE.xml:S1:1684:3	O
0.2%	DUAVEE.xml:S1:1688:4	O
in	DUAVEE.xml:S1:1693:2	O
the	DUAVEE.xml:S1:1696:3	O
placebo	DUAVEE.xml:S1:1700:7	O
group	DUAVEE.xml:S1:1708:5	O
.	DUAVEE.xml:S1:1713:1	O

The	DUAVEE.xml:S1:1715:3	O
incidence	DUAVEE.xml:S1:1719:9	O
of	DUAVEE.xml:S1:1729:2	O
serious	DUAVEE.xml:S1:1732:7	O
adverse	DUAVEE.xml:S1:1740:7	O
reactions	DUAVEE.xml:S1:1748:9	O
was	DUAVEE.xml:S1:1758:3	O
3.5%	DUAVEE.xml:S1:1762:4	O
in	DUAVEE.xml:S1:1767:2	O
the	DUAVEE.xml:S1:1770:3	O
DUAVEE	DUAVEE.xml:S1:1774:6	O
group	DUAVEE.xml:S1:1781:5	O
and	DUAVEE.xml:S1:1787:3	O
4.8%	DUAVEE.xml:S1:1791:4	O
in	DUAVEE.xml:S1:1796:2	O
the	DUAVEE.xml:S1:1799:3	O
placebo	DUAVEE.xml:S1:1803:7	O
group	DUAVEE.xml:S1:1811:5	O
.	DUAVEE.xml:S1:1816:1	O

The	DUAVEE.xml:S1:1818:3	O
percentage	DUAVEE.xml:S1:1822:10	O
of	DUAVEE.xml:S1:1833:2	O
patients	DUAVEE.xml:S1:1836:8	O
who	DUAVEE.xml:S1:1845:3	O
withdrew	DUAVEE.xml:S1:1849:8	O
from	DUAVEE.xml:S1:1858:4	O
treatment	DUAVEE.xml:S1:1863:9	O
due	DUAVEE.xml:S1:1873:3	O
to	DUAVEE.xml:S1:1877:2	O
adverse	DUAVEE.xml:S1:1880:7	O
reactions	DUAVEE.xml:S1:1888:9	O
was	DUAVEE.xml:S1:1898:3	O
7.5%	DUAVEE.xml:S1:1902:4	O
in	DUAVEE.xml:S1:1907:2	O
the	DUAVEE.xml:S1:1910:3	O
DUAVEE	DUAVEE.xml:S1:1914:6	O
group	DUAVEE.xml:S1:1921:5	O
and	DUAVEE.xml:S1:1927:3	O
10.0%	DUAVEE.xml:S1:1931:5	O
in	DUAVEE.xml:S1:1937:2	O
the	DUAVEE.xml:S1:1940:3	O
placebo	DUAVEE.xml:S1:1944:7	O
group	DUAVEE.xml:S1:1952:5	O
.	DUAVEE.xml:S1:1957:1	O

The	DUAVEE.xml:S1:1959:3	O
most	DUAVEE.xml:S1:1963:4	O
common	DUAVEE.xml:S1:1968:6	O
adverse	DUAVEE.xml:S1:1975:7	O
reactions	DUAVEE.xml:S1:1983:9	O
leading	DUAVEE.xml:S1:1993:7	O
to	DUAVEE.xml:S1:2001:2	O
discontinuation	DUAVEE.xml:S1:2004:15	O
were	DUAVEE.xml:S1:2020:4	O
hot	DUAVEE.xml:S1:2025:3	B-AdverseReaction
flush	DUAVEE.xml:S1:2029:5	I-AdverseReaction
,	DUAVEE.xml:S1:2034:1	O
abdominal	DUAVEE.xml:S1:2036:9	B-AdverseReaction
pain	DUAVEE.xml:S1:2046:4	I-AdverseReaction
upper	DUAVEE.xml:S1:2051:5	I-AdverseReaction
,	DUAVEE.xml:S1:2056:1	O
and	DUAVEE.xml:S1:2058:3	O
nausea	DUAVEE.xml:S1:2062:6	B-AdverseReaction
.	DUAVEE.xml:S1:2068:1	O

The	DUAVEE.xml:S1:2074:3	O
most	DUAVEE.xml:S1:2078:4	O
commonly	DUAVEE.xml:S1:2083:8	O
observed	DUAVEE.xml:S1:2092:8	O
adverse	DUAVEE.xml:S1:2101:7	O
reactions	DUAVEE.xml:S1:2109:9	O
(	DUAVEE.xml:S1:2119:1	O
incidence	DUAVEE.xml:S1:2120:9	O
5%	DUAVEE.xml:S1:2133:2	O
)	DUAVEE.xml:S1:2135:1	O
more	DUAVEE.xml:S1:2137:4	O
frequently	DUAVEE.xml:S1:2142:10	O
reported	DUAVEE.xml:S1:2153:8	O
in	DUAVEE.xml:S1:2162:2	O
women	DUAVEE.xml:S1:2165:5	O
treated	DUAVEE.xml:S1:2171:7	O
with	DUAVEE.xml:S1:2179:4	O
DUAVEE	DUAVEE.xml:S1:2184:6	O
than	DUAVEE.xml:S1:2191:4	O
placebo	DUAVEE.xml:S1:2196:7	O
are	DUAVEE.xml:S1:2204:3	O
presented	DUAVEE.xml:S1:2208:9	O
in	DUAVEE.xml:S1:2218:2	O
Table	DUAVEE.xml:S1:2221:5	O
1	DUAVEE.xml:S1:2227:1	O
.	DUAVEE.xml:S1:2228:1	O

Table	DUAVEE.xml:S1:2234:5	O
1	DUAVEE.xml:S1:2240:1	O
:	DUAVEE.xml:S1:2241:1	O
Adverse	DUAVEE.xml:S1:2243:7	O
Reactions	DUAVEE.xml:S1:2251:9	O
(	DUAVEE.xml:S1:2261:1	O
Incidence	DUAVEE.xml:S1:2262:9	O
5%	DUAVEE.xml:S1:2275:2	O
)	DUAVEE.xml:S1:2277:1	O
More	DUAVEE.xml:S1:2279:4	O
Common	DUAVEE.xml:S1:2284:6	O
in	DUAVEE.xml:S1:2291:2	O
the	DUAVEE.xml:S1:2294:3	O
DUAVEE	DUAVEE.xml:S1:2298:6	O
Treatment	DUAVEE.xml:S1:2305:9	O
Group	DUAVEE.xml:S1:2315:5	O
in	DUAVEE.xml:S1:2321:2	O
Placebo	DUAVEE.xml:S1:2324:7	O
-	DUAVEE.xml:S1:2331:1	O
controlled	DUAVEE.xml:S1:2332:10	O
Trials	DUAVEE.xml:S1:2343:6	O

DUAVEE	DUAVEE.xml:S1:2394:6	O
(	DUAVEE.xml:S1:2401:1	O
N	DUAVEE.xml:S1:2402:1	O
1224	DUAVEE.xml:S1:2404:4	O
)	DUAVEE.xml:S1:2408:1	O
n	DUAVEE.xml:S1:2409:1	O
(	DUAVEE.xml:S1:2411:1	O
)	DUAVEE.xml:S1:2413:1	O
Placebo	DUAVEE.xml:S1:2429:7	O
(	DUAVEE.xml:S1:2437:1	O
N	DUAVEE.xml:S1:2438:1	O
1069	DUAVEE.xml:S1:2440:4	O
)	DUAVEE.xml:S1:2444:1	O
n	DUAVEE.xml:S1:2445:1	O
(	DUAVEE.xml:S1:2447:1	O
)	DUAVEE.xml:S1:2449:1	O

Gastrointestinal	DUAVEE.xml:S1:2466:16	O

disorders	DUAVEE.xml:S1:2483:9	O

Nausea	DUAVEE.xml:S1:2502:6	B-AdverseReaction
100	DUAVEE.xml:S1:2550:3	O
(	DUAVEE.xml:S1:2554:1	O
8	DUAVEE.xml:S1:2555:1	O
)	DUAVEE.xml:S1:2556:1	O
58	DUAVEE.xml:S1:2586:2	O
(	DUAVEE.xml:S1:2589:1	O
5	DUAVEE.xml:S1:2590:1	O
)	DUAVEE.xml:S1:2591:1	O

Diarrhea	DUAVEE.xml:S1:2611:8	B-AdverseReaction
96	DUAVEE.xml:S1:2660:2	O
(	DUAVEE.xml:S1:2663:1	O
8	DUAVEE.xml:S1:2664:1	O
)	DUAVEE.xml:S1:2665:1	O
57	DUAVEE.xml:S1:2695:2	O
(	DUAVEE.xml:S1:2698:1	O
5	DUAVEE.xml:S1:2699:1	O
)	DUAVEE.xml:S1:2700:1	O

Dyspepsia	DUAVEE.xml:S1:2720:9	B-AdverseReaction
84	DUAVEE.xml:S1:2769:2	O
(	DUAVEE.xml:S1:2772:1	O
7	DUAVEE.xml:S1:2773:1	O
)	DUAVEE.xml:S1:2774:1	O
59	DUAVEE.xml:S1:2804:2	O
(	DUAVEE.xml:S1:2807:1	O
6	DUAVEE.xml:S1:2808:1	O
)	DUAVEE.xml:S1:2809:1	O

Abdominal	DUAVEE.xml:S1:2829:9	B-AdverseReaction
pain	DUAVEE.xml:S1:2839:4	I-AdverseReaction
upper	DUAVEE.xml:S1:2844:5	I-AdverseReaction
81	DUAVEE.xml:S1:2878:2	O
(	DUAVEE.xml:S1:2881:1	O
7	DUAVEE.xml:S1:2882:1	O
)	DUAVEE.xml:S1:2883:1	O
58	DUAVEE.xml:S1:2913:2	O
(	DUAVEE.xml:S1:2916:1	O
5	DUAVEE.xml:S1:2917:1	O
)	DUAVEE.xml:S1:2918:1	O

Musculoskeletal	DUAVEE.xml:S1:2940:15	O
and	DUAVEE.xml:S1:2956:3	O
connective	DUAVEE.xml:S1:2960:10	O
tissue	DUAVEE.xml:S1:2971:6	O
disorders	DUAVEE.xml:S1:2978:9	O

Muscle	DUAVEE.xml:S1:2994:6	B-AdverseReaction
spasms	DUAVEE.xml:S1:3001:6	I-AdverseReaction
110	DUAVEE.xml:S1:3042:3	O
(	DUAVEE.xml:S1:3046:1	O
9	DUAVEE.xml:S1:3047:1	O
)	DUAVEE.xml:S1:3048:1	O
63	DUAVEE.xml:S1:3078:2	O
(	DUAVEE.xml:S1:3081:1	O
6	DUAVEE.xml:S1:3082:1	O
)	DUAVEE.xml:S1:3083:1	O

Neck	DUAVEE.xml:S1:3103:4	B-AdverseReaction
pain	DUAVEE.xml:S1:3108:4	I-AdverseReaction
62	DUAVEE.xml:S1:3152:2	O
(	DUAVEE.xml:S1:3155:1	O
5	DUAVEE.xml:S1:3156:1	O
)	DUAVEE.xml:S1:3157:1	O
46	DUAVEE.xml:S1:3187:2	O
(	DUAVEE.xml:S1:3190:1	O
4	DUAVEE.xml:S1:3191:1	O
)	DUAVEE.xml:S1:3192:1	O

Nervous	DUAVEE.xml:S1:3214:7	O
system	DUAVEE.xml:S1:3222:6	O
disorders	DUAVEE.xml:S1:3229:9	O

Dizziness	DUAVEE.xml:S1:3250:9	B-AdverseReaction
65	DUAVEE.xml:S1:3299:2	O
(	DUAVEE.xml:S1:3302:1	O
5	DUAVEE.xml:S1:3303:1	O
)	DUAVEE.xml:S1:3304:1	O
37	DUAVEE.xml:S1:3334:2	O
(	DUAVEE.xml:S1:3337:1	O
3	DUAVEE.xml:S1:3338:1	O
)	DUAVEE.xml:S1:3339:1	O

Respiratory	DUAVEE.xml:S1:3361:11	O
,	DUAVEE.xml:S1:3372:1	O
thoracic	DUAVEE.xml:S1:3374:8	O
,	DUAVEE.xml:S1:3382:1	O
and	DUAVEE.xml:S1:3384:3	O
mediastinal	DUAVEE.xml:S1:3388:11	O
disorders	DUAVEE.xml:S1:3400:9	O

Oropharyngeal	DUAVEE.xml:S1:3416:13	B-AdverseReaction
pain	DUAVEE.xml:S1:3430:4	I-AdverseReaction
80	DUAVEE.xml:S1:3465:2	O
(	DUAVEE.xml:S1:3468:1	O
7	DUAVEE.xml:S1:3469:1	O
)	DUAVEE.xml:S1:3470:1	O
61	DUAVEE.xml:S1:3500:2	O
(	DUAVEE.xml:S1:3503:1	O
6	DUAVEE.xml:S1:3504:1	O
)	DUAVEE.xml:S1:3505:1	O

Venous	DUAVEE.xml:S1:3537:6	O
thromboembolism	DUAVEE.xml:S1:3544:15	O
:	DUAVEE.xml:S1:3561:1	O
In	DUAVEE.xml:S1:3563:2	O
the	DUAVEE.xml:S1:3566:3	O
clinical	DUAVEE.xml:S1:3570:8	O
studies	DUAVEE.xml:S1:3579:7	O
with	DUAVEE.xml:S1:3587:4	O
DUAVEE	DUAVEE.xml:S1:3592:6	O
,	DUAVEE.xml:S1:3598:1	O
the	DUAVEE.xml:S1:3600:3	O
reporting	DUAVEE.xml:S1:3604:9	O
rates	DUAVEE.xml:S1:3614:5	O
for	DUAVEE.xml:S1:3620:3	O
venous	DUAVEE.xml:S1:3624:6	B-AdverseReaction
thromboembolism	DUAVEE.xml:S1:3631:15	I-AdverseReaction
(	DUAVEE.xml:S1:3647:1	O
deep	DUAVEE.xml:S1:3648:4	B-AdverseReaction
venous	DUAVEE.xml:S1:3653:6	I-AdverseReaction
thrombosis	DUAVEE.xml:S1:3660:10	I-AdverseReaction
,	DUAVEE.xml:S1:3670:1	O
pulmonary	DUAVEE.xml:S1:3672:9	B-AdverseReaction
embolism	DUAVEE.xml:S1:3682:8	I-AdverseReaction
,	DUAVEE.xml:S1:3690:1	O
and	DUAVEE.xml:S1:3692:3	O
retinal	DUAVEE.xml:S1:3696:7	B-AdverseReaction
vein	DUAVEE.xml:S1:3704:4	I-AdverseReaction
thrombosis	DUAVEE.xml:S1:3709:10	I-AdverseReaction
)	DUAVEE.xml:S1:3719:1	O
were	DUAVEE.xml:S1:3721:4	O
low	DUAVEE.xml:S1:3726:3	O
in	DUAVEE.xml:S1:3730:2	O
all	DUAVEE.xml:S1:3733:3	O
treatment	DUAVEE.xml:S1:3737:9	O
groups	DUAVEE.xml:S1:3747:6	O
.	DUAVEE.xml:S1:3753:1	O

Adverse	DUAVEE.xml:S1:3755:7	O
reactions	DUAVEE.xml:S1:3763:9	O
of	DUAVEE.xml:S1:3773:2	O
venous	DUAVEE.xml:S1:3776:6	B-AdverseReaction
thromboembolism	DUAVEE.xml:S1:3783:15	I-AdverseReaction
were	DUAVEE.xml:S1:3799:4	O
reported	DUAVEE.xml:S1:3804:8	O
in	DUAVEE.xml:S1:3813:2	O
0.0%	DUAVEE.xml:S1:3816:4	B-Negation
of	DUAVEE.xml:S1:3821:2	O
patients	DUAVEE.xml:S1:3824:8	O
treated	DUAVEE.xml:S1:3833:7	O
with	DUAVEE.xml:S1:3841:4	O
DUAVEE	DUAVEE.xml:S1:3846:6	O
and	DUAVEE.xml:S1:3853:3	O
0.1%	DUAVEE.xml:S1:3857:4	O
of	DUAVEE.xml:S1:3862:2	O
patients	DUAVEE.xml:S1:3865:8	O
treated	DUAVEE.xml:S1:3874:7	O
with	DUAVEE.xml:S1:3882:4	O
placebo	DUAVEE.xml:S1:3887:7	O
.	DUAVEE.xml:S1:3894:1	O

Due	DUAVEE.xml:S1:3896:3	O
to	DUAVEE.xml:S1:3900:2	O
the	DUAVEE.xml:S1:3903:3	O
low	DUAVEE.xml:S1:3907:3	O
rate	DUAVEE.xml:S1:3911:4	O
of	DUAVEE.xml:S1:3916:2	O
events	DUAVEE.xml:S1:3919:6	O
in	DUAVEE.xml:S1:3926:2	O
both	DUAVEE.xml:S1:3929:4	O
groups	DUAVEE.xml:S1:3934:6	O
,	DUAVEE.xml:S1:3940:1	O
it	DUAVEE.xml:S1:3942:2	O
is	DUAVEE.xml:S1:3945:2	O
not	DUAVEE.xml:S1:3948:3	O
possible	DUAVEE.xml:S1:3952:8	O
to	DUAVEE.xml:S1:3961:2	O
conclude	DUAVEE.xml:S1:3964:8	O
that	DUAVEE.xml:S1:3973:4	O
the	DUAVEE.xml:S1:3978:3	O
risk	DUAVEE.xml:S1:3982:4	B-Factor
of	DUAVEE.xml:S1:3987:2	O
venous	DUAVEE.xml:S1:3990:6	B-AdverseReaction
thromboembolism	DUAVEE.xml:S1:3997:15	I-AdverseReaction
with	DUAVEE.xml:S1:4013:4	O
DUAVEE	DUAVEE.xml:S1:4018:6	O
is	DUAVEE.xml:S1:4025:2	O
different	DUAVEE.xml:S1:4028:9	O
from	DUAVEE.xml:S1:4038:4	O
that	DUAVEE.xml:S1:4043:4	O
seen	DUAVEE.xml:S1:4048:4	O
with	DUAVEE.xml:S1:4053:4	O
other	DUAVEE.xml:S1:4058:5	O
estrogen	DUAVEE.xml:S1:4064:8	O
therapies	DUAVEE.xml:S1:4073:9	O
[	DUAVEE.xml:S1:4084:1	O
see	DUAVEE.xml:S1:4085:3	O
Warnings	DUAVEE.xml:S1:4090:8	O
and	DUAVEE.xml:S1:4099:3	O
Precautions	DUAVEE.xml:S1:4103:11	O
(	DUAVEE.xml:S1:4115:1	O
5.2	DUAVEE.xml:S1:4116:3	O
)	DUAVEE.xml:S1:4119:1	O
]	DUAVEE.xml:S1:4122:1	O
.	DUAVEE.xml:S1:4125:1	O
\n\n	DUAVEE.xml:S2:0:2	O
BOXED	DUAVEE.xml:S2:6:5	O
WARNING	DUAVEE.xml:S2:12:7	O
:	DUAVEE.xml:S2:19:1	O
WARNING	DUAVEE.xml:S2:21:7	O
:	DUAVEE.xml:S2:28:1	O
ENDOMETRIAL	DUAVEE.xml:S2:30:11	B-AdverseReaction
CANCER	DUAVEE.xml:S2:42:6	I-AdverseReaction
,	DUAVEE.xml:S2:48:1	O
CARDIOVASCULAR	DUAVEE.xml:S2:50:14	B-AdverseReaction
DISORDERS	DUAVEE.xml:S2:65:9	I-AdverseReaction
,	DUAVEE.xml:S2:74:1	O
AND	DUAVEE.xml:S2:76:3	O
PROBABLE	DUAVEE.xml:S2:80:8	B-Factor
DEMENTIA	DUAVEE.xml:S2:89:8	B-AdverseReaction
\n\n	DUAVEE.xml:S2:98:2	O
WARNING	DUAVEE.xml:S2:104:7	O
:	DUAVEE.xml:S2:111:1	O
ENDOMETRIAL	DUAVEE.xml:S2:113:11	B-AdverseReaction
CANCER	DUAVEE.xml:S2:125:6	I-AdverseReaction
,	DUAVEE.xml:S2:131:1	O
CARDIOVASCULAR	DUAVEE.xml:S2:133:14	B-AdverseReaction
DISORDERS	DUAVEE.xml:S2:148:9	I-AdverseReaction
,	DUAVEE.xml:S2:157:1	O
AND	DUAVEE.xml:S2:159:3	O
PROBABLE	DUAVEE.xml:S2:163:8	B-Factor
DEMENTIA	DUAVEE.xml:S2:172:8	B-AdverseReaction
\n\n	DUAVEE.xml:S2:183:2	O
Women	DUAVEE.xml:S2:192:5	O
taking	DUAVEE.xml:S2:198:6	O
DUAVEE	DUAVEE.xml:S2:205:6	O
should	DUAVEE.xml:S2:212:6	O
not	DUAVEE.xml:S2:219:3	O
take	DUAVEE.xml:S2:223:4	O
additional	DUAVEE.xml:S2:228:10	O
estrogens	DUAVEE.xml:S2:239:9	O
[	DUAVEE.xml:S2:249:1	O
see	DUAVEE.xml:S2:250:3	O
Warnings	DUAVEE.xml:S2:254:8	O
and	DUAVEE.xml:S2:263:3	O
Precautions	DUAVEE.xml:S2:267:11	O
(	DUAVEE.xml:S2:279:1	O
5.1	DUAVEE.xml:S2:280:3	O
)]	DUAVEE.xml:S2:283:2	O
\n	DUAVEE.xml:S2:286:1	O
There	DUAVEE.xml:S2:291:5	O
is	DUAVEE.xml:S2:297:2	O
an	DUAVEE.xml:S2:300:2	O
increased	DUAVEE.xml:S2:303:9	O
risk	DUAVEE.xml:S2:313:4	O
of	DUAVEE.xml:S2:318:2	O
endometrial	DUAVEE.xml:S2:321:11	B-AdverseReaction
cancer	DUAVEE.xml:S2:333:6	I-AdverseReaction
in	DUAVEE.xml:S2:340:2	O
a	DUAVEE.xml:S2:343:1	O
woman	DUAVEE.xml:S2:345:5	O
with	DUAVEE.xml:S2:351:4	O
a	DUAVEE.xml:S2:356:1	O
uterus	DUAVEE.xml:S2:358:6	O
who	DUAVEE.xml:S2:365:3	O
uses	DUAVEE.xml:S2:369:4	O
unopposed	DUAVEE.xml:S2:374:9	O
estrogens	DUAVEE.xml:S2:384:9	B-DrugClass
.	DUAVEE.xml:S2:393:1	O

DUAVEE	DUAVEE.xml:S2:395:6	O
has	DUAVEE.xml:S2:402:3	O
been	DUAVEE.xml:S2:406:4	O
shown	DUAVEE.xml:S2:411:5	O
to	DUAVEE.xml:S2:417:2	O
reduce	DUAVEE.xml:S2:420:6	B-Factor
the	DUAVEE.xml:S2:427:3	I-Factor
risk	DUAVEE.xml:S2:431:4	I-Factor
of	DUAVEE.xml:S2:436:2	O
endometrial	DUAVEE.xml:S2:439:11	B-AdverseReaction
hyperplasia	DUAVEE.xml:S2:451:11	I-AdverseReaction
,	DUAVEE.xml:S2:462:1	O
which	DUAVEE.xml:S2:464:5	O
may	DUAVEE.xml:S2:470:3	O
be	DUAVEE.xml:S2:474:2	O
a	DUAVEE.xml:S2:477:1	O
precursor	DUAVEE.xml:S2:479:9	O
to	DUAVEE.xml:S2:489:2	O
endometrial	DUAVEE.xml:S2:492:11	O
cancer	DUAVEE.xml:S2:504:6	O
.	DUAVEE.xml:S2:510:1	O

Adequate	DUAVEE.xml:S2:512:8	O
diagnostic	DUAVEE.xml:S2:521:10	O
measures	DUAVEE.xml:S2:532:8	O
,	DUAVEE.xml:S2:540:1	O
including	DUAVEE.xml:S2:542:9	O
directed	DUAVEE.xml:S2:552:8	O
or	DUAVEE.xml:S2:561:2	O
random	DUAVEE.xml:S2:564:6	O
endometrial	DUAVEE.xml:S2:571:11	O
sampling	DUAVEE.xml:S2:583:8	O
when	DUAVEE.xml:S2:592:4	O
indicated	DUAVEE.xml:S2:597:9	O
,	DUAVEE.xml:S2:606:1	O
should	DUAVEE.xml:S2:608:6	O
be	DUAVEE.xml:S2:615:2	O
undertaken	DUAVEE.xml:S2:618:10	O
to	DUAVEE.xml:S2:629:2	O
rule	DUAVEE.xml:S2:632:4	O
out	DUAVEE.xml:S2:637:3	O
malignancy	DUAVEE.xml:S2:641:10	O
in	DUAVEE.xml:S2:652:2	O
postmenopausal	DUAVEE.xml:S2:655:14	O
women	DUAVEE.xml:S2:670:5	O
with	DUAVEE.xml:S2:676:4	O
undiagnosed	DUAVEE.xml:S2:681:11	O
persistent	DUAVEE.xml:S2:693:10	O
or	DUAVEE.xml:S2:704:2	O
recurring	DUAVEE.xml:S2:707:9	O
abnormal	DUAVEE.xml:S2:717:8	O
genital	DUAVEE.xml:S2:726:7	O
bleeding	DUAVEE.xml:S2:734:8	O
[	DUAVEE.xml:S2:743:1	O
see	DUAVEE.xml:S2:744:3	O
Warnings	DUAVEE.xml:S2:748:8	O
and	DUAVEE.xml:S2:757:3	O
Precautions	DUAVEE.xml:S2:761:11	O
(	DUAVEE.xml:S2:773:1	O
5.3	DUAVEE.xml:S2:774:3	O
)]	DUAVEE.xml:S2:777:2	O
\n	DUAVEE.xml:S2:780:1	O
Estrogen	DUAVEE.xml:S2:785:8	O
therapy	DUAVEE.xml:S2:794:7	O
should	DUAVEE.xml:S2:802:6	O
not	DUAVEE.xml:S2:809:3	O
be	DUAVEE.xml:S2:813:2	O
used	DUAVEE.xml:S2:816:4	O
for	DUAVEE.xml:S2:821:3	O
the	DUAVEE.xml:S2:825:3	O
prevention	DUAVEE.xml:S2:829:10	O
of	DUAVEE.xml:S2:840:2	O
cardiovascular	DUAVEE.xml:S2:843:14	O
disease	DUAVEE.xml:S2:858:7	O
or	DUAVEE.xml:S2:866:2	O
dementia	DUAVEE.xml:S2:869:8	O
[	DUAVEE.xml:S2:878:1	O
see	DUAVEE.xml:S2:879:3	O
Warnings	DUAVEE.xml:S2:883:8	O
and	DUAVEE.xml:S2:892:3	O
Precautions	DUAVEE.xml:S2:896:11	O
(	DUAVEE.xml:S2:908:1	O
5.2	DUAVEE.xml:S2:909:3	O
,	DUAVEE.xml:S2:912:1	O
5.4	DUAVEE.xml:S2:914:3	O
)]	DUAVEE.xml:S2:917:2	O
\n	DUAVEE.xml:S2:920:1	O
The	DUAVEE.xml:S2:925:3	O
Women	DUAVEE.xml:S2:929:5	O
's	DUAVEE.xml:S2:934:2	O
Health	DUAVEE.xml:S2:937:6	O
Initiative	DUAVEE.xml:S2:944:10	O
(	DUAVEE.xml:S2:955:1	O
WHI	DUAVEE.xml:S2:956:3	O
)	DUAVEE.xml:S2:959:1	O
estrogen	DUAVEE.xml:S2:961:8	O
-	DUAVEE.xml:S2:969:1	O
alone	DUAVEE.xml:S2:970:5	O
substudy	DUAVEE.xml:S2:976:8	O
reported	DUAVEE.xml:S2:985:8	O
increased	DUAVEE.xml:S2:994:9	O
risks	DUAVEE.xml:S2:1004:5	O
of	DUAVEE.xml:S2:1010:2	O
stroke	DUAVEE.xml:S2:1013:6	B-AdverseReaction
and	DUAVEE.xml:S2:1020:3	O
deep	DUAVEE.xml:S2:1024:4	B-AdverseReaction
vein	DUAVEE.xml:S2:1029:4	I-AdverseReaction
thrombosis	DUAVEE.xml:S2:1034:10	I-AdverseReaction
(	DUAVEE.xml:S2:1045:1	O
DVT	DUAVEE.xml:S2:1046:3	B-AdverseReaction
)	DUAVEE.xml:S2:1049:1	O
in	DUAVEE.xml:S2:1051:2	O
postmenopausal	DUAVEE.xml:S2:1054:14	O
women	DUAVEE.xml:S2:1069:5	O
(	DUAVEE.xml:S2:1075:1	O
50	DUAVEE.xml:S2:1076:2	O
to	DUAVEE.xml:S2:1079:2	O
79	DUAVEE.xml:S2:1082:2	O
years	DUAVEE.xml:S2:1085:5	O
of	DUAVEE.xml:S2:1091:2	O
age	DUAVEE.xml:S2:1094:3	O
)	DUAVEE.xml:S2:1097:1	O
during	DUAVEE.xml:S2:1099:6	O
7.1	DUAVEE.xml:S2:1106:3	O
years	DUAVEE.xml:S2:1110:5	O
of	DUAVEE.xml:S2:1116:2	O
treatment	DUAVEE.xml:S2:1119:9	O
with	DUAVEE.xml:S2:1129:4	O
daily	DUAVEE.xml:S2:1134:5	O
oral	DUAVEE.xml:S2:1140:4	B-DrugClass
conjugated	DUAVEE.xml:S2:1145:10	I-DrugClass
estrogens	DUAVEE.xml:S2:1156:9	I-DrugClass
(	DUAVEE.xml:S2:1166:1	O
0.625	DUAVEE.xml:S2:1167:5	O
mg	DUAVEE.xml:S2:1173:2	O
)-	DUAVEE.xml:S2:1175:2	O
alone	DUAVEE.xml:S2:1177:5	O
,	DUAVEE.xml:S2:1182:1	O
relative	DUAVEE.xml:S2:1184:8	O
to	DUAVEE.xml:S2:1193:2	O
placebo	DUAVEE.xml:S2:1196:7	O
[	DUAVEE.xml:S2:1204:1	O
see	DUAVEE.xml:S2:1205:3	O
Warnings	DUAVEE.xml:S2:1209:8	O
and	DUAVEE.xml:S2:1218:3	O
Precautions	DUAVEE.xml:S2:1222:11	O
(	DUAVEE.xml:S2:1234:1	O
5.2	DUAVEE.xml:S2:1235:3	O
)]	DUAVEE.xml:S2:1238:2	O
\n	DUAVEE.xml:S2:1241:1	O
The	DUAVEE.xml:S2:1246:3	O
WHI	DUAVEE.xml:S2:1250:3	O
Memory	DUAVEE.xml:S2:1254:6	O
Study	DUAVEE.xml:S2:1261:5	O
(	DUAVEE.xml:S2:1267:1	O
WHIMS	DUAVEE.xml:S2:1268:5	O
)	DUAVEE.xml:S2:1273:1	O
estrogen	DUAVEE.xml:S2:1275:8	O
-	DUAVEE.xml:S2:1283:1	O
alone	DUAVEE.xml:S2:1284:5	O
ancillary	DUAVEE.xml:S2:1290:9	O
study	DUAVEE.xml:S2:1300:5	O
of	DUAVEE.xml:S2:1306:2	O
WHI	DUAVEE.xml:S2:1309:3	O
reported	DUAVEE.xml:S2:1313:8	O
an	DUAVEE.xml:S2:1322:2	O
increased	DUAVEE.xml:S2:1325:9	O
risk	DUAVEE.xml:S2:1335:4	O
of	DUAVEE.xml:S2:1340:2	O
probable	DUAVEE.xml:S2:1343:8	O
dementia	DUAVEE.xml:S2:1352:8	B-AdverseReaction
in	DUAVEE.xml:S2:1361:2	O
postmenopausal	DUAVEE.xml:S2:1364:14	O
women	DUAVEE.xml:S2:1379:5	O
65	DUAVEE.xml:S2:1385:2	O
years	DUAVEE.xml:S2:1388:5	O
of	DUAVEE.xml:S2:1394:2	O
age	DUAVEE.xml:S2:1397:3	O
and	DUAVEE.xml:S2:1401:3	O
older	DUAVEE.xml:S2:1405:5	O
during	DUAVEE.xml:S2:1411:6	O
5.2	DUAVEE.xml:S2:1418:3	O
years	DUAVEE.xml:S2:1422:5	O
of	DUAVEE.xml:S2:1428:2	O
treatment	DUAVEE.xml:S2:1431:9	O
with	DUAVEE.xml:S2:1441:4	O
daily	DUAVEE.xml:S2:1446:5	O
conjugated	DUAVEE.xml:S2:1452:10	B-DrugClass
estrogens	DUAVEE.xml:S2:1463:9	I-DrugClass
(	DUAVEE.xml:S2:1473:1	O
0.625	DUAVEE.xml:S2:1474:5	O
mg	DUAVEE.xml:S2:1480:2	O
)-	DUAVEE.xml:S2:1482:2	O
alone	DUAVEE.xml:S2:1484:5	O
,	DUAVEE.xml:S2:1489:1	O
relative	DUAVEE.xml:S2:1491:8	O
to	DUAVEE.xml:S2:1500:2	O
placebo	DUAVEE.xml:S2:1503:7	O
.	DUAVEE.xml:S2:1510:1	O

It	DUAVEE.xml:S2:1512:2	O
is	DUAVEE.xml:S2:1515:2	O
unknown	DUAVEE.xml:S2:1518:7	O
whether	DUAVEE.xml:S2:1526:7	O
this	DUAVEE.xml:S2:1534:4	O
finding	DUAVEE.xml:S2:1539:7	O
applies	DUAVEE.xml:S2:1547:7	O
to	DUAVEE.xml:S2:1555:2	O
younger	DUAVEE.xml:S2:1558:7	O
postmenopausal	DUAVEE.xml:S2:1566:14	O
women	DUAVEE.xml:S2:1581:5	O
[	DUAVEE.xml:S2:1587:1	O
see	DUAVEE.xml:S2:1588:3	O
Warnings	DUAVEE.xml:S2:1592:8	O
and	DUAVEE.xml:S2:1601:3	O
Precautions	DUAVEE.xml:S2:1605:11	O
(	DUAVEE.xml:S2:1617:1	O
5.4	DUAVEE.xml:S2:1618:3	O
)]	DUAVEE.xml:S2:1621:2	O
\n	DUAVEE.xml:S2:1624:1	O
In	DUAVEE.xml:S2:1631:2	O
the	DUAVEE.xml:S2:1634:3	O
absence	DUAVEE.xml:S2:1638:7	O
of	DUAVEE.xml:S2:1646:2	O
comparable	DUAVEE.xml:S2:1649:10	O
data	DUAVEE.xml:S2:1660:4	O
,	DUAVEE.xml:S2:1664:1	O
these	DUAVEE.xml:S2:1666:5	O
risks	DUAVEE.xml:S2:1672:5	O
should	DUAVEE.xml:S2:1678:6	O
be	DUAVEE.xml:S2:1685:2	O
assumed	DUAVEE.xml:S2:1688:7	O
to	DUAVEE.xml:S2:1696:2	O
be	DUAVEE.xml:S2:1699:2	O
similar	DUAVEE.xml:S2:1702:7	O
for	DUAVEE.xml:S2:1710:3	O
other	DUAVEE.xml:S2:1714:5	O
doses	DUAVEE.xml:S2:1720:5	O
of	DUAVEE.xml:S2:1726:2	O
conjugated	DUAVEE.xml:S2:1729:10	O
estrogens	DUAVEE.xml:S2:1740:9	O
and	DUAVEE.xml:S2:1750:3	O
other	DUAVEE.xml:S2:1754:5	O
dosage	DUAVEE.xml:S2:1760:6	O
forms	DUAVEE.xml:S2:1767:5	O
of	DUAVEE.xml:S2:1773:2	O
estrogens	DUAVEE.xml:S2:1776:9	O
.	DUAVEE.xml:S2:1785:1	O

Estrogens	DUAVEE.xml:S2:1795:9	O
should	DUAVEE.xml:S2:1805:6	O
be	DUAVEE.xml:S2:1812:2	O
prescribed	DUAVEE.xml:S2:1815:10	O
at	DUAVEE.xml:S2:1826:2	O
the	DUAVEE.xml:S2:1829:3	O
lowest	DUAVEE.xml:S2:1833:6	O
effective	DUAVEE.xml:S2:1840:9	O
doses	DUAVEE.xml:S2:1850:5	O
and	DUAVEE.xml:S2:1856:3	O
for	DUAVEE.xml:S2:1860:3	O
the	DUAVEE.xml:S2:1864:3	O
shortest	DUAVEE.xml:S2:1868:8	O
duration	DUAVEE.xml:S2:1877:8	O
consistent	DUAVEE.xml:S2:1886:10	O
with	DUAVEE.xml:S2:1897:4	O
treatment	DUAVEE.xml:S2:1902:9	O
goals	DUAVEE.xml:S2:1912:5	O
and	DUAVEE.xml:S2:1918:3	O
risks	DUAVEE.xml:S2:1922:5	O
for	DUAVEE.xml:S2:1928:3	O
the	DUAVEE.xml:S2:1932:3	O
individual	DUAVEE.xml:S2:1936:10	O
woman	DUAVEE.xml:S2:1947:5	O
.	DUAVEE.xml:S2:1952:1	O

EXCERPT	DUAVEE.xml:S2:1962:7	O
:	DUAVEE.xml:S2:1969:1	O
WARNING	DUAVEE.xml:S2:1975:7	O
:	DUAVEE.xml:S2:1982:1	O
ENDOMETRIAL	DUAVEE.xml:S2:1984:11	B-AdverseReaction
CANCER	DUAVEE.xml:S2:1996:6	I-AdverseReaction
,	DUAVEE.xml:S2:2002:1	O
CARDIOVASCULAR	DUAVEE.xml:S2:2004:14	B-AdverseReaction
DISORDERS	DUAVEE.xml:S2:2019:9	I-AdverseReaction
,	DUAVEE.xml:S2:2028:1	O
AND	DUAVEE.xml:S2:2030:3	O
PROBABLE	DUAVEE.xml:S2:2034:8	B-Factor
DEMENTIA	DUAVEE.xml:S2:2043:8	B-AdverseReaction
\n\n\n\n	DUAVEE.xml:S2:2053:4	O
See	DUAVEE.xml:S2:2060:3	O
full	DUAVEE.xml:S2:2064:4	O
prescribing	DUAVEE.xml:S2:2069:11	O
information	DUAVEE.xml:S2:2081:11	O
for	DUAVEE.xml:S2:2093:3	O
complete	DUAVEE.xml:S2:2097:8	O
Boxed	DUAVEE.xml:S2:2106:5	O
Warning	DUAVEE.xml:S2:2112:7	O
.	DUAVEE.xml:S2:2119:1	O

Women	DUAVEE.xml:S2:2130:5	O
taking	DUAVEE.xml:S2:2136:6	O
DUAVEE	DUAVEE.xml:S2:2143:6	O
should	DUAVEE.xml:S2:2150:6	O
not	DUAVEE.xml:S2:2157:3	O
take	DUAVEE.xml:S2:2161:4	O
additional	DUAVEE.xml:S2:2166:10	O
estrogens	DUAVEE.xml:S2:2177:9	O
(	DUAVEE.xml:S2:2187:1	O
5.1	DUAVEE.xml:S2:2188:3	O
)	DUAVEE.xml:S2:2191:1	O
\n	DUAVEE.xml:S2:2193:1	O
There	DUAVEE.xml:S2:2198:5	O
is	DUAVEE.xml:S2:2204:2	O
an	DUAVEE.xml:S2:2207:2	O
increased	DUAVEE.xml:S2:2210:9	O
risk	DUAVEE.xml:S2:2220:4	O
of	DUAVEE.xml:S2:2225:2	O
endometrial	DUAVEE.xml:S2:2228:11	B-AdverseReaction
cancer	DUAVEE.xml:S2:2240:6	I-AdverseReaction
in	DUAVEE.xml:S2:2247:2	O
a	DUAVEE.xml:S2:2250:1	O
woman	DUAVEE.xml:S2:2252:5	O
with	DUAVEE.xml:S2:2258:4	O
a	DUAVEE.xml:S2:2263:1	O
uterus	DUAVEE.xml:S2:2265:6	O
who	DUAVEE.xml:S2:2272:3	O
uses	DUAVEE.xml:S2:2276:4	O
unopposed	DUAVEE.xml:S2:2281:9	O
estrogens	DUAVEE.xml:S2:2291:9	B-DrugClass
(	DUAVEE.xml:S2:2301:1	O
5.1	DUAVEE.xml:S2:2302:3	O
,	DUAVEE.xml:S2:2305:1	O
5.3	DUAVEE.xml:S2:2307:3	O
)	DUAVEE.xml:S2:2310:1	O
\n	DUAVEE.xml:S2:2312:1	O
Estrogen	DUAVEE.xml:S2:2317:8	O
therapy	DUAVEE.xml:S2:2326:7	O
should	DUAVEE.xml:S2:2334:6	O
not	DUAVEE.xml:S2:2341:3	O
be	DUAVEE.xml:S2:2345:2	O
used	DUAVEE.xml:S2:2348:4	O
for	DUAVEE.xml:S2:2353:3	O
the	DUAVEE.xml:S2:2357:3	O
prevention	DUAVEE.xml:S2:2361:10	O
of	DUAVEE.xml:S2:2372:2	O
cardiovascular	DUAVEE.xml:S2:2375:14	O
disease	DUAVEE.xml:S2:2390:7	O
or	DUAVEE.xml:S2:2398:2	O
dementia	DUAVEE.xml:S2:2401:8	O
(	DUAVEE.xml:S2:2410:1	O
5.2	DUAVEE.xml:S2:2411:3	O
,	DUAVEE.xml:S2:2414:1	O
5.4	DUAVEE.xml:S2:2416:3	O
)	DUAVEE.xml:S2:2419:1	O
\n	DUAVEE.xml:S2:2421:1	O
The	DUAVEE.xml:S2:2426:3	O
Women	DUAVEE.xml:S2:2430:5	O
's	DUAVEE.xml:S2:2435:2	O
Health	DUAVEE.xml:S2:2438:6	O
Initiative	DUAVEE.xml:S2:2445:10	O
(	DUAVEE.xml:S2:2456:1	O
WHI	DUAVEE.xml:S2:2457:3	O
)	DUAVEE.xml:S2:2460:1	O
estrogen	DUAVEE.xml:S2:2462:8	B-DrugClass
-	DUAVEE.xml:S2:2470:1	O
alone	DUAVEE.xml:S2:2471:5	O
substudy	DUAVEE.xml:S2:2477:8	O
reported	DUAVEE.xml:S2:2486:8	O
increased	DUAVEE.xml:S2:2495:9	O
risks	DUAVEE.xml:S2:2505:5	O
of	DUAVEE.xml:S2:2511:2	O
stroke	DUAVEE.xml:S2:2514:6	B-AdverseReaction
and	DUAVEE.xml:S2:2521:3	O
deep	DUAVEE.xml:S2:2525:4	B-AdverseReaction
vein	DUAVEE.xml:S2:2530:4	I-AdverseReaction
thrombosis	DUAVEE.xml:S2:2535:10	I-AdverseReaction
(	DUAVEE.xml:S2:2546:1	O
DVT	DUAVEE.xml:S2:2547:3	B-AdverseReaction
)	DUAVEE.xml:S2:2550:1	O
(	DUAVEE.xml:S2:2552:1	O
5.2	DUAVEE.xml:S2:2553:3	O
)	DUAVEE.xml:S2:2556:1	O
\n	DUAVEE.xml:S2:2558:1	O
The	DUAVEE.xml:S2:2563:3	O
WHI	DUAVEE.xml:S2:2567:3	O
Memory	DUAVEE.xml:S2:2571:6	O
Study	DUAVEE.xml:S2:2578:5	O
(	DUAVEE.xml:S2:2584:1	O
WHIMS	DUAVEE.xml:S2:2585:5	O
)	DUAVEE.xml:S2:2590:1	O
estrogen	DUAVEE.xml:S2:2592:8	B-DrugClass
-	DUAVEE.xml:S2:2600:1	O
alone	DUAVEE.xml:S2:2601:5	O
ancillary	DUAVEE.xml:S2:2607:9	O
study	DUAVEE.xml:S2:2617:5	O
of	DUAVEE.xml:S2:2623:2	O
WHI	DUAVEE.xml:S2:2626:3	O
reported	DUAVEE.xml:S2:2630:8	O
an	DUAVEE.xml:S2:2639:2	O
increased	DUAVEE.xml:S2:2642:9	O
risk	DUAVEE.xml:S2:2652:4	O
of	DUAVEE.xml:S2:2657:2	O
probable	DUAVEE.xml:S2:2660:8	O
dementia	DUAVEE.xml:S2:2669:8	B-AdverseReaction
in	DUAVEE.xml:S2:2678:2	O
postmenopausal	DUAVEE.xml:S2:2681:14	O
women	DUAVEE.xml:S2:2696:5	O
65	DUAVEE.xml:S2:2702:2	O
years	DUAVEE.xml:S2:2705:5	O
of	DUAVEE.xml:S2:2711:2	O
age	DUAVEE.xml:S2:2714:3	O
and	DUAVEE.xml:S2:2718:3	O
older	DUAVEE.xml:S2:2722:5	O
(	DUAVEE.xml:S2:2728:1	O
5.4	DUAVEE.xml:S2:2729:3	O
)	DUAVEE.xml:S2:2732:1	O
\n	DUAVEE.xml:S2:2734:1	O
\n	DUAVEE.xml:S2:2739:1	O
\n\n\n\n\n\n\n\n	DUAVEE.xml:S2:2741:8	O
BOXED	DUAVEE.xml:S2:2753:5	O
WARNING	DUAVEE.xml:S2:2759:7	O
:	DUAVEE.xml:S2:2766:1	O
\n\n	DUAVEE.xml:S2:2768:2	O
Patient	DUAVEE.xml:S2:2774:7	O
InformationDUAVEE	DUAVEE.xml:S2:2782:17	O
(	DUAVEE.xml:S2:2801:1	O
r	DUAVEE.xml:S2:2802:1	O
)	DUAVEE.xml:S2:2803:1	O
(	DUAVEE.xml:S2:2807:1	O
DEW	DUAVEE.xml:S2:2808:3	O
ah	DUAVEE.xml:S2:2813:2	O
-	DUAVEE.xml:S2:2815:1	O
vee	DUAVEE.xml:S2:2816:3	O
)(	DUAVEE.xml:S2:2819:2	O
conjugated	DUAVEE.xml:S2:2821:10	O
estrogens	DUAVEE.xml:S2:2832:9	O
bazedoxifene	DUAVEE.xml:S2:2842:12	O
)	DUAVEE.xml:S2:2854:1	O
Tablets	DUAVEE.xml:S2:2855:7	O
\n\n\n\n	DUAVEE.xml:S2:2864:4	O
Read	DUAVEE.xml:S2:2869:4	O
this	DUAVEE.xml:S2:2874:4	O
Patient	DUAVEE.xml:S2:2879:7	O
Information	DUAVEE.xml:S2:2887:11	O
before	DUAVEE.xml:S2:2899:6	O
you	DUAVEE.xml:S2:2906:3	O
start	DUAVEE.xml:S2:2910:5	O
taking	DUAVEE.xml:S2:2916:6	O
DUAVEE	DUAVEE.xml:S2:2923:6	O
and	DUAVEE.xml:S2:2930:3	O
each	DUAVEE.xml:S2:2934:4	O
time	DUAVEE.xml:S2:2939:4	O
you	DUAVEE.xml:S2:2944:3	O
get	DUAVEE.xml:S2:2948:3	O
a	DUAVEE.xml:S2:2952:1	O
refill	DUAVEE.xml:S2:2954:6	O
.	DUAVEE.xml:S2:2960:1	O

There	DUAVEE.xml:S2:2962:5	O
may	DUAVEE.xml:S2:2968:3	O
be	DUAVEE.xml:S2:2972:2	O
new	DUAVEE.xml:S2:2975:3	O
information	DUAVEE.xml:S2:2979:11	O
.	DUAVEE.xml:S2:2990:1	O

This	DUAVEE.xml:S2:2992:4	O
information	DUAVEE.xml:S2:2997:11	O
does	DUAVEE.xml:S2:3009:4	O
not	DUAVEE.xml:S2:3014:3	O
take	DUAVEE.xml:S2:3018:4	O
the	DUAVEE.xml:S2:3023:3	O
place	DUAVEE.xml:S2:3027:5	O
of	DUAVEE.xml:S2:3033:2	O
talking	DUAVEE.xml:S2:3036:7	O
to	DUAVEE.xml:S2:3044:2	O
your	DUAVEE.xml:S2:3047:4	O
healthcare	DUAVEE.xml:S2:3052:10	O
provider	DUAVEE.xml:S2:3063:8	O
about	DUAVEE.xml:S2:3072:5	O
your	DUAVEE.xml:S2:3078:4	O
medical	DUAVEE.xml:S2:3083:7	O
condition	DUAVEE.xml:S2:3091:9	O
or	DUAVEE.xml:S2:3101:2	O
your	DUAVEE.xml:S2:3104:4	O
treatment	DUAVEE.xml:S2:3109:9	O
.	DUAVEE.xml:S2:3118:1	O

What	DUAVEE.xml:S2:3128:4	O
is	DUAVEE.xml:S2:3133:2	O
the	DUAVEE.xml:S2:3136:3	O
most	DUAVEE.xml:S2:3140:4	O
important	DUAVEE.xml:S2:3145:9	O
information	DUAVEE.xml:S2:3155:11	O
I	DUAVEE.xml:S2:3167:1	O
should	DUAVEE.xml:S2:3169:6	O
know	DUAVEE.xml:S2:3176:4	O
about	DUAVEE.xml:S2:3181:5	O
DUAVEE	DUAVEE.xml:S2:3187:6	O
?	DUAVEE.xml:S2:3193:1	O

Do	DUAVEE.xml:S2:3204:2	O
not	DUAVEE.xml:S2:3207:3	O
take	DUAVEE.xml:S2:3211:4	O
additional	DUAVEE.xml:S2:3216:10	O
estrogen	DUAVEE.xml:S2:3227:8	O
products	DUAVEE.xml:S2:3236:8	O
while	DUAVEE.xml:S2:3245:5	O
you	DUAVEE.xml:S2:3251:3	O
are	DUAVEE.xml:S2:3255:3	O
taking	DUAVEE.xml:S2:3259:6	O
DUAVEE	DUAVEE.xml:S2:3266:6	O
.	DUAVEE.xml:S2:3272:1	O

Using	DUAVEE.xml:S2:3279:5	O
estrogens	DUAVEE.xml:S2:3285:9	O
may	DUAVEE.xml:S2:3295:3	O
increase	DUAVEE.xml:S2:3299:8	O
your	DUAVEE.xml:S2:3308:4	O
chance	DUAVEE.xml:S2:3313:6	O
of	DUAVEE.xml:S2:3320:2	O
getting	DUAVEE.xml:S2:3323:7	O
cancer	DUAVEE.xml:S2:3331:6	O
of	DUAVEE.xml:S2:3338:2	O
the	DUAVEE.xml:S2:3341:3	O
uterus	DUAVEE.xml:S2:3345:6	O
(	DUAVEE.xml:S2:3352:1	O
womb	DUAVEE.xml:S2:3353:4	O
)	DUAVEE.xml:S2:3357:1	O
.	DUAVEE.xml:S2:3358:1	O

Report	DUAVEE.xml:S2:3365:6	O
any	DUAVEE.xml:S2:3372:3	O
unusual	DUAVEE.xml:S2:3376:7	O
vaginal	DUAVEE.xml:S2:3384:7	O
bleeding	DUAVEE.xml:S2:3392:8	O
right	DUAVEE.xml:S2:3401:5	O
away	DUAVEE.xml:S2:3407:4	O
while	DUAVEE.xml:S2:3412:5	O
you	DUAVEE.xml:S2:3418:3	O
are	DUAVEE.xml:S2:3422:3	O
taking	DUAVEE.xml:S2:3426:6	O
DUAVEE	DUAVEE.xml:S2:3433:6	O
.	DUAVEE.xml:S2:3439:1	O

Vaginal	DUAVEE.xml:S2:3441:7	O
bleeding	DUAVEE.xml:S2:3449:8	O
after	DUAVEE.xml:S2:3458:5	O
menopause	DUAVEE.xml:S2:3464:9	O
may	DUAVEE.xml:S2:3474:3	O
be	DUAVEE.xml:S2:3478:2	O
a	DUAVEE.xml:S2:3481:1	O
warning	DUAVEE.xml:S2:3483:7	O
sign	DUAVEE.xml:S2:3491:4	O
of	DUAVEE.xml:S2:3496:2	O
cancer	DUAVEE.xml:S2:3499:6	O
of	DUAVEE.xml:S2:3506:2	O
the	DUAVEE.xml:S2:3509:3	O
uterus	DUAVEE.xml:S2:3513:6	O
(	DUAVEE.xml:S2:3520:1	O
womb	DUAVEE.xml:S2:3521:4	O
)	DUAVEE.xml:S2:3525:1	O
.	DUAVEE.xml:S2:3526:1	O

Your	DUAVEE.xml:S2:3528:4	O
healthcare	DUAVEE.xml:S2:3533:10	O
provider	DUAVEE.xml:S2:3544:8	O
should	DUAVEE.xml:S2:3553:6	O
check	DUAVEE.xml:S2:3560:5	O
any	DUAVEE.xml:S2:3566:3	O
unusual	DUAVEE.xml:S2:3570:7	O
vaginal	DUAVEE.xml:S2:3578:7	O
bleeding	DUAVEE.xml:S2:3586:8	O
to	DUAVEE.xml:S2:3595:2	O
find	DUAVEE.xml:S2:3598:4	O
out	DUAVEE.xml:S2:3603:3	O
the	DUAVEE.xml:S2:3607:3	O
cause	DUAVEE.xml:S2:3611:5	O
.	DUAVEE.xml:S2:3616:1	O

Do	DUAVEE.xml:S2:3623:2	O
not	DUAVEE.xml:S2:3626:3	O
use	DUAVEE.xml:S2:3630:3	O
estrogens	DUAVEE.xml:S2:3634:9	O
to	DUAVEE.xml:S2:3644:2	O
prevent	DUAVEE.xml:S2:3647:7	O
heart	DUAVEE.xml:S2:3655:5	O
disease	DUAVEE.xml:S2:3661:7	O
,	DUAVEE.xml:S2:3668:1	O
heart	DUAVEE.xml:S2:3670:5	O
attacks	DUAVEE.xml:S2:3676:7	O
,	DUAVEE.xml:S2:3683:1	O
strokes	DUAVEE.xml:S2:3685:7	O
or	DUAVEE.xml:S2:3693:2	O
dementia	DUAVEE.xml:S2:3696:8	O
(	DUAVEE.xml:S2:3705:1	O
decline	DUAVEE.xml:S2:3706:7	O
in	DUAVEE.xml:S2:3714:2	O
brain	DUAVEE.xml:S2:3717:5	O
function	DUAVEE.xml:S2:3723:8	O
)	DUAVEE.xml:S2:3731:1	O
.	DUAVEE.xml:S2:3732:1	O

Using	DUAVEE.xml:S2:3739:5	O
estrogens	DUAVEE.xml:S2:3745:9	O
may	DUAVEE.xml:S2:3755:3	O
increase	DUAVEE.xml:S2:3759:8	O
your	DUAVEE.xml:S2:3768:4	O
chances	DUAVEE.xml:S2:3773:7	O
of	DUAVEE.xml:S2:3781:2	O
getting	DUAVEE.xml:S2:3784:7	O
strokes	DUAVEE.xml:S2:3792:7	O
or	DUAVEE.xml:S2:3800:2	O
blood	DUAVEE.xml:S2:3803:5	O
clots	DUAVEE.xml:S2:3809:5	O
.	DUAVEE.xml:S2:3814:1	O

Using	DUAVEE.xml:S2:3821:5	O
estrogens	DUAVEE.xml:S2:3827:9	O
may	DUAVEE.xml:S2:3837:3	O
increase	DUAVEE.xml:S2:3841:8	O
your	DUAVEE.xml:S2:3850:4	O
chance	DUAVEE.xml:S2:3855:6	O
of	DUAVEE.xml:S2:3862:2	O
getting	DUAVEE.xml:S2:3865:7	O
dementia	DUAVEE.xml:S2:3873:8	O
,	DUAVEE.xml:S2:3881:1	O
based	DUAVEE.xml:S2:3883:5	O
on	DUAVEE.xml:S2:3889:2	O
a	DUAVEE.xml:S2:3892:1	O
study	DUAVEE.xml:S2:3894:5	O
of	DUAVEE.xml:S2:3900:2	O
women	DUAVEE.xml:S2:3903:5	O
65	DUAVEE.xml:S2:3909:2	O
years	DUAVEE.xml:S2:3912:5	O
of	DUAVEE.xml:S2:3918:2	O
age	DUAVEE.xml:S2:3921:3	O
or	DUAVEE.xml:S2:3925:2	O
older	DUAVEE.xml:S2:3928:5	O
.	DUAVEE.xml:S2:3933:1	O

You	DUAVEE.xml:S2:3940:3	O
and	DUAVEE.xml:S2:3944:3	O
your	DUAVEE.xml:S2:3948:4	O
healthcare	DUAVEE.xml:S2:3953:10	O
provider	DUAVEE.xml:S2:3964:8	O
should	DUAVEE.xml:S2:3973:6	O
talk	DUAVEE.xml:S2:3980:4	O
regularly	DUAVEE.xml:S2:3985:9	O
about	DUAVEE.xml:S2:3995:5	O
whether	DUAVEE.xml:S2:4001:7	O
you	DUAVEE.xml:S2:4009:3	O
still	DUAVEE.xml:S2:4013:5	O
need	DUAVEE.xml:S2:4019:4	O
treatment	DUAVEE.xml:S2:4024:9	O
with	DUAVEE.xml:S2:4034:4	O
DUAVEE	DUAVEE.xml:S2:4039:6	O
.	DUAVEE.xml:S2:4045:1	O

What	DUAVEE.xml:S2:4056:4	O
is	DUAVEE.xml:S2:4061:2	O
DUAVEE	DUAVEE.xml:S2:4064:6	O
?	DUAVEE.xml:S2:4070:1	O

DUAVEE	DUAVEE.xml:S2:4078:6	O
is	DUAVEE.xml:S2:4085:2	O
a	DUAVEE.xml:S2:4088:1	O
prescription	DUAVEE.xml:S2:4090:12	O
medicine	DUAVEE.xml:S2:4103:8	O
that	DUAVEE.xml:S2:4112:4	O
contains	DUAVEE.xml:S2:4117:8	O
a	DUAVEE.xml:S2:4126:1	O
mixture	DUAVEE.xml:S2:4128:7	O
of	DUAVEE.xml:S2:4136:2	O
estrogens	DUAVEE.xml:S2:4139:9	O
and	DUAVEE.xml:S2:4149:3	O
bazedoxifene	DUAVEE.xml:S2:4153:12	O
.	DUAVEE.xml:S2:4165:1	O

What	DUAVEE.xml:S2:4173:4	O
is	DUAVEE.xml:S2:4178:2	O
DUAVEE	DUAVEE.xml:S2:4181:6	O
used	DUAVEE.xml:S2:4188:4	O
for	DUAVEE.xml:S2:4193:3	O
?	DUAVEE.xml:S2:4196:1	O

DUAVEE	DUAVEE.xml:S2:4204:6	O
is	DUAVEE.xml:S2:4211:2	O
used	DUAVEE.xml:S2:4214:4	O
after	DUAVEE.xml:S2:4219:5	O
menopause	DUAVEE.xml:S2:4225:9	O
for	DUAVEE.xml:S2:4235:3	O
women	DUAVEE.xml:S2:4239:5	O
with	DUAVEE.xml:S2:4245:4	O
a	DUAVEE.xml:S2:4250:1	O
uterus	DUAVEE.xml:S2:4252:6	O
to	DUAVEE.xml:S2:4259:2	O
:	DUAVEE.xml:S2:4261:1	O
\n\n\n\n	DUAVEE.xml:S2:4262:4	O
reduce	DUAVEE.xml:S2:4270:6	O
moderate	DUAVEE.xml:S2:4277:8	O
to	DUAVEE.xml:S2:4286:2	O
severe	DUAVEE.xml:S2:4289:6	O
hot	DUAVEE.xml:S2:4296:3	O
flushesEstrogens	DUAVEE.xml:S2:4300:16	O
are	DUAVEE.xml:S2:4317:3	O
hormones	DUAVEE.xml:S2:4321:8	O
made	DUAVEE.xml:S2:4330:4	O
by	DUAVEE.xml:S2:4335:2	O
a	DUAVEE.xml:S2:4338:1	O
woman	DUAVEE.xml:S2:4340:5	O
's	DUAVEE.xml:S2:4345:2	O
ovaries	DUAVEE.xml:S2:4348:7	O
.	DUAVEE.xml:S2:4355:1	O

The	DUAVEE.xml:S2:4357:3	O
ovaries	DUAVEE.xml:S2:4361:7	O
normally	DUAVEE.xml:S2:4369:8	O
stop	DUAVEE.xml:S2:4378:4	O
making	DUAVEE.xml:S2:4383:6	O
estrogens	DUAVEE.xml:S2:4390:9	O
when	DUAVEE.xml:S2:4400:4	O
a	DUAVEE.xml:S2:4405:1	O
woman	DUAVEE.xml:S2:4407:5	O
is	DUAVEE.xml:S2:4413:2	O
between	DUAVEE.xml:S2:4416:7	O
45	DUAVEE.xml:S2:4424:2	O
and	DUAVEE.xml:S2:4427:3	O
55	DUAVEE.xml:S2:4431:2	O
years	DUAVEE.xml:S2:4434:5	O
old	DUAVEE.xml:S2:4440:3	O
.	DUAVEE.xml:S2:4443:1	O

This	DUAVEE.xml:S2:4445:4	O
drop	DUAVEE.xml:S2:4450:4	O
in	DUAVEE.xml:S2:4455:2	O
body	DUAVEE.xml:S2:4458:4	O
estrogen	DUAVEE.xml:S2:4463:8	O
levels	DUAVEE.xml:S2:4472:6	O
causes	DUAVEE.xml:S2:4479:6	O
the	DUAVEE.xml:S2:4486:3	O
"	DUAVEE.xml:S2:4490:1	O
change	DUAVEE.xml:S2:4491:6	O
of	DUAVEE.xml:S2:4498:2	O
life	DUAVEE.xml:S2:4501:4	O
"	DUAVEE.xml:S2:4505:1	O
or	DUAVEE.xml:S2:4507:2	O
menopause	DUAVEE.xml:S2:4510:9	O
(	DUAVEE.xml:S2:4520:1	O
the	DUAVEE.xml:S2:4521:3	O
end	DUAVEE.xml:S2:4525:3	O
of	DUAVEE.xml:S2:4529:2	O
monthly	DUAVEE.xml:S2:4532:7	O
menstrual	DUAVEE.xml:S2:4540:9	O
periods	DUAVEE.xml:S2:4550:7	O
)	DUAVEE.xml:S2:4557:1	O
.	DUAVEE.xml:S2:4558:1	O

Sometimes	DUAVEE.xml:S2:4560:9	O
both	DUAVEE.xml:S2:4570:4	O
ovaries	DUAVEE.xml:S2:4575:7	O
are	DUAVEE.xml:S2:4583:3	O
removed	DUAVEE.xml:S2:4587:7	O
during	DUAVEE.xml:S2:4595:6	O
an	DUAVEE.xml:S2:4602:2	O
operation	DUAVEE.xml:S2:4605:9	O
before	DUAVEE.xml:S2:4615:6	O
natural	DUAVEE.xml:S2:4622:7	O
menopause	DUAVEE.xml:S2:4630:9	O
takes	DUAVEE.xml:S2:4640:5	O
place	DUAVEE.xml:S2:4646:5	O
.	DUAVEE.xml:S2:4651:1	O

The	DUAVEE.xml:S2:4653:3	O
sudden	DUAVEE.xml:S2:4657:6	O
drop	DUAVEE.xml:S2:4664:4	O
in	DUAVEE.xml:S2:4669:2	O
estrogen	DUAVEE.xml:S2:4672:8	O
levels	DUAVEE.xml:S2:4681:6	O
causes	DUAVEE.xml:S2:4688:6	O
"	DUAVEE.xml:S2:4695:1	O
surgical	DUAVEE.xml:S2:4696:8	O
menopause	DUAVEE.xml:S2:4705:9	O
.	DUAVEE.xml:S2:4714:1	O

"	DUAVEE.xml:S2:4715:1	O
When	DUAVEE.xml:S2:4716:4	O
the	DUAVEE.xml:S2:4721:3	O
estrogen	DUAVEE.xml:S2:4725:8	O
levels	DUAVEE.xml:S2:4734:6	O
begin	DUAVEE.xml:S2:4741:5	O
dropping	DUAVEE.xml:S2:4747:8	O
,	DUAVEE.xml:S2:4755:1	O
some	DUAVEE.xml:S2:4757:4	O
women	DUAVEE.xml:S2:4762:5	O
get	DUAVEE.xml:S2:4768:3	O
very	DUAVEE.xml:S2:4772:4	O
uncomfortable	DUAVEE.xml:S2:4777:13	O
symptoms	DUAVEE.xml:S2:4791:8	O
,	DUAVEE.xml:S2:4799:1	O
such	DUAVEE.xml:S2:4801:4	O
as	DUAVEE.xml:S2:4806:2	O
feelings	DUAVEE.xml:S2:4809:8	O
of	DUAVEE.xml:S2:4818:2	O
warmth	DUAVEE.xml:S2:4821:6	O
in	DUAVEE.xml:S2:4828:2	O
the	DUAVEE.xml:S2:4831:3	O
face	DUAVEE.xml:S2:4835:4	O
,	DUAVEE.xml:S2:4839:1	O
neck	DUAVEE.xml:S2:4841:4	O
,	DUAVEE.xml:S2:4845:1	O
and	DUAVEE.xml:S2:4847:3	O
chest	DUAVEE.xml:S2:4851:5	O
,	DUAVEE.xml:S2:4856:1	O
or	DUAVEE.xml:S2:4858:2	O
sudden	DUAVEE.xml:S2:4861:6	O
intense	DUAVEE.xml:S2:4868:7	O
episodes	DUAVEE.xml:S2:4876:8	O
of	DUAVEE.xml:S2:4885:2	O
heat	DUAVEE.xml:S2:4888:4	O
and	DUAVEE.xml:S2:4893:3	O
sweating	DUAVEE.xml:S2:4897:8	O
(	DUAVEE.xml:S2:4906:1	O
"	DUAVEE.xml:S2:4907:1	O
hot	DUAVEE.xml:S2:4908:3	O
flashes	DUAVEE.xml:S2:4912:7	O
"	DUAVEE.xml:S2:4919:1	O
or	DUAVEE.xml:S2:4921:2	O
"	DUAVEE.xml:S2:4924:1	O
hot	DUAVEE.xml:S2:4925:3	O
flushes	DUAVEE.xml:S2:4929:7	O
"	DUAVEE.xml:S2:4936:1	O
)	DUAVEE.xml:S2:4937:1	O
.	DUAVEE.xml:S2:4938:1	O

In	DUAVEE.xml:S2:4940:2	O
some	DUAVEE.xml:S2:4943:4	O
women	DUAVEE.xml:S2:4948:5	O
,	DUAVEE.xml:S2:4953:1	O
the	DUAVEE.xml:S2:4955:3	O
symptoms	DUAVEE.xml:S2:4959:8	O
are	DUAVEE.xml:S2:4968:3	O
mild	DUAVEE.xml:S2:4972:4	O
,	DUAVEE.xml:S2:4976:1	O
and	DUAVEE.xml:S2:4978:3	O
they	DUAVEE.xml:S2:4982:4	O
will	DUAVEE.xml:S2:4987:4	O
not	DUAVEE.xml:S2:4992:3	O
need	DUAVEE.xml:S2:4996:4	O
to	DUAVEE.xml:S2:5001:2	O
take	DUAVEE.xml:S2:5004:4	O
medicines	DUAVEE.xml:S2:5009:9	O
.	DUAVEE.xml:S2:5018:1	O

In	DUAVEE.xml:S2:5020:2	O
other	DUAVEE.xml:S2:5023:5	O
women	DUAVEE.xml:S2:5029:5	O
,	DUAVEE.xml:S2:5034:1	O
symptoms	DUAVEE.xml:S2:5036:8	O
can	DUAVEE.xml:S2:5045:3	O
be	DUAVEE.xml:S2:5049:2	O
more	DUAVEE.xml:S2:5052:4	O
severe	DUAVEE.xml:S2:5057:6	O
.	DUAVEE.xml:S2:5063:1	O

help	DUAVEE.xml:S2:5070:4	O
reduce	DUAVEE.xml:S2:5075:6	O
your	DUAVEE.xml:S2:5082:4	O
chances	DUAVEE.xml:S2:5087:7	O
of	DUAVEE.xml:S2:5095:2	O
developing	DUAVEE.xml:S2:5098:10	O
osteoporosis	DUAVEE.xml:S2:5109:12	O
(	DUAVEE.xml:S2:5122:1	O
thin	DUAVEE.xml:S2:5123:4	O
,	DUAVEE.xml:S2:5127:1	O
weak	DUAVEE.xml:S2:5129:4	O
bones	DUAVEE.xml:S2:5134:5	O
)	DUAVEE.xml:S2:5139:1	O
If	DUAVEE.xml:S2:5140:2	O
you	DUAVEE.xml:S2:5143:3	O
use	DUAVEE.xml:S2:5147:3	O
DUAVEE	DUAVEE.xml:S2:5151:6	O
only	DUAVEE.xml:S2:5158:4	O
to	DUAVEE.xml:S2:5163:2	O
prevent	DUAVEE.xml:S2:5166:7	O
osteoporosis	DUAVEE.xml:S2:5174:12	O
due	DUAVEE.xml:S2:5187:3	O
to	DUAVEE.xml:S2:5191:2	O
menopause	DUAVEE.xml:S2:5194:9	O
,	DUAVEE.xml:S2:5203:1	O
talk	DUAVEE.xml:S2:5205:4	O
with	DUAVEE.xml:S2:5210:4	O
your	DUAVEE.xml:S2:5215:4	O
healthcare	DUAVEE.xml:S2:5220:10	O
provider	DUAVEE.xml:S2:5231:8	O
about	DUAVEE.xml:S2:5240:5	O
whether	DUAVEE.xml:S2:5246:7	O
a	DUAVEE.xml:S2:5254:1	O
different	DUAVEE.xml:S2:5256:9	O
treatment	DUAVEE.xml:S2:5266:9	O
or	DUAVEE.xml:S2:5276:2	O
medicine	DUAVEE.xml:S2:5279:8	O
without	DUAVEE.xml:S2:5288:7	O
estrogens	DUAVEE.xml:S2:5296:9	O
might	DUAVEE.xml:S2:5306:5	O
be	DUAVEE.xml:S2:5312:2	O
better	DUAVEE.xml:S2:5315:6	O
for	DUAVEE.xml:S2:5322:3	O
you	DUAVEE.xml:S2:5326:3	O
.	DUAVEE.xml:S2:5329:1	O
DUAVEE	DUAVEE.xml:S2:5330:6	O
should	DUAVEE.xml:S2:5337:6	O
be	DUAVEE.xml:S2:5344:2	O
taken	DUAVEE.xml:S2:5347:5	O
for	DUAVEE.xml:S2:5353:3	O
the	DUAVEE.xml:S2:5357:3	O
shortest	DUAVEE.xml:S2:5361:8	O
time	DUAVEE.xml:S2:5370:4	O
possible	DUAVEE.xml:S2:5375:8	O
and	DUAVEE.xml:S2:5384:3	O
only	DUAVEE.xml:S2:5388:4	O
for	DUAVEE.xml:S2:5393:3	O
as	DUAVEE.xml:S2:5397:2	O
long	DUAVEE.xml:S2:5400:4	O
as	DUAVEE.xml:S2:5405:2	O
treatment	DUAVEE.xml:S2:5408:9	O
is	DUAVEE.xml:S2:5418:2	O
needed	DUAVEE.xml:S2:5421:6	O
.	DUAVEE.xml:S2:5427:1	O

You	DUAVEE.xml:S2:5434:3	O
and	DUAVEE.xml:S2:5438:3	O
your	DUAVEE.xml:S2:5442:4	O
healthcare	DUAVEE.xml:S2:5447:10	O
provider	DUAVEE.xml:S2:5458:8	O
should	DUAVEE.xml:S2:5467:6	O
talk	DUAVEE.xml:S2:5474:4	O
regularly	DUAVEE.xml:S2:5479:9	O
about	DUAVEE.xml:S2:5489:5	O
whether	DUAVEE.xml:S2:5495:7	O
you	DUAVEE.xml:S2:5503:3	O
still	DUAVEE.xml:S2:5507:5	O
need	DUAVEE.xml:S2:5513:4	O
treatment	DUAVEE.xml:S2:5518:9	O
with	DUAVEE.xml:S2:5528:4	O
DUAVEE	DUAVEE.xml:S2:5533:6	O
.	DUAVEE.xml:S2:5539:1	O

DUAVEE	DUAVEE.xml:S2:5545:6	O
is	DUAVEE.xml:S2:5552:2	O
not	DUAVEE.xml:S2:5555:3	O
for	DUAVEE.xml:S2:5559:3	O
use	DUAVEE.xml:S2:5563:3	O
in	DUAVEE.xml:S2:5567:2	O
children	DUAVEE.xml:S2:5570:8	O
.	DUAVEE.xml:S2:5578:1	O

It	DUAVEE.xml:S2:5584:2	O
is	DUAVEE.xml:S2:5587:2	O
not	DUAVEE.xml:S2:5590:3	O
known	DUAVEE.xml:S2:5594:5	O
if	DUAVEE.xml:S2:5600:2	O
DUAVEE	DUAVEE.xml:S2:5603:6	O
is	DUAVEE.xml:S2:5610:2	O
safe	DUAVEE.xml:S2:5613:4	O
and	DUAVEE.xml:S2:5618:3	O
effective	DUAVEE.xml:S2:5622:9	O
in	DUAVEE.xml:S2:5632:2	O
people	DUAVEE.xml:S2:5635:6	O
with	DUAVEE.xml:S2:5642:4	O
kidney	DUAVEE.xml:S2:5647:6	O
problems	DUAVEE.xml:S2:5654:8	O
.	DUAVEE.xml:S2:5662:1	O

Who	DUAVEE.xml:S2:5670:3	O
should	DUAVEE.xml:S2:5674:6	O
not	DUAVEE.xml:S2:5681:3	O
take	DUAVEE.xml:S2:5685:4	O
DUAVEE	DUAVEE.xml:S2:5690:6	O
?	DUAVEE.xml:S2:5696:1	O

Do	DUAVEE.xml:S2:5706:2	O
not	DUAVEE.xml:S2:5709:3	O
take	DUAVEE.xml:S2:5713:4	O
DUAVEE	DUAVEE.xml:S2:5718:6	O
if	DUAVEE.xml:S2:5725:2	O
you	DUAVEE.xml:S2:5728:3	O
:	DUAVEE.xml:S2:5731:1	O
\n\n\n\n	DUAVEE.xml:S2:5734:4	O
currently	DUAVEE.xml:S2:5742:9	O
have	DUAVEE.xml:S2:5752:4	O
or	DUAVEE.xml:S2:5757:2	O
have	DUAVEE.xml:S2:5760:4	O
had	DUAVEE.xml:S2:5765:3	O
blood	DUAVEE.xml:S2:5769:5	O
clots	DUAVEE.xml:S2:5775:5	O
\n	DUAVEE.xml:S2:5781:1	O
are	DUAVEE.xml:S2:5786:3	O
allergic	DUAVEE.xml:S2:5790:8	O
to	DUAVEE.xml:S2:5799:2	O
estrogens	DUAVEE.xml:S2:5802:9	O
or	DUAVEE.xml:S2:5812:2	O
bazedoxifene	DUAVEE.xml:S2:5815:12	O
,	DUAVEE.xml:S2:5827:1	O
the	DUAVEE.xml:S2:5829:3	O
active	DUAVEE.xml:S2:5833:6	O
ingredients	DUAVEE.xml:S2:5840:11	O
in	DUAVEE.xml:S2:5852:2	O
DUAVEE	DUAVEE.xml:S2:5855:6	O
,	DUAVEE.xml:S2:5861:1	O
or	DUAVEE.xml:S2:5863:2	O
any	DUAVEE.xml:S2:5866:3	O
of	DUAVEE.xml:S2:5870:2	O
its	DUAVEE.xml:S2:5873:3	O
ingredients	DUAVEE.xml:S2:5877:11	O
.	DUAVEE.xml:S2:5888:1	O

See	DUAVEE.xml:S2:5890:3	O
the	DUAVEE.xml:S2:5894:3	O
list	DUAVEE.xml:S2:5898:4	O
of	DUAVEE.xml:S2:5903:2	O
ingredients	DUAVEE.xml:S2:5906:11	O
in	DUAVEE.xml:S2:5918:2	O
DUAVEE	DUAVEE.xml:S2:5921:6	O
at	DUAVEE.xml:S2:5928:2	O
the	DUAVEE.xml:S2:5931:3	O
end	DUAVEE.xml:S2:5935:3	O
of	DUAVEE.xml:S2:5939:2	O
this	DUAVEE.xml:S2:5942:4	O
leaflet	DUAVEE.xml:S2:5947:7	O
.	DUAVEE.xml:S2:5954:1	O

have	DUAVEE.xml:S2:5961:4	O
unusual	DUAVEE.xml:S2:5966:7	O
vaginal	DUAVEE.xml:S2:5974:7	O
bleeding	DUAVEE.xml:S2:5982:8	O
.	DUAVEE.xml:S2:5990:1	O

Vaginal	DUAVEE.xml:S2:5992:7	O
bleeding	DUAVEE.xml:S2:6000:8	O
after	DUAVEE.xml:S2:6009:5	O
menopause	DUAVEE.xml:S2:6015:9	O
may	DUAVEE.xml:S2:6025:3	O
be	DUAVEE.xml:S2:6029:2	O
a	DUAVEE.xml:S2:6032:1	O
warning	DUAVEE.xml:S2:6034:7	O
sign	DUAVEE.xml:S2:6042:4	O
of	DUAVEE.xml:S2:6047:2	O
cancer	DUAVEE.xml:S2:6050:6	O
of	DUAVEE.xml:S2:6057:2	O
the	DUAVEE.xml:S2:6060:3	O
uterus	DUAVEE.xml:S2:6064:6	O
(	DUAVEE.xml:S2:6071:1	O
womb	DUAVEE.xml:S2:6072:4	O
)	DUAVEE.xml:S2:6076:1	O
.	DUAVEE.xml:S2:6077:1	O

Your	DUAVEE.xml:S2:6079:4	O
healthcare	DUAVEE.xml:S2:6084:10	O
provider	DUAVEE.xml:S2:6095:8	O
should	DUAVEE.xml:S2:6104:6	O
check	DUAVEE.xml:S2:6111:5	O
any	DUAVEE.xml:S2:6117:3	O
unusual	DUAVEE.xml:S2:6121:7	O
vaginal	DUAVEE.xml:S2:6129:7	O
bleeding	DUAVEE.xml:S2:6137:8	O
to	DUAVEE.xml:S2:6146:2	O
find	DUAVEE.xml:S2:6149:4	O
out	DUAVEE.xml:S2:6154:3	O
the	DUAVEE.xml:S2:6158:3	O
cause	DUAVEE.xml:S2:6162:5	O
.	DUAVEE.xml:S2:6167:1	O

currently	DUAVEE.xml:S2:6174:9	O
have	DUAVEE.xml:S2:6184:4	O
or	DUAVEE.xml:S2:6189:2	O
have	DUAVEE.xml:S2:6192:4	O
had	DUAVEE.xml:S2:6197:3	O
certain	DUAVEE.xml:S2:6201:7	O
cancers	DUAVEE.xml:S2:6209:7	O
.	DUAVEE.xml:S2:6216:1	O

Estrogens	DUAVEE.xml:S2:6218:9	O
may	DUAVEE.xml:S2:6228:3	O
increase	DUAVEE.xml:S2:6232:8	O
the	DUAVEE.xml:S2:6241:3	O
chances	DUAVEE.xml:S2:6245:7	O
of	DUAVEE.xml:S2:6253:2	O
getting	DUAVEE.xml:S2:6256:7	O
certain	DUAVEE.xml:S2:6264:7	O
types	DUAVEE.xml:S2:6272:5	O
of	DUAVEE.xml:S2:6278:2	O
cancers	DUAVEE.xml:S2:6281:7	O
,	DUAVEE.xml:S2:6288:1	O
including	DUAVEE.xml:S2:6290:9	O
cancer	DUAVEE.xml:S2:6300:6	O
of	DUAVEE.xml:S2:6307:2	O
the	DUAVEE.xml:S2:6310:3	O
breast	DUAVEE.xml:S2:6314:6	O
or	DUAVEE.xml:S2:6321:2	O
uterus	DUAVEE.xml:S2:6324:6	O
.	DUAVEE.xml:S2:6330:1	O

If	DUAVEE.xml:S2:6332:2	O
you	DUAVEE.xml:S2:6335:3	O
have	DUAVEE.xml:S2:6339:4	O
or	DUAVEE.xml:S2:6344:2	O
have	DUAVEE.xml:S2:6347:4	O
had	DUAVEE.xml:S2:6352:3	O
cancer	DUAVEE.xml:S2:6356:6	O
,	DUAVEE.xml:S2:6362:1	O
talk	DUAVEE.xml:S2:6364:4	O
with	DUAVEE.xml:S2:6369:4	O
your	DUAVEE.xml:S2:6374:4	O
healthcare	DUAVEE.xml:S2:6379:10	O
provider	DUAVEE.xml:S2:6390:8	O
about	DUAVEE.xml:S2:6399:5	O
whether	DUAVEE.xml:S2:6405:7	O
you	DUAVEE.xml:S2:6413:3	O
should	DUAVEE.xml:S2:6417:6	O
use	DUAVEE.xml:S2:6424:3	O
DUAVEE	DUAVEE.xml:S2:6428:6	O
.	DUAVEE.xml:S2:6434:1	O

currently	DUAVEE.xml:S2:6441:9	O
have	DUAVEE.xml:S2:6451:4	O
or	DUAVEE.xml:S2:6456:2	O
have	DUAVEE.xml:S2:6459:4	O
had	DUAVEE.xml:S2:6464:3	O
liver	DUAVEE.xml:S2:6468:5	O
problems	DUAVEE.xml:S2:6474:8	O
\n	DUAVEE.xml:S2:6483:1	O
have	DUAVEE.xml:S2:6488:4	O
been	DUAVEE.xml:S2:6493:4	O
diagnosed	DUAVEE.xml:S2:6498:9	O
with	DUAVEE.xml:S2:6508:4	O
a	DUAVEE.xml:S2:6513:1	O
bleeding	DUAVEE.xml:S2:6515:8	O
disorder	DUAVEE.xml:S2:6524:8	O
\n	DUAVEE.xml:S2:6533:1	O
think	DUAVEE.xml:S2:6538:5	O
you	DUAVEE.xml:S2:6544:3	O
may	DUAVEE.xml:S2:6548:3	O
be	DUAVEE.xml:S2:6552:2	O
pregnant	DUAVEE.xml:S2:6555:8	O
.	DUAVEE.xml:S2:6563:1	O

DUAVEE	DUAVEE.xml:S2:6565:6	O
is	DUAVEE.xml:S2:6572:2	O
not	DUAVEE.xml:S2:6575:3	O
for	DUAVEE.xml:S2:6579:3	O
pregnant	DUAVEE.xml:S2:6583:8	O
women	DUAVEE.xml:S2:6592:5	O
.	DUAVEE.xml:S2:6597:1	O

If	DUAVEE.xml:S2:6599:2	O
you	DUAVEE.xml:S2:6602:3	O
think	DUAVEE.xml:S2:6606:5	O
you	DUAVEE.xml:S2:6612:3	O
may	DUAVEE.xml:S2:6616:3	O
be	DUAVEE.xml:S2:6620:2	O
pregnant	DUAVEE.xml:S2:6623:8	O
,	DUAVEE.xml:S2:6631:1	O
you	DUAVEE.xml:S2:6633:3	O
should	DUAVEE.xml:S2:6637:6	O
have	DUAVEE.xml:S2:6644:4	O
a	DUAVEE.xml:S2:6649:1	O
pregnancy	DUAVEE.xml:S2:6651:9	O
test	DUAVEE.xml:S2:6661:4	O
and	DUAVEE.xml:S2:6666:3	O
know	DUAVEE.xml:S2:6670:4	O
the	DUAVEE.xml:S2:6675:3	O
results	DUAVEE.xml:S2:6679:7	O
.	DUAVEE.xml:S2:6686:1	O

Do	DUAVEE.xml:S2:6688:2	O
not	DUAVEE.xml:S2:6691:3	O
take	DUAVEE.xml:S2:6695:4	O
DUAVEE	DUAVEE.xml:S2:6700:6	O
if	DUAVEE.xml:S2:6707:2	O
the	DUAVEE.xml:S2:6710:3	O
test	DUAVEE.xml:S2:6714:4	O
is	DUAVEE.xml:S2:6719:2	O
positive	DUAVEE.xml:S2:6722:8	O
and	DUAVEE.xml:S2:6731:3	O
talk	DUAVEE.xml:S2:6735:4	O
to	DUAVEE.xml:S2:6740:2	O
your	DUAVEE.xml:S2:6743:4	O
healthcare	DUAVEE.xml:S2:6748:10	O
provider	DUAVEE.xml:S2:6759:8	O
.	DUAVEE.xml:S2:6767:1	O

are	DUAVEE.xml:S2:6774:3	O
breastfeeding	DUAVEE.xml:S2:6778:13	O
or	DUAVEE.xml:S2:6792:2	O
plan	DUAVEE.xml:S2:6795:4	O
to	DUAVEE.xml:S2:6800:2	O
breastfeed	DUAVEE.xml:S2:6803:10	O
.	DUAVEE.xml:S2:6813:1	O

It	DUAVEE.xml:S2:6815:2	O
is	DUAVEE.xml:S2:6818:2	O
not	DUAVEE.xml:S2:6821:3	O
known	DUAVEE.xml:S2:6825:5	O
if	DUAVEE.xml:S2:6831:2	O
DUAVEE	DUAVEE.xml:S2:6834:6	O
passes	DUAVEE.xml:S2:6841:6	O
into	DUAVEE.xml:S2:6848:4	O
your	DUAVEE.xml:S2:6853:4	O
breast	DUAVEE.xml:S2:6858:6	O
milk	DUAVEE.xml:S2:6865:4	O
.	DUAVEE.xml:S2:6869:1	O

You	DUAVEE.xml:S2:6871:3	O
and	DUAVEE.xml:S2:6875:3	O
your	DUAVEE.xml:S2:6879:4	O
healthcare	DUAVEE.xml:S2:6884:10	O
provider	DUAVEE.xml:S2:6895:8	O
should	DUAVEE.xml:S2:6904:6	O
decide	DUAVEE.xml:S2:6911:6	O
if	DUAVEE.xml:S2:6918:2	O
you	DUAVEE.xml:S2:6921:3	O
will	DUAVEE.xml:S2:6925:4	O
take	DUAVEE.xml:S2:6930:4	O
DUAVEE	DUAVEE.xml:S2:6935:6	O
or	DUAVEE.xml:S2:6942:2	O
breastfeed	DUAVEE.xml:S2:6945:10	O
.	DUAVEE.xml:S2:6955:1	O

You	DUAVEE.xml:S2:6957:3	O
should	DUAVEE.xml:S2:6961:6	O
not	DUAVEE.xml:S2:6968:3	O
do	DUAVEE.xml:S2:6972:2	O
both	DUAVEE.xml:S2:6975:4	O
.	DUAVEE.xml:S2:6979:1	O

What	DUAVEE.xml:S2:6988:4	O
should	DUAVEE.xml:S2:6993:6	O
I	DUAVEE.xml:S2:7000:1	O
tell	DUAVEE.xml:S2:7002:4	O
my	DUAVEE.xml:S2:7007:2	O
healthcare	DUAVEE.xml:S2:7010:10	O
provider	DUAVEE.xml:S2:7021:8	O
before	DUAVEE.xml:S2:7030:6	O
taking	DUAVEE.xml:S2:7037:6	O
DUAVEE	DUAVEE.xml:S2:7044:6	O
?	DUAVEE.xml:S2:7050:1	O

Before	DUAVEE.xml:S2:7060:6	O
you	DUAVEE.xml:S2:7067:3	O
take	DUAVEE.xml:S2:7071:4	O
DUAVEE	DUAVEE.xml:S2:7076:6	O
,	DUAVEE.xml:S2:7082:1	O
tell	DUAVEE.xml:S2:7084:4	O
your	DUAVEE.xml:S2:7089:4	O
healthcare	DUAVEE.xml:S2:7094:10	O
provider	DUAVEE.xml:S2:7105:8	O
if	DUAVEE.xml:S2:7114:2	O
you	DUAVEE.xml:S2:7117:3	O
:	DUAVEE.xml:S2:7120:1	O
\n\n\n\n	DUAVEE.xml:S2:7123:4	O
have	DUAVEE.xml:S2:7131:4	O
any	DUAVEE.xml:S2:7136:3	O
unusual	DUAVEE.xml:S2:7140:7	O
vaginal	DUAVEE.xml:S2:7148:7	O
bleeding	DUAVEE.xml:S2:7156:8	O
.	DUAVEE.xml:S2:7164:1	O

have	DUAVEE.xml:S2:7171:4	O
any	DUAVEE.xml:S2:7176:3	O
other	DUAVEE.xml:S2:7180:5	O
medical	DUAVEE.xml:S2:7186:7	O
conditions	DUAVEE.xml:S2:7194:10	O
.	DUAVEE.xml:S2:7204:1	O

Your	DUAVEE.xml:S2:7206:4	O
healthcare	DUAVEE.xml:S2:7211:10	O
provider	DUAVEE.xml:S2:7222:8	O
may	DUAVEE.xml:S2:7231:3	O
need	DUAVEE.xml:S2:7235:4	O
to	DUAVEE.xml:S2:7240:2	O
check	DUAVEE.xml:S2:7243:5	O
you	DUAVEE.xml:S2:7249:3	O
more	DUAVEE.xml:S2:7253:4	O
carefully	DUAVEE.xml:S2:7258:9	O
if	DUAVEE.xml:S2:7268:2	O
you	DUAVEE.xml:S2:7271:3	O
have	DUAVEE.xml:S2:7275:4	O
certain	DUAVEE.xml:S2:7280:7	O
conditions	DUAVEE.xml:S2:7288:10	O
,	DUAVEE.xml:S2:7298:1	O
such	DUAVEE.xml:S2:7300:4	O
as	DUAVEE.xml:S2:7305:2	O
asthma	DUAVEE.xml:S2:7308:6	O
(	DUAVEE.xml:S2:7315:1	O
wheezing	DUAVEE.xml:S2:7316:8	O
)	DUAVEE.xml:S2:7324:1	O
,	DUAVEE.xml:S2:7325:1	O
epilepsy	DUAVEE.xml:S2:7327:8	O
(	DUAVEE.xml:S2:7336:1	O
seizures	DUAVEE.xml:S2:7337:8	O
)	DUAVEE.xml:S2:7345:1	O
,	DUAVEE.xml:S2:7346:1	O
diabetes	DUAVEE.xml:S2:7348:8	O
,	DUAVEE.xml:S2:7356:1	O
migraine	DUAVEE.xml:S2:7358:8	O
,	DUAVEE.xml:S2:7366:1	O
endometriosis	DUAVEE.xml:S2:7368:13	O
,	DUAVEE.xml:S2:7381:1	O
lupus	DUAVEE.xml:S2:7383:5	O
,	DUAVEE.xml:S2:7388:1	O
or	DUAVEE.xml:S2:7390:2	O
problems	DUAVEE.xml:S2:7393:8	O
with	DUAVEE.xml:S2:7402:4	O
your	DUAVEE.xml:S2:7407:4	O
heart	DUAVEE.xml:S2:7412:5	O
,	DUAVEE.xml:S2:7417:1	O
liver	DUAVEE.xml:S2:7419:5	O
,	DUAVEE.xml:S2:7424:1	O
thyroid	DUAVEE.xml:S2:7426:7	O
,	DUAVEE.xml:S2:7433:1	O
kidneys	DUAVEE.xml:S2:7435:7	O
,	DUAVEE.xml:S2:7442:1	O
or	DUAVEE.xml:S2:7444:2	O
have	DUAVEE.xml:S2:7447:4	O
high	DUAVEE.xml:S2:7452:4	O
calcium	DUAVEE.xml:S2:7457:7	O
levels	DUAVEE.xml:S2:7465:6	O
in	DUAVEE.xml:S2:7472:2	O
your	DUAVEE.xml:S2:7475:4	O
blood	DUAVEE.xml:S2:7480:5	O
.	DUAVEE.xml:S2:7485:1	O

are	DUAVEE.xml:S2:7492:3	O
going	DUAVEE.xml:S2:7496:5	O
to	DUAVEE.xml:S2:7502:2	O
have	DUAVEE.xml:S2:7505:4	O
surgery	DUAVEE.xml:S2:7510:7	O
or	DUAVEE.xml:S2:7518:2	O
will	DUAVEE.xml:S2:7521:4	O
be	DUAVEE.xml:S2:7526:2	O
on	DUAVEE.xml:S2:7529:2	O
bed	DUAVEE.xml:S2:7532:3	O
rest	DUAVEE.xml:S2:7536:4	O
.	DUAVEE.xml:S2:7540:1	O

Your	DUAVEE.xml:S2:7542:4	O
healthcare	DUAVEE.xml:S2:7547:10	O
provider	DUAVEE.xml:S2:7558:8	O
will	DUAVEE.xml:S2:7567:4	O
let	DUAVEE.xml:S2:7572:3	O
you	DUAVEE.xml:S2:7576:3	O
know	DUAVEE.xml:S2:7580:4	O
if	DUAVEE.xml:S2:7585:2	O
you	DUAVEE.xml:S2:7588:3	O
need	DUAVEE.xml:S2:7592:4	O
to	DUAVEE.xml:S2:7597:2	O
stop	DUAVEE.xml:S2:7600:4	O
taking	DUAVEE.xml:S2:7605:6	O
DUAVEE	DUAVEE.xml:S2:7612:6	O
.	DUAVEE.xml:S2:7618:1	O

Tell	DUAVEE.xml:S2:7627:4	O
your	DUAVEE.xml:S2:7632:4	O
healthcare	DUAVEE.xml:S2:7637:10	O
provider	DUAVEE.xml:S2:7648:8	O
about	DUAVEE.xml:S2:7657:5	O
all	DUAVEE.xml:S2:7663:3	O
the	DUAVEE.xml:S2:7667:3	O
medicines	DUAVEE.xml:S2:7671:9	O
you	DUAVEE.xml:S2:7681:3	O
take	DUAVEE.xml:S2:7685:4	O
,	DUAVEE.xml:S2:7689:1	O
including	DUAVEE.xml:S2:7693:9	O
prescription	DUAVEE.xml:S2:7703:12	O
and	DUAVEE.xml:S2:7716:3	O
over	DUAVEE.xml:S2:7720:4	O
-	DUAVEE.xml:S2:7724:1	O
the	DUAVEE.xml:S2:7725:3	O
-	DUAVEE.xml:S2:7728:1	O
counter	DUAVEE.xml:S2:7729:7	O
medicines	DUAVEE.xml:S2:7737:9	O
,	DUAVEE.xml:S2:7746:1	O
vitamins	DUAVEE.xml:S2:7748:8	O
,	DUAVEE.xml:S2:7756:1	O
and	DUAVEE.xml:S2:7758:3	O
herbal	DUAVEE.xml:S2:7762:6	O
supplements	DUAVEE.xml:S2:7769:11	O
.	DUAVEE.xml:S2:7780:1	O

Especially	DUAVEE.xml:S2:7786:10	O
tell	DUAVEE.xml:S2:7797:4	O
your	DUAVEE.xml:S2:7802:4	O
healthcare	DUAVEE.xml:S2:7807:10	O
provider	DUAVEE.xml:S2:7818:8	O
if	DUAVEE.xml:S2:7827:2	O
you	DUAVEE.xml:S2:7830:3	O
take	DUAVEE.xml:S2:7834:4	O
other	DUAVEE.xml:S2:7839:5	O
hormonal	DUAVEE.xml:S2:7845:8	O
medicines	DUAVEE.xml:S2:7854:9	O
,	DUAVEE.xml:S2:7863:1	O
including	DUAVEE.xml:S2:7865:9	O
progestins	DUAVEE.xml:S2:7875:10	O
or	DUAVEE.xml:S2:7886:2	O
other	DUAVEE.xml:S2:7889:5	O
medicines	DUAVEE.xml:S2:7895:9	O
like	DUAVEE.xml:S2:7905:4	O
DUAVEE	DUAVEE.xml:S2:7910:6	O
.	DUAVEE.xml:S2:7916:1	O

Ask	DUAVEE.xml:S2:7918:3	O
your	DUAVEE.xml:S2:7922:4	O
healthcare	DUAVEE.xml:S2:7927:10	O
provider	DUAVEE.xml:S2:7938:8	O
if	DUAVEE.xml:S2:7947:2	O
you	DUAVEE.xml:S2:7950:3	O
do	DUAVEE.xml:S2:7954:2	O
not	DUAVEE.xml:S2:7957:3	O
know	DUAVEE.xml:S2:7961:4	O
if	DUAVEE.xml:S2:7966:2	O
you	DUAVEE.xml:S2:7969:3	O
take	DUAVEE.xml:S2:7973:4	O
any	DUAVEE.xml:S2:7978:3	O
of	DUAVEE.xml:S2:7982:2	O
these	DUAVEE.xml:S2:7985:5	O
medicines	DUAVEE.xml:S2:7991:9	O
.	DUAVEE.xml:S2:8000:1	O

Some	DUAVEE.xml:S2:8006:4	O
medicines	DUAVEE.xml:S2:8011:9	O
may	DUAVEE.xml:S2:8021:3	O
affect	DUAVEE.xml:S2:8025:6	O
how	DUAVEE.xml:S2:8032:3	O
DUAVEE	DUAVEE.xml:S2:8036:6	O
works	DUAVEE.xml:S2:8043:5	O
.	DUAVEE.xml:S2:8048:1	O

DUAVEE	DUAVEE.xml:S2:8050:6	O
may	DUAVEE.xml:S2:8057:3	O
also	DUAVEE.xml:S2:8061:4	O
affect	DUAVEE.xml:S2:8066:6	O
how	DUAVEE.xml:S2:8073:3	O
your	DUAVEE.xml:S2:8077:4	O
other	DUAVEE.xml:S2:8082:5	O
medicines	DUAVEE.xml:S2:8088:9	O
work	DUAVEE.xml:S2:8098:4	O
.	DUAVEE.xml:S2:8102:1	O

Keep	DUAVEE.xml:S2:8104:4	O
a	DUAVEE.xml:S2:8109:1	O
list	DUAVEE.xml:S2:8111:4	O
of	DUAVEE.xml:S2:8116:2	O
your	DUAVEE.xml:S2:8119:4	O
medicines	DUAVEE.xml:S2:8124:9	O
and	DUAVEE.xml:S2:8134:3	O
show	DUAVEE.xml:S2:8138:4	O
it	DUAVEE.xml:S2:8143:2	O
to	DUAVEE.xml:S2:8146:2	O
your	DUAVEE.xml:S2:8149:4	O
healthcare	DUAVEE.xml:S2:8154:10	O
provider	DUAVEE.xml:S2:8165:8	O
and	DUAVEE.xml:S2:8174:3	O
pharmacist	DUAVEE.xml:S2:8178:10	O
when	DUAVEE.xml:S2:8189:4	O
you	DUAVEE.xml:S2:8194:3	O
get	DUAVEE.xml:S2:8198:3	O
a	DUAVEE.xml:S2:8202:1	O
new	DUAVEE.xml:S2:8204:3	O
medicine	DUAVEE.xml:S2:8208:8	O
.	DUAVEE.xml:S2:8216:1	O

How	DUAVEE.xml:S2:8224:3	O
should	DUAVEE.xml:S2:8228:6	O
I	DUAVEE.xml:S2:8235:1	O
take	DUAVEE.xml:S2:8237:4	O
DUAVEE	DUAVEE.xml:S2:8242:6	O
?	DUAVEE.xml:S2:8248:1	O

DUAVEE	DUAVEE.xml:S2:8261:6	O
comes	DUAVEE.xml:S2:8268:5	O
in	DUAVEE.xml:S2:8274:2	O
a	DUAVEE.xml:S2:8277:1	O
blister	DUAVEE.xml:S2:8279:7	O
package	DUAVEE.xml:S2:8287:7	O
.	DUAVEE.xml:S2:8294:1	O

Record	DUAVEE.xml:S2:8301:6	O
the	DUAVEE.xml:S2:8308:3	O
date	DUAVEE.xml:S2:8312:4	O
you	DUAVEE.xml:S2:8317:3	O
open	DUAVEE.xml:S2:8321:4	O
the	DUAVEE.xml:S2:8326:3	O
foil	DUAVEE.xml:S2:8330:4	O
pouch	DUAVEE.xml:S2:8335:5	O
in	DUAVEE.xml:S2:8341:2	O
the	DUAVEE.xml:S2:8344:3	O
space	DUAVEE.xml:S2:8348:5	O
provided	DUAVEE.xml:S2:8354:8	O
on	DUAVEE.xml:S2:8363:2	O
the	DUAVEE.xml:S2:8366:3	O
blister	DUAVEE.xml:S2:8370:7	O
package	DUAVEE.xml:S2:8378:7	O
label	DUAVEE.xml:S2:8386:5	O
.	DUAVEE.xml:S2:8391:1	O

Do	DUAVEE.xml:S2:8393:2	O
not	DUAVEE.xml:S2:8396:3	O
use	DUAVEE.xml:S2:8400:3	O
if	DUAVEE.xml:S2:8404:2	O
the	DUAVEE.xml:S2:8407:3	O
blister	DUAVEE.xml:S2:8411:7	O
package	DUAVEE.xml:S2:8419:7	O
has	DUAVEE.xml:S2:8427:3	O
been	DUAVEE.xml:S2:8431:4	O
open	DUAVEE.xml:S2:8436:4	O
for	DUAVEE.xml:S2:8441:3	O
more	DUAVEE.xml:S2:8445:4	O
than	DUAVEE.xml:S2:8450:4	O
60	DUAVEE.xml:S2:8455:2	O
days	DUAVEE.xml:S2:8458:4	O
.	DUAVEE.xml:S2:8462:1	O

Take	DUAVEE.xml:S2:8469:4	O
DUAVEE	DUAVEE.xml:S2:8474:6	O
exactly	DUAVEE.xml:S2:8481:7	O
as	DUAVEE.xml:S2:8489:2	O
your	DUAVEE.xml:S2:8492:4	O
healthcare	DUAVEE.xml:S2:8497:10	O
provider	DUAVEE.xml:S2:8508:8	O
tells	DUAVEE.xml:S2:8517:5	O
you	DUAVEE.xml:S2:8523:3	O
to	DUAVEE.xml:S2:8527:2	O
take	DUAVEE.xml:S2:8530:4	O
it	DUAVEE.xml:S2:8535:2	O
.	DUAVEE.xml:S2:8537:1	O

Take	DUAVEE.xml:S2:8544:4	O
1	DUAVEE.xml:S2:8549:1	O
DUAVEE	DUAVEE.xml:S2:8551:6	O
tablet	DUAVEE.xml:S2:8558:6	O
at	DUAVEE.xml:S2:8565:2	O
the	DUAVEE.xml:S2:8568:3	O
same	DUAVEE.xml:S2:8572:4	O
time	DUAVEE.xml:S2:8577:4	O
each	DUAVEE.xml:S2:8582:4	O
day	DUAVEE.xml:S2:8587:3	O
.	DUAVEE.xml:S2:8590:1	O

DUAVEE	DUAVEE.xml:S2:8597:6	O
should	DUAVEE.xml:S2:8604:6	O
be	DUAVEE.xml:S2:8611:2	O
swallowed	DUAVEE.xml:S2:8614:9	O
whole	DUAVEE.xml:S2:8624:5	O
.	DUAVEE.xml:S2:8629:1	O

Take	DUAVEE.xml:S2:8636:4	O
DUAVEE	DUAVEE.xml:S2:8641:6	O
with	DUAVEE.xml:S2:8648:4	O
or	DUAVEE.xml:S2:8653:2	O
without	DUAVEE.xml:S2:8656:7	O
food	DUAVEE.xml:S2:8664:4	O
.	DUAVEE.xml:S2:8668:1	O

You	DUAVEE.xml:S2:8675:3	O
should	DUAVEE.xml:S2:8679:6	O
not	DUAVEE.xml:S2:8686:3	O
remove	DUAVEE.xml:S2:8690:6	O
DUAVEE	DUAVEE.xml:S2:8697:6	O
from	DUAVEE.xml:S2:8704:4	O
the	DUAVEE.xml:S2:8709:3	O
blister	DUAVEE.xml:S2:8713:7	O
until	DUAVEE.xml:S2:8721:5	O
right	DUAVEE.xml:S2:8727:5	O
before	DUAVEE.xml:S2:8733:6	O
you	DUAVEE.xml:S2:8740:3	O
are	DUAVEE.xml:S2:8744:3	O
ready	DUAVEE.xml:S2:8748:5	O
to	DUAVEE.xml:S2:8754:2	O
take	DUAVEE.xml:S2:8757:4	O
it	DUAVEE.xml:S2:8762:2	O
.	DUAVEE.xml:S2:8764:1	O

Remove	DUAVEE.xml:S2:8766:6	O
1	DUAVEE.xml:S2:8773:1	O
tablet	DUAVEE.xml:S2:8775:6	O
at	DUAVEE.xml:S2:8782:2	O
a	DUAVEE.xml:S2:8785:1	O
time	DUAVEE.xml:S2:8787:4	O
from	DUAVEE.xml:S2:8792:4	O
the	DUAVEE.xml:S2:8797:3	O
blister	DUAVEE.xml:S2:8801:7	O
package	DUAVEE.xml:S2:8809:7	O
.	DUAVEE.xml:S2:8816:1	O

Do	DUAVEE.xml:S2:8818:2	O
not	DUAVEE.xml:S2:8821:3	O
place	DUAVEE.xml:S2:8825:5	O
DUAVEE	DUAVEE.xml:S2:8831:6	O
in	DUAVEE.xml:S2:8838:2	O
pill	DUAVEE.xml:S2:8841:4	O
boxes	DUAVEE.xml:S2:8846:5	O
or	DUAVEE.xml:S2:8852:2	O
pill	DUAVEE.xml:S2:8855:4	O
organizers	DUAVEE.xml:S2:8860:10	O
.	DUAVEE.xml:S2:8870:1	O

If	DUAVEE.xml:S2:8877:2	O
you	DUAVEE.xml:S2:8880:3	O
miss	DUAVEE.xml:S2:8884:4	O
a	DUAVEE.xml:S2:8889:1	O
dose	DUAVEE.xml:S2:8891:4	O
of	DUAVEE.xml:S2:8896:2	O
DUAVEE	DUAVEE.xml:S2:8899:6	O
,	DUAVEE.xml:S2:8905:1	O
take	DUAVEE.xml:S2:8907:4	O
it	DUAVEE.xml:S2:8912:2	O
as	DUAVEE.xml:S2:8915:2	O
soon	DUAVEE.xml:S2:8918:4	O
as	DUAVEE.xml:S2:8923:2	O
you	DUAVEE.xml:S2:8926:3	O
remember	DUAVEE.xml:S2:8930:8	O
.	DUAVEE.xml:S2:8938:1	O

If	DUAVEE.xml:S2:8940:2	O
it	DUAVEE.xml:S2:8943:2	O
is	DUAVEE.xml:S2:8946:2	O
almost	DUAVEE.xml:S2:8949:6	O
time	DUAVEE.xml:S2:8956:4	O
for	DUAVEE.xml:S2:8961:3	O
your	DUAVEE.xml:S2:8965:4	O
next	DUAVEE.xml:S2:8970:4	O
dose	DUAVEE.xml:S2:8975:4	O
,	DUAVEE.xml:S2:8979:1	O
skip	DUAVEE.xml:S2:8981:4	O
the	DUAVEE.xml:S2:8986:3	O
missed	DUAVEE.xml:S2:8990:6	O
dose	DUAVEE.xml:S2:8997:4	O
.	DUAVEE.xml:S2:9001:1	O

Take	DUAVEE.xml:S2:9003:4	O
the	DUAVEE.xml:S2:9008:3	O
next	DUAVEE.xml:S2:9012:4	O
dose	DUAVEE.xml:S2:9017:4	O
at	DUAVEE.xml:S2:9022:2	O
your	DUAVEE.xml:S2:9025:4	O
regular	DUAVEE.xml:S2:9030:7	O
time	DUAVEE.xml:S2:9038:4	O
.	DUAVEE.xml:S2:9042:1	O

Do	DUAVEE.xml:S2:9044:2	O
not	DUAVEE.xml:S2:9047:3	O
take	DUAVEE.xml:S2:9051:4	O
2	DUAVEE.xml:S2:9056:1	O
doses	DUAVEE.xml:S2:9058:5	O
at	DUAVEE.xml:S2:9064:2	O
the	DUAVEE.xml:S2:9067:3	O
same	DUAVEE.xml:S2:9071:4	O
time	DUAVEE.xml:S2:9076:4	O
unless	DUAVEE.xml:S2:9081:6	O
your	DUAVEE.xml:S2:9088:4	O
healthcare	DUAVEE.xml:S2:9093:10	O
provider	DUAVEE.xml:S2:9104:8	O
tells	DUAVEE.xml:S2:9113:5	O
you	DUAVEE.xml:S2:9119:3	O
to	DUAVEE.xml:S2:9123:2	O
.	DUAVEE.xml:S2:9125:1	O

If	DUAVEE.xml:S2:9127:2	O
you	DUAVEE.xml:S2:9130:3	O
are	DUAVEE.xml:S2:9134:3	O
not	DUAVEE.xml:S2:9138:3	O
sure	DUAVEE.xml:S2:9142:4	O
about	DUAVEE.xml:S2:9147:5	O
your	DUAVEE.xml:S2:9153:4	O
dosing	DUAVEE.xml:S2:9158:6	O
,	DUAVEE.xml:S2:9164:1	O
call	DUAVEE.xml:S2:9166:4	O
your	DUAVEE.xml:S2:9171:4	O
healthcare	DUAVEE.xml:S2:9176:10	O
provider	DUAVEE.xml:S2:9187:8	O
.	DUAVEE.xml:S2:9195:1	O

If	DUAVEE.xml:S2:9202:2	O
you	DUAVEE.xml:S2:9205:3	O
take	DUAVEE.xml:S2:9209:4	O
a	DUAVEE.xml:S2:9214:1	O
calcium	DUAVEE.xml:S2:9216:7	O
or	DUAVEE.xml:S2:9224:2	O
vitamin	DUAVEE.xml:S2:9227:7	O
D	DUAVEE.xml:S2:9235:1	O
supplement	DUAVEE.xml:S2:9237:10	O
,	DUAVEE.xml:S2:9247:1	O
you	DUAVEE.xml:S2:9249:3	O
may	DUAVEE.xml:S2:9253:3	O
take	DUAVEE.xml:S2:9257:4	O
it	DUAVEE.xml:S2:9262:2	O
at	DUAVEE.xml:S2:9265:2	O
the	DUAVEE.xml:S2:9268:3	O
same	DUAVEE.xml:S2:9272:4	O
time	DUAVEE.xml:S2:9277:4	O
you	DUAVEE.xml:S2:9282:3	O
take	DUAVEE.xml:S2:9286:4	O
DUAVEE	DUAVEE.xml:S2:9291:6	O
.	DUAVEE.xml:S2:9297:1	O

If	DUAVEE.xml:S2:9304:2	O
you	DUAVEE.xml:S2:9307:3	O
take	DUAVEE.xml:S2:9311:4	O
too	DUAVEE.xml:S2:9316:3	O
much	DUAVEE.xml:S2:9320:4	O
DUAVEE	DUAVEE.xml:S2:9325:6	O
,	DUAVEE.xml:S2:9331:1	O
call	DUAVEE.xml:S2:9333:4	O
your	DUAVEE.xml:S2:9338:4	O
healthcare	DUAVEE.xml:S2:9343:10	O
provider	DUAVEE.xml:S2:9354:8	O
.	DUAVEE.xml:S2:9362:1	O

Symptoms	DUAVEE.xml:S2:9364:8	O
of	DUAVEE.xml:S2:9373:2	O
taking	DUAVEE.xml:S2:9376:6	O
too	DUAVEE.xml:S2:9383:3	O
much	DUAVEE.xml:S2:9387:4	O
DUAVEE	DUAVEE.xml:S2:9392:6	O
include	DUAVEE.xml:S2:9399:7	O
:	DUAVEE.xml:S2:9406:1	O
nauseavomitingbreast	DUAVEE.xml:S2:9408:20	O
tendernessdizzinessabdominal	DUAVEE.xml:S2:9429:28	O
painfeeling	DUAVEE.xml:S2:9458:11	O
tiredvaginal	DUAVEE.xml:S2:9470:12	O
bleeding	DUAVEE.xml:S2:9483:8	O
\n	DUAVEE.xml:S2:9492:1	O
What	DUAVEE.xml:S2:9499:4	O
are	DUAVEE.xml:S2:9504:3	O
the	DUAVEE.xml:S2:9508:3	O
possible	DUAVEE.xml:S2:9512:8	O
side	DUAVEE.xml:S2:9521:4	O
effects	DUAVEE.xml:S2:9526:7	O
of	DUAVEE.xml:S2:9534:2	O
DUAVEE	DUAVEE.xml:S2:9537:6	O
?	DUAVEE.xml:S2:9543:1	O

Side	DUAVEE.xml:S2:9553:4	O
effects	DUAVEE.xml:S2:9558:7	O
are	DUAVEE.xml:S2:9566:3	O
grouped	DUAVEE.xml:S2:9570:7	O
by	DUAVEE.xml:S2:9578:2	O
how	DUAVEE.xml:S2:9581:3	O
serious	DUAVEE.xml:S2:9585:7	O
they	DUAVEE.xml:S2:9593:4	O
are	DUAVEE.xml:S2:9598:3	O
and	DUAVEE.xml:S2:9602:3	O
how	DUAVEE.xml:S2:9606:3	O
often	DUAVEE.xml:S2:9610:5	O
they	DUAVEE.xml:S2:9616:4	O
happen	DUAVEE.xml:S2:9621:6	O
when	DUAVEE.xml:S2:9628:4	O
you	DUAVEE.xml:S2:9633:3	O
are	DUAVEE.xml:S2:9637:3	O
treated	DUAVEE.xml:S2:9641:7	O
.	DUAVEE.xml:S2:9648:1	O

Serious	DUAVEE.xml:S2:9658:7	O
side	DUAVEE.xml:S2:9666:4	O
effects	DUAVEE.xml:S2:9671:7	O
include	DUAVEE.xml:S2:9679:7	O
:	DUAVEE.xml:S2:9686:1	O
\n\n\n\n	DUAVEE.xml:S2:9689:4	O
blood	DUAVEE.xml:S2:9697:5	O
clots	DUAVEE.xml:S2:9703:5	O
\n	DUAVEE.xml:S2:9709:1	O
stroke	DUAVEE.xml:S2:9714:6	O
\n	DUAVEE.xml:S2:9721:1	O
heart	DUAVEE.xml:S2:9726:5	O
attack	DUAVEE.xml:S2:9732:6	O
\n	DUAVEE.xml:S2:9739:1	O
cancer	DUAVEE.xml:S2:9744:6	O
of	DUAVEE.xml:S2:9751:2	O
the	DUAVEE.xml:S2:9754:3	O
lining	DUAVEE.xml:S2:9758:6	O
of	DUAVEE.xml:S2:9765:2	O
the	DUAVEE.xml:S2:9768:3	O
uterus	DUAVEE.xml:S2:9772:6	O
\n	DUAVEE.xml:S2:9779:1	O
breast	DUAVEE.xml:S2:9784:6	O
cancer	DUAVEE.xml:S2:9791:6	O
\n	DUAVEE.xml:S2:9798:1	O
cancer	DUAVEE.xml:S2:9803:6	O
of	DUAVEE.xml:S2:9810:2	O
the	DUAVEE.xml:S2:9813:3	O
ovary	DUAVEE.xml:S2:9817:5	O
\n	DUAVEE.xml:S2:9823:1	O
dementia	DUAVEE.xml:S2:9828:8	O
\n	DUAVEE.xml:S2:9837:1	O
gallbladder	DUAVEE.xml:S2:9842:11	O
problems	DUAVEE.xml:S2:9854:8	O
\n	DUAVEE.xml:S2:9863:1	O
loss	DUAVEE.xml:S2:9868:4	O
of	DUAVEE.xml:S2:9873:2	O
vision	DUAVEE.xml:S2:9876:6	O
\n	DUAVEE.xml:S2:9883:1	O
high	DUAVEE.xml:S2:9888:4	O
blood	DUAVEE.xml:S2:9893:5	O
pressure	DUAVEE.xml:S2:9899:8	O
\n	DUAVEE.xml:S2:9908:1	O
increased	DUAVEE.xml:S2:9913:9	O
fats	DUAVEE.xml:S2:9923:4	O
in	DUAVEE.xml:S2:9928:2	O
your	DUAVEE.xml:S2:9931:4	O
blood	DUAVEE.xml:S2:9936:5	O
\n	DUAVEE.xml:S2:9942:1	O
liver	DUAVEE.xml:S2:9947:5	O
problems	DUAVEE.xml:S2:9953:8	O
\n	DUAVEE.xml:S2:9962:1	O
thyroid	DUAVEE.xml:S2:9967:7	O
problems	DUAVEE.xml:S2:9975:8	O
\n	DUAVEE.xml:S2:9984:1	O
fluid	DUAVEE.xml:S2:9989:5	O
retention	DUAVEE.xml:S2:9995:9	O
\n	DUAVEE.xml:S2:10005:1	O
low	DUAVEE.xml:S2:10010:3	O
calcium	DUAVEE.xml:S2:10014:7	O
\n	DUAVEE.xml:S2:10022:1	O
swelling	DUAVEE.xml:S2:10027:8	O
of	DUAVEE.xml:S2:10036:2	O
your	DUAVEE.xml:S2:10039:4	O
mouth	DUAVEE.xml:S2:10044:5	O
or	DUAVEE.xml:S2:10050:2	O
tongue	DUAVEE.xml:S2:10053:6	O
\n	DUAVEE.xml:S2:10060:1	O
worsening	DUAVEE.xml:S2:10065:9	O
of	DUAVEE.xml:S2:10075:2	O
other	DUAVEE.xml:S2:10078:5	O
medical	DUAVEE.xml:S2:10084:7	O
problems	DUAVEE.xml:S2:10092:8	O
such	DUAVEE.xml:S2:10101:4	O
as	DUAVEE.xml:S2:10106:2	O
asthma	DUAVEE.xml:S2:10109:6	O
,	DUAVEE.xml:S2:10115:1	O
diabetes	DUAVEE.xml:S2:10117:8	O
,	DUAVEE.xml:S2:10125:1	O
epilepsy	DUAVEE.xml:S2:10127:8	O
,	DUAVEE.xml:S2:10135:1	O
migraines	DUAVEE.xml:S2:10137:9	O
,	DUAVEE.xml:S2:10146:1	O
a	DUAVEE.xml:S2:10148:1	O
genetic	DUAVEE.xml:S2:10150:7	O
problem	DUAVEE.xml:S2:10158:7	O
called	DUAVEE.xml:S2:10166:6	O
porphyria	DUAVEE.xml:S2:10173:9	O
,	DUAVEE.xml:S2:10182:1	O
lupus	DUAVEE.xml:S2:10184:5	O
and	DUAVEE.xml:S2:10190:3	O
liver	DUAVEE.xml:S2:10194:5	O
problems	DUAVEE.xml:S2:10200:8	O
\n	DUAVEE.xml:S2:10209:1	O
Call	DUAVEE.xml:S2:10216:4	O
your	DUAVEE.xml:S2:10221:4	O
healthcare	DUAVEE.xml:S2:10226:10	O
provider	DUAVEE.xml:S2:10237:8	O
right	DUAVEE.xml:S2:10246:5	O
away	DUAVEE.xml:S2:10252:4	O
if	DUAVEE.xml:S2:10257:2	O
you	DUAVEE.xml:S2:10260:3	O
get	DUAVEE.xml:S2:10264:3	O
any	DUAVEE.xml:S2:10268:3	O
of	DUAVEE.xml:S2:10272:2	O
the	DUAVEE.xml:S2:10275:3	O
following	DUAVEE.xml:S2:10279:9	O
warning	DUAVEE.xml:S2:10289:7	O
signs	DUAVEE.xml:S2:10297:5	O
,	DUAVEE.xml:S2:10302:1	O
or	DUAVEE.xml:S2:10304:2	O
any	DUAVEE.xml:S2:10307:3	O
other	DUAVEE.xml:S2:10311:5	O
unusual	DUAVEE.xml:S2:10317:7	O
symptoms	DUAVEE.xml:S2:10325:8	O
that	DUAVEE.xml:S2:10334:4	O
concern	DUAVEE.xml:S2:10339:7	O
you	DUAVEE.xml:S2:10347:3	O
:	DUAVEE.xml:S2:10350:1	O
\n	DUAVEE.xml:S2:10353:1	O
\n\n	DUAVEE.xml:S2:10355:2	O
new	DUAVEE.xml:S2:10361:3	O
breast	DUAVEE.xml:S2:10365:6	O
lumps	DUAVEE.xml:S2:10372:5	O
\n	DUAVEE.xml:S2:10378:1	O
unusual	DUAVEE.xml:S2:10383:7	O
vaginal	DUAVEE.xml:S2:10391:7	O
bleeding	DUAVEE.xml:S2:10399:8	O
\n	DUAVEE.xml:S2:10408:1	O
changes	DUAVEE.xml:S2:10413:7	O
in	DUAVEE.xml:S2:10421:2	O
vision	DUAVEE.xml:S2:10424:6	O
or	DUAVEE.xml:S2:10431:2	O
speech	DUAVEE.xml:S2:10434:6	O
\n	DUAVEE.xml:S2:10441:1	O
sudden	DUAVEE.xml:S2:10446:6	O
new	DUAVEE.xml:S2:10453:3	O
severe	DUAVEE.xml:S2:10457:6	O
headaches	DUAVEE.xml:S2:10464:9	O
\n	DUAVEE.xml:S2:10474:1	O
severe	DUAVEE.xml:S2:10479:6	O
pains	DUAVEE.xml:S2:10486:5	O
in	DUAVEE.xml:S2:10492:2	O
your	DUAVEE.xml:S2:10495:4	O
chest	DUAVEE.xml:S2:10500:5	O
or	DUAVEE.xml:S2:10506:2	O
legs	DUAVEE.xml:S2:10509:4	O
with	DUAVEE.xml:S2:10514:4	O
or	DUAVEE.xml:S2:10519:2	O
without	DUAVEE.xml:S2:10522:7	O
shortness	DUAVEE.xml:S2:10530:9	O
of	DUAVEE.xml:S2:10540:2	O
breath	DUAVEE.xml:S2:10543:6	O
,	DUAVEE.xml:S2:10549:1	O
weakness	DUAVEE.xml:S2:10551:8	O
and	DUAVEE.xml:S2:10560:3	O
fatigue	DUAVEE.xml:S2:10564:7	O
\n	DUAVEE.xml:S2:10572:1	O
Less	DUAVEE.xml:S2:10579:4	O
serious	DUAVEE.xml:S2:10584:7	O
,	DUAVEE.xml:S2:10591:1	O
but	DUAVEE.xml:S2:10593:3	O
common	DUAVEE.xml:S2:10597:6	O
side	DUAVEE.xml:S2:10604:4	O
effects	DUAVEE.xml:S2:10609:7	O
include	DUAVEE.xml:S2:10617:7	O
:	DUAVEE.xml:S2:10624:1	O
\n	DUAVEE.xml:S2:10627:1	O
\n\n	DUAVEE.xml:S2:10629:2	O
muscle	DUAVEE.xml:S2:10635:6	O
spasms	DUAVEE.xml:S2:10642:6	O
\n	DUAVEE.xml:S2:10649:1	O
nausea	DUAVEE.xml:S2:10654:6	O
\n	DUAVEE.xml:S2:10661:1	O
diarrhea	DUAVEE.xml:S2:10666:8	O
\n	DUAVEE.xml:S2:10675:1	O
upset	DUAVEE.xml:S2:10680:5	O
stomach	DUAVEE.xml:S2:10686:7	O
\n	DUAVEE.xml:S2:10694:1	O
abdominal	DUAVEE.xml:S2:10699:9	O
pain	DUAVEE.xml:S2:10709:4	O
\n	DUAVEE.xml:S2:10714:1	O
throat	DUAVEE.xml:S2:10719:6	O
pain	DUAVEE.xml:S2:10726:4	O
\n	DUAVEE.xml:S2:10731:1	O
dizziness	DUAVEE.xml:S2:10736:9	O
\n	DUAVEE.xml:S2:10746:1	O
neck	DUAVEE.xml:S2:10751:4	O
pain	DUAVEE.xml:S2:10756:4	O
\n	DUAVEE.xml:S2:10761:1	O
These	DUAVEE.xml:S2:10766:5	O
are	DUAVEE.xml:S2:10772:3	O
not	DUAVEE.xml:S2:10776:3	O
all	DUAVEE.xml:S2:10780:3	O
the	DUAVEE.xml:S2:10784:3	O
possible	DUAVEE.xml:S2:10788:8	O
side	DUAVEE.xml:S2:10797:4	O
effects	DUAVEE.xml:S2:10802:7	O
of	DUAVEE.xml:S2:10810:2	O
DUAVEE	DUAVEE.xml:S2:10813:6	O
.	DUAVEE.xml:S2:10819:1	O

For	DUAVEE.xml:S2:10821:3	O
more	DUAVEE.xml:S2:10825:4	O
information	DUAVEE.xml:S2:10830:11	O
,	DUAVEE.xml:S2:10841:1	O
ask	DUAVEE.xml:S2:10843:3	O
your	DUAVEE.xml:S2:10847:4	O
healthcare	DUAVEE.xml:S2:10852:10	O
provider	DUAVEE.xml:S2:10863:8	O
or	DUAVEE.xml:S2:10872:2	O
pharmacist	DUAVEE.xml:S2:10875:10	O
.	DUAVEE.xml:S2:10885:1	O

Tell	DUAVEE.xml:S2:10887:4	O
your	DUAVEE.xml:S2:10892:4	O
healthcare	DUAVEE.xml:S2:10897:10	O
provider	DUAVEE.xml:S2:10908:8	O
if	DUAVEE.xml:S2:10917:2	O
you	DUAVEE.xml:S2:10920:3	O
have	DUAVEE.xml:S2:10924:4	O
any	DUAVEE.xml:S2:10929:3	O
side	DUAVEE.xml:S2:10933:4	O
effects	DUAVEE.xml:S2:10938:7	O
that	DUAVEE.xml:S2:10946:4	O
bother	DUAVEE.xml:S2:10951:6	O
you	DUAVEE.xml:S2:10958:3	O
or	DUAVEE.xml:S2:10962:2	O
do	DUAVEE.xml:S2:10965:2	O
not	DUAVEE.xml:S2:10968:3	O
go	DUAVEE.xml:S2:10972:2	O
away	DUAVEE.xml:S2:10975:4	O
.	DUAVEE.xml:S2:10979:1	O

Call	DUAVEE.xml:S2:10985:4	O
your	DUAVEE.xml:S2:10990:4	O
doctor	DUAVEE.xml:S2:10995:6	O
for	DUAVEE.xml:S2:11002:3	O
medical	DUAVEE.xml:S2:11006:7	O
advice	DUAVEE.xml:S2:11014:6	O
about	DUAVEE.xml:S2:11021:5	O
side	DUAVEE.xml:S2:11027:4	O
effects	DUAVEE.xml:S2:11032:7	O
.	DUAVEE.xml:S2:11039:1	O

You	DUAVEE.xml:S2:11041:3	O
may	DUAVEE.xml:S2:11045:3	O
report	DUAVEE.xml:S2:11049:6	O
side	DUAVEE.xml:S2:11056:4	O
effects	DUAVEE.xml:S2:11061:7	O
to	DUAVEE.xml:S2:11069:2	O
FDA	DUAVEE.xml:S2:11072:3	O
at	DUAVEE.xml:S2:11076:2	O
1	DUAVEE.xml:S2:11079:1	O
-	DUAVEE.xml:S2:11080:1	O
800	DUAVEE.xml:S2:11081:3	O
-	DUAVEE.xml:S2:11084:1	O
FDA	DUAVEE.xml:S2:11085:3	O
-	DUAVEE.xml:S2:11088:1	O
1088	DUAVEE.xml:S2:11089:4	O
.	DUAVEE.xml:S2:11093:1	O

What	DUAVEE.xml:S2:11101:4	O
can	DUAVEE.xml:S2:11106:3	O
I	DUAVEE.xml:S2:11110:1	O
do	DUAVEE.xml:S2:11112:2	O
to	DUAVEE.xml:S2:11115:2	O
lower	DUAVEE.xml:S2:11118:5	O
my	DUAVEE.xml:S2:11124:2	O
chances	DUAVEE.xml:S2:11127:7	O
of	DUAVEE.xml:S2:11135:2	O
a	DUAVEE.xml:S2:11138:1	O
serious	DUAVEE.xml:S2:11140:7	O
side	DUAVEE.xml:S2:11148:4	O
effect	DUAVEE.xml:S2:11153:6	O
with	DUAVEE.xml:S2:11160:4	O
DUAVEE	DUAVEE.xml:S2:11165:6	O
?	DUAVEE.xml:S2:11171:1	O

Talk	DUAVEE.xml:S2:11182:4	O
with	DUAVEE.xml:S2:11187:4	O
your	DUAVEE.xml:S2:11192:4	O
healthcare	DUAVEE.xml:S2:11197:10	O
provider	DUAVEE.xml:S2:11208:8	O
regularly	DUAVEE.xml:S2:11217:9	O
about	DUAVEE.xml:S2:11227:5	O
whether	DUAVEE.xml:S2:11233:7	O
you	DUAVEE.xml:S2:11241:3	O
should	DUAVEE.xml:S2:11245:6	O
continue	DUAVEE.xml:S2:11252:8	O
taking	DUAVEE.xml:S2:11261:6	O
DUAVEE	DUAVEE.xml:S2:11268:6	O
.	DUAVEE.xml:S2:11274:1	O

See	DUAVEE.xml:S2:11281:3	O
you	DUAVEE.xml:S2:11285:3	O
healthcare	DUAVEE.xml:S2:11289:10	O
provider	DUAVEE.xml:S2:11300:8	O
right	DUAVEE.xml:S2:11309:5	O
away	DUAVEE.xml:S2:11315:4	O
if	DUAVEE.xml:S2:11320:2	O
you	DUAVEE.xml:S2:11323:3	O
get	DUAVEE.xml:S2:11327:3	O
vaginal	DUAVEE.xml:S2:11331:7	O
bleeding	DUAVEE.xml:S2:11339:8	O
while	DUAVEE.xml:S2:11348:5	O
taking	DUAVEE.xml:S2:11354:6	O
DUAVEE	DUAVEE.xml:S2:11361:6	O
.	DUAVEE.xml:S2:11367:1	O

Have	DUAVEE.xml:S2:11374:4	O
a	DUAVEE.xml:S2:11379:1	O
pelvic	DUAVEE.xml:S2:11381:6	O
exam	DUAVEE.xml:S2:11388:4	O
,	DUAVEE.xml:S2:11392:1	O
breast	DUAVEE.xml:S2:11394:6	O
exam	DUAVEE.xml:S2:11401:4	O
and	DUAVEE.xml:S2:11406:3	O
mammogram	DUAVEE.xml:S2:11410:9	O
(	DUAVEE.xml:S2:11420:1	O
breast	DUAVEE.xml:S2:11421:6	O
X	DUAVEE.xml:S2:11428:1	O
-	DUAVEE.xml:S2:11429:1	O
ray	DUAVEE.xml:S2:11430:3	O
)	DUAVEE.xml:S2:11433:1	O
every	DUAVEE.xml:S2:11435:5	O
year	DUAVEE.xml:S2:11441:4	O
unless	DUAVEE.xml:S2:11446:6	O
your	DUAVEE.xml:S2:11453:4	O
healthcare	DUAVEE.xml:S2:11458:10	O
provider	DUAVEE.xml:S2:11469:8	O
tells	DUAVEE.xml:S2:11478:5	O
you	DUAVEE.xml:S2:11484:3	O
something	DUAVEE.xml:S2:11488:9	O
else	DUAVEE.xml:S2:11498:4	O
.	DUAVEE.xml:S2:11502:1	O

If	DUAVEE.xml:S2:11509:2	O
members	DUAVEE.xml:S2:11512:7	O
of	DUAVEE.xml:S2:11520:2	O
your	DUAVEE.xml:S2:11523:4	O
family	DUAVEE.xml:S2:11528:6	O
have	DUAVEE.xml:S2:11535:4	O
had	DUAVEE.xml:S2:11540:3	O
breast	DUAVEE.xml:S2:11544:6	O
cancer	DUAVEE.xml:S2:11551:6	O
or	DUAVEE.xml:S2:11558:2	O
if	DUAVEE.xml:S2:11561:2	O
you	DUAVEE.xml:S2:11564:3	O
have	DUAVEE.xml:S2:11568:4	O
ever	DUAVEE.xml:S2:11573:4	O
had	DUAVEE.xml:S2:11578:3	O
breast	DUAVEE.xml:S2:11582:6	O
lumps	DUAVEE.xml:S2:11589:5	O
or	DUAVEE.xml:S2:11595:2	O
an	DUAVEE.xml:S2:11598:2	O
abnormal	DUAVEE.xml:S2:11601:8	O
mammogram	DUAVEE.xml:S2:11610:9	O
,	DUAVEE.xml:S2:11619:1	O
you	DUAVEE.xml:S2:11621:3	O
may	DUAVEE.xml:S2:11625:3	O
need	DUAVEE.xml:S2:11629:4	O
to	DUAVEE.xml:S2:11634:2	O
have	DUAVEE.xml:S2:11637:4	O
breast	DUAVEE.xml:S2:11642:6	O
exams	DUAVEE.xml:S2:11649:5	O
more	DUAVEE.xml:S2:11655:4	O
often	DUAVEE.xml:S2:11660:5	O
.	DUAVEE.xml:S2:11665:1	O

If	DUAVEE.xml:S2:11672:2	O
you	DUAVEE.xml:S2:11675:3	O
have	DUAVEE.xml:S2:11679:4	O
high	DUAVEE.xml:S2:11684:4	O
blood	DUAVEE.xml:S2:11689:5	O
pressure	DUAVEE.xml:S2:11695:8	O
,	DUAVEE.xml:S2:11703:1	O
high	DUAVEE.xml:S2:11705:4	O
cholesterol	DUAVEE.xml:S2:11710:11	O
(	DUAVEE.xml:S2:11722:1	O
fat	DUAVEE.xml:S2:11723:3	O
in	DUAVEE.xml:S2:11727:2	O
the	DUAVEE.xml:S2:11730:3	O
blood	DUAVEE.xml:S2:11734:5	O
)	DUAVEE.xml:S2:11739:1	O
,	DUAVEE.xml:S2:11740:1	O
diabetes	DUAVEE.xml:S2:11742:8	O
,	DUAVEE.xml:S2:11750:1	O
are	DUAVEE.xml:S2:11752:3	O
overweight	DUAVEE.xml:S2:11756:10	O
,	DUAVEE.xml:S2:11766:1	O
or	DUAVEE.xml:S2:11768:2	O
if	DUAVEE.xml:S2:11771:2	O
you	DUAVEE.xml:S2:11774:3	O
use	DUAVEE.xml:S2:11778:3	O
tobacco	DUAVEE.xml:S2:11782:7	O
,	DUAVEE.xml:S2:11789:1	O
you	DUAVEE.xml:S2:11791:3	O
may	DUAVEE.xml:S2:11795:3	O
have	DUAVEE.xml:S2:11799:4	O
higher	DUAVEE.xml:S2:11804:6	O
chances	DUAVEE.xml:S2:11811:7	O
of	DUAVEE.xml:S2:11819:2	O
getting	DUAVEE.xml:S2:11822:7	O
heart	DUAVEE.xml:S2:11830:5	O
disease	DUAVEE.xml:S2:11836:7	O
.	DUAVEE.xml:S2:11843:1	O

Ask	DUAVEE.xml:S2:11850:3	O
your	DUAVEE.xml:S2:11854:4	O
healthcare	DUAVEE.xml:S2:11859:10	O
provider	DUAVEE.xml:S2:11870:8	O
for	DUAVEE.xml:S2:11879:3	O
ways	DUAVEE.xml:S2:11883:4	O
to	DUAVEE.xml:S2:11888:2	O
lower	DUAVEE.xml:S2:11891:5	O
your	DUAVEE.xml:S2:11897:4	O
chances	DUAVEE.xml:S2:11902:7	O
of	DUAVEE.xml:S2:11910:2	O
getting	DUAVEE.xml:S2:11913:7	O
heart	DUAVEE.xml:S2:11921:5	O
disease	DUAVEE.xml:S2:11927:7	O
.	DUAVEE.xml:S2:11934:1	O

How	DUAVEE.xml:S2:11942:3	O
do	DUAVEE.xml:S2:11946:2	O
I	DUAVEE.xml:S2:11949:1	O
store	DUAVEE.xml:S2:11951:5	O
DUAVEE	DUAVEE.xml:S2:11957:6	O
?	DUAVEE.xml:S2:11963:1	O

Store	DUAVEE.xml:S2:11974:5	O
DUAVEE	DUAVEE.xml:S2:11980:6	O
at	DUAVEE.xml:S2:11987:2	O
room	DUAVEE.xml:S2:11990:4	O
temperature	DUAVEE.xml:S2:11995:11	O
between	DUAVEE.xml:S2:12007:7	O
68	DUAVEE.xml:S2:12015:2	O
degrees	DUAVEE.xml:S2:12018:7	O
F	DUAVEE.xml:S2:12026:1	O
to	DUAVEE.xml:S2:12028:2	O
77	DUAVEE.xml:S2:12031:2	O
degrees	DUAVEE.xml:S2:12034:7	O
F	DUAVEE.xml:S2:12042:1	O
(	DUAVEE.xml:S2:12044:1	O
20	DUAVEE.xml:S2:12045:2	O
degrees	DUAVEE.xml:S2:12048:7	O
C	DUAVEE.xml:S2:12056:1	O
to	DUAVEE.xml:S2:12058:2	O
25	DUAVEE.xml:S2:12061:2	O
degrees	DUAVEE.xml:S2:12064:7	O
C	DUAVEE.xml:S2:12072:1	O
)	DUAVEE.xml:S2:12073:1	O
.	DUAVEE.xml:S2:12074:1	O

Keep	DUAVEE.xml:S2:12081:4	O
DUAVEE	DUAVEE.xml:S2:12086:6	O
in	DUAVEE.xml:S2:12093:2	O
the	DUAVEE.xml:S2:12096:3	O
blister	DUAVEE.xml:S2:12100:7	O
until	DUAVEE.xml:S2:12108:5	O
you	DUAVEE.xml:S2:12114:3	O
are	DUAVEE.xml:S2:12118:3	O
ready	DUAVEE.xml:S2:12122:5	O
to	DUAVEE.xml:S2:12128:2	O
take	DUAVEE.xml:S2:12131:4	O
it	DUAVEE.xml:S2:12136:2	O
to	DUAVEE.xml:S2:12139:2	O
protect	DUAVEE.xml:S2:12142:7	O
the	DUAVEE.xml:S2:12150:3	O
tablet	DUAVEE.xml:S2:12154:6	O
from	DUAVEE.xml:S2:12161:4	O
moisture	DUAVEE.xml:S2:12166:8	O
.	DUAVEE.xml:S2:12174:1	O

Do	DUAVEE.xml:S2:12181:2	O
not	DUAVEE.xml:S2:12184:3	O
place	DUAVEE.xml:S2:12188:5	O
DUAVEE	DUAVEE.xml:S2:12194:6	O
in	DUAVEE.xml:S2:12201:2	O
pill	DUAVEE.xml:S2:12204:4	O
boxes	DUAVEE.xml:S2:12209:5	O
or	DUAVEE.xml:S2:12215:2	O
pill	DUAVEE.xml:S2:12218:4	O
organizers	DUAVEE.xml:S2:12223:10	O
.	DUAVEE.xml:S2:12233:1	O

After	DUAVEE.xml:S2:12240:5	O
opening	DUAVEE.xml:S2:12246:7	O
the	DUAVEE.xml:S2:12254:3	O
foil	DUAVEE.xml:S2:12258:4	O
pouch	DUAVEE.xml:S2:12263:5	O
the	DUAVEE.xml:S2:12269:3	O
DUAVEE	DUAVEE.xml:S2:12273:6	O
blisters	DUAVEE.xml:S2:12280:8	O
come	DUAVEE.xml:S2:12289:4	O
in	DUAVEE.xml:S2:12294:2	O
,	DUAVEE.xml:S2:12296:1	O
DUAVEE	DUAVEE.xml:S2:12298:6	O
must	DUAVEE.xml:S2:12305:4	O
be	DUAVEE.xml:S2:12310:2	O
used	DUAVEE.xml:S2:12313:4	O
within	DUAVEE.xml:S2:12318:6	O
60	DUAVEE.xml:S2:12325:2	O
days	DUAVEE.xml:S2:12328:4	O
.	DUAVEE.xml:S2:12332:1	O

Keep	DUAVEE.xml:S2:12341:4	O
DUAVEE	DUAVEE.xml:S2:12346:6	O
and	DUAVEE.xml:S2:12353:3	O
all	DUAVEE.xml:S2:12357:3	O
other	DUAVEE.xml:S2:12361:5	O
medicines	DUAVEE.xml:S2:12367:9	O
out	DUAVEE.xml:S2:12377:3	O
of	DUAVEE.xml:S2:12381:2	O
the	DUAVEE.xml:S2:12384:3	O
reach	DUAVEE.xml:S2:12388:5	O
of	DUAVEE.xml:S2:12394:2	O
children	DUAVEE.xml:S2:12397:8	O
.	DUAVEE.xml:S2:12405:1	O

General	DUAVEE.xml:S2:12415:7	O
information	DUAVEE.xml:S2:12423:11	O
about	DUAVEE.xml:S2:12435:5	O
the	DUAVEE.xml:S2:12441:3	O
safe	DUAVEE.xml:S2:12445:4	O
and	DUAVEE.xml:S2:12450:3	O
effective	DUAVEE.xml:S2:12454:9	O
use	DUAVEE.xml:S2:12464:3	O
of	DUAVEE.xml:S2:12468:2	O
DUAVEE	DUAVEE.xml:S2:12471:6	O
\n\n\n\n	DUAVEE.xml:S2:12479:4	O
Medicines	DUAVEE.xml:S2:12484:9	O
are	DUAVEE.xml:S2:12494:3	O
sometimes	DUAVEE.xml:S2:12498:9	O
prescribed	DUAVEE.xml:S2:12508:10	O
for	DUAVEE.xml:S2:12519:3	O
purposes	DUAVEE.xml:S2:12523:8	O
other	DUAVEE.xml:S2:12532:5	O
than	DUAVEE.xml:S2:12538:4	O
those	DUAVEE.xml:S2:12543:5	O
listed	DUAVEE.xml:S2:12549:6	O
in	DUAVEE.xml:S2:12556:2	O
a	DUAVEE.xml:S2:12559:1	O
Patient	DUAVEE.xml:S2:12561:7	O
Information	DUAVEE.xml:S2:12569:11	O
leaflet	DUAVEE.xml:S2:12581:7	O
.	DUAVEE.xml:S2:12588:1	O

Do	DUAVEE.xml:S2:12590:2	O
not	DUAVEE.xml:S2:12593:3	O
use	DUAVEE.xml:S2:12597:3	O
DUAVEE	DUAVEE.xml:S2:12601:6	O
for	DUAVEE.xml:S2:12608:3	O
a	DUAVEE.xml:S2:12612:1	O
condition	DUAVEE.xml:S2:12614:9	O
for	DUAVEE.xml:S2:12624:3	O
which	DUAVEE.xml:S2:12628:5	O
it	DUAVEE.xml:S2:12634:2	O
was	DUAVEE.xml:S2:12637:3	O
not	DUAVEE.xml:S2:12641:3	O
prescribed	DUAVEE.xml:S2:12645:10	O
.	DUAVEE.xml:S2:12655:1	O

Do	DUAVEE.xml:S2:12657:2	O
not	DUAVEE.xml:S2:12660:3	O
give	DUAVEE.xml:S2:12664:4	O
DUAVEE	DUAVEE.xml:S2:12669:6	O
to	DUAVEE.xml:S2:12676:2	O
other	DUAVEE.xml:S2:12679:5	O
people	DUAVEE.xml:S2:12685:6	O
,	DUAVEE.xml:S2:12691:1	O
even	DUAVEE.xml:S2:12693:4	O
if	DUAVEE.xml:S2:12698:2	O
they	DUAVEE.xml:S2:12701:4	O
have	DUAVEE.xml:S2:12706:4	O
the	DUAVEE.xml:S2:12711:3	O
same	DUAVEE.xml:S2:12715:4	O
symptoms	DUAVEE.xml:S2:12720:8	O
you	DUAVEE.xml:S2:12729:3	O
have	DUAVEE.xml:S2:12733:4	O
.	DUAVEE.xml:S2:12737:1	O

It	DUAVEE.xml:S2:12739:2	O
may	DUAVEE.xml:S2:12742:3	O
harm	DUAVEE.xml:S2:12746:4	O
them	DUAVEE.xml:S2:12751:4	O
.	DUAVEE.xml:S2:12755:1	O

This	DUAVEE.xml:S2:12761:4	O
Patient	DUAVEE.xml:S2:12766:7	O
Information	DUAVEE.xml:S2:12774:11	O
summarizes	DUAVEE.xml:S2:12786:10	O
the	DUAVEE.xml:S2:12797:3	O
most	DUAVEE.xml:S2:12801:4	O
important	DUAVEE.xml:S2:12806:9	O
information	DUAVEE.xml:S2:12816:11	O
about	DUAVEE.xml:S2:12828:5	O
DUAVEE	DUAVEE.xml:S2:12834:6	O
.	DUAVEE.xml:S2:12840:1	O

If	DUAVEE.xml:S2:12842:2	O
you	DUAVEE.xml:S2:12845:3	O
would	DUAVEE.xml:S2:12849:5	O
like	DUAVEE.xml:S2:12855:4	O
more	DUAVEE.xml:S2:12860:4	O
information	DUAVEE.xml:S2:12865:11	O
,	DUAVEE.xml:S2:12876:1	O
talk	DUAVEE.xml:S2:12878:4	O
with	DUAVEE.xml:S2:12883:4	O
your	DUAVEE.xml:S2:12888:4	O
healthcare	DUAVEE.xml:S2:12893:10	O
provider	DUAVEE.xml:S2:12904:8	O
.	DUAVEE.xml:S2:12912:1	O

You	DUAVEE.xml:S2:12914:3	O
can	DUAVEE.xml:S2:12918:3	O
ask	DUAVEE.xml:S2:12922:3	O
your	DUAVEE.xml:S2:12926:4	O
pharmacist	DUAVEE.xml:S2:12931:10	O
or	DUAVEE.xml:S2:12942:2	O
healthcare	DUAVEE.xml:S2:12945:10	O
provider	DUAVEE.xml:S2:12956:8	O
for	DUAVEE.xml:S2:12965:3	O
information	DUAVEE.xml:S2:12969:11	O
about	DUAVEE.xml:S2:12981:5	O
DUAVEE	DUAVEE.xml:S2:12987:6	O
that	DUAVEE.xml:S2:12994:4	O
is	DUAVEE.xml:S2:12999:2	O
written	DUAVEE.xml:S2:13002:7	O
for	DUAVEE.xml:S2:13010:3	O
health	DUAVEE.xml:S2:13014:6	O
professionals	DUAVEE.xml:S2:13021:13	O
.	DUAVEE.xml:S2:13034:1	O

For	DUAVEE.xml:S2:13040:3	O
more	DUAVEE.xml:S2:13044:4	O
information	DUAVEE.xml:S2:13049:11	O
,	DUAVEE.xml:S2:13060:1	O
go	DUAVEE.xml:S2:13062:2	O
to	DUAVEE.xml:S2:13065:2	O
www	DUAVEE.xml:S2:13068:3	O
.	DUAVEE.xml:S2:13071:1	O
DUAVEE	DUAVEE.xml:S2:13072:6	O
.	DUAVEE.xml:S2:13078:1	O
com	DUAVEE.xml:S2:13079:3	O
,	DUAVEE.xml:S2:13082:1	O
or	DUAVEE.xml:S2:13084:2	O
call	DUAVEE.xml:S2:13087:4	O
1	DUAVEE.xml:S2:13092:1	O
-	DUAVEE.xml:S2:13093:1	O
800	DUAVEE.xml:S2:13094:3	O
-	DUAVEE.xml:S2:13097:1	O
438	DUAVEE.xml:S2:13098:3	O
-	DUAVEE.xml:S2:13101:1	O
1985	DUAVEE.xml:S2:13102:4	O
.	DUAVEE.xml:S2:13106:1	O

What	DUAVEE.xml:S2:13114:4	O
are	DUAVEE.xml:S2:13119:3	O
the	DUAVEE.xml:S2:13123:3	O
ingredients	DUAVEE.xml:S2:13127:11	O
in	DUAVEE.xml:S2:13139:2	O
DUAVEE	DUAVEE.xml:S2:13142:6	O
?	DUAVEE.xml:S2:13148:1	O

Active	DUAVEE.xml:S2:13158:6	O
Ingredients	DUAVEE.xml:S2:13165:11	O
:	DUAVEE.xml:S2:13178:1	O
conjugated	DUAVEE.xml:S2:13180:10	O
estrogens	DUAVEE.xml:S2:13191:9	O
and	DUAVEE.xml:S2:13201:3	O
bazedoxifene	DUAVEE.xml:S2:13205:12	O
.	DUAVEE.xml:S2:13217:1	O

Conjugated	DUAVEE.xml:S2:13219:10	O
estrogens	DUAVEE.xml:S2:13230:9	O
are	DUAVEE.xml:S2:13240:3	O
a	DUAVEE.xml:S2:13244:1	O
mixture	DUAVEE.xml:S2:13246:7	O
of	DUAVEE.xml:S2:13254:2	O
sodium	DUAVEE.xml:S2:13257:6	O
estrone	DUAVEE.xml:S2:13264:7	O
sulfate	DUAVEE.xml:S2:13272:7	O
and	DUAVEE.xml:S2:13280:3	O
sodium	DUAVEE.xml:S2:13284:6	O
equilin	DUAVEE.xml:S2:13291:7	O
sulfate	DUAVEE.xml:S2:13299:7	O
and	DUAVEE.xml:S2:13307:3	O
other	DUAVEE.xml:S2:13311:5	O
components	DUAVEE.xml:S2:13317:10	O
,	DUAVEE.xml:S2:13327:1	O
including	DUAVEE.xml:S2:13329:9	O
sodium	DUAVEE.xml:S2:13339:6	O
sulfate	DUAVEE.xml:S2:13346:7	O
conjugates	DUAVEE.xml:S2:13354:10	O
,	DUAVEE.xml:S2:13364:1	O
17	DUAVEE.xml:S2:13366:2	O
alpha	DUAVEE.xml:S2:13368:5	O
-	DUAVEE.xml:S2:13373:1	O
dihydroequilin	DUAVEE.xml:S2:13374:14	O
,	DUAVEE.xml:S2:13388:1	O
17	DUAVEE.xml:S2:13390:2	O
alpha	DUAVEE.xml:S2:13392:5	O
-	DUAVEE.xml:S2:13397:1	O
estradiol	DUAVEE.xml:S2:13398:9	O
,	DUAVEE.xml:S2:13407:1	O
and	DUAVEE.xml:S2:13409:3	O
17	DUAVEE.xml:S2:13413:2	O
beta	DUAVEE.xml:S2:13415:4	O
-	DUAVEE.xml:S2:13419:1	O
dihydroequilin	DUAVEE.xml:S2:13420:14	O
.	DUAVEE.xml:S2:13434:1	O

Inactive	DUAVEE.xml:S2:13442:8	O
Ingredients	DUAVEE.xml:S2:13451:11	O
:	DUAVEE.xml:S2:13462:1	O
calcium	DUAVEE.xml:S2:13466:7	O
phosphate	DUAVEE.xml:S2:13474:9	O
tribasic	DUAVEE.xml:S2:13484:8	O
,	DUAVEE.xml:S2:13492:1	O
hydroxypropyl	DUAVEE.xml:S2:13494:13	O
cellulose	DUAVEE.xml:S2:13508:9	O
,	DUAVEE.xml:S2:13517:1	O
microcrystalline	DUAVEE.xml:S2:13519:16	O
cellulose	DUAVEE.xml:S2:13536:9	O
,	DUAVEE.xml:S2:13545:1	O
powdered	DUAVEE.xml:S2:13547:8	O
cellulose	DUAVEE.xml:S2:13556:9	O
,	DUAVEE.xml:S2:13565:1	O
hypromellose	DUAVEE.xml:S2:13567:12	O
,	DUAVEE.xml:S2:13579:1	O
lactose	DUAVEE.xml:S2:13581:7	O
monohydrate	DUAVEE.xml:S2:13589:11	O
,	DUAVEE.xml:S2:13600:1	O
magnesium	DUAVEE.xml:S2:13602:9	O
stearate	DUAVEE.xml:S2:13612:8	O
,	DUAVEE.xml:S2:13620:1	O
polyethylene	DUAVEE.xml:S2:13622:12	O
glycol	DUAVEE.xml:S2:13635:6	O
,	DUAVEE.xml:S2:13641:1	O
sucrose	DUAVEE.xml:S2:13643:7	O
,	DUAVEE.xml:S2:13650:1	O
ascorbic	DUAVEE.xml:S2:13652:8	O
acid	DUAVEE.xml:S2:13661:4	O
,	DUAVEE.xml:S2:13665:1	O
sucrose	DUAVEE.xml:S2:13667:7	O
palmitic	DUAVEE.xml:S2:13675:8	O
acid	DUAVEE.xml:S2:13684:4	O
ester	DUAVEE.xml:S2:13689:5	O
,	DUAVEE.xml:S2:13694:1	O
hydroxyethylcellulose	DUAVEE.xml:S2:13696:21	O
,	DUAVEE.xml:S2:13717:1	O
titanium	DUAVEE.xml:S2:13719:8	O
dioxide	DUAVEE.xml:S2:13728:7	O
,	DUAVEE.xml:S2:13735:1	O
red	DUAVEE.xml:S2:13737:3	O
iron	DUAVEE.xml:S2:13741:4	O
oxide	DUAVEE.xml:S2:13746:5	O
,	DUAVEE.xml:S2:13751:1	O
yellow	DUAVEE.xml:S2:13753:6	O
iron	DUAVEE.xml:S2:13760:4	O
oxide	DUAVEE.xml:S2:13765:5	O
,	DUAVEE.xml:S2:13770:1	O
black	DUAVEE.xml:S2:13772:5	O
iron	DUAVEE.xml:S2:13778:4	O
oxide	DUAVEE.xml:S2:13783:5	O
,	DUAVEE.xml:S2:13788:1	O
povidone	DUAVEE.xml:S2:13790:8	O
,	DUAVEE.xml:S2:13798:1	O
polydextrose	DUAVEE.xml:S2:13800:12	O
,	DUAVEE.xml:S2:13812:1	O
maltitol	DUAVEE.xml:S2:13814:8	O
,	DUAVEE.xml:S2:13822:1	O
poloxamer	DUAVEE.xml:S2:13824:9	O
188	DUAVEE.xml:S2:13834:3	O
,	DUAVEE.xml:S2:13837:1	O
propylene	DUAVEE.xml:S2:13839:9	O
glycol	DUAVEE.xml:S2:13849:6	O
,	DUAVEE.xml:S2:13855:1	O
isopropyl	DUAVEE.xml:S2:13857:9	O
alcohol	DUAVEE.xml:S2:13867:7	O
.	DUAVEE.xml:S2:13874:1	O

This	DUAVEE.xml:S2:13880:4	O
Patient	DUAVEE.xml:S2:13885:7	O
Information	DUAVEE.xml:S2:13893:11	O
has	DUAVEE.xml:S2:13905:3	O
been	DUAVEE.xml:S2:13909:4	O
approved	DUAVEE.xml:S2:13914:8	O
by	DUAVEE.xml:S2:13923:2	O
the	DUAVEE.xml:S2:13926:3	O
U.S.	DUAVEE.xml:S2:13930:4	O

Food	DUAVEE.xml:S2:13935:4	O
and	DUAVEE.xml:S2:13940:3	O
Drug	DUAVEE.xml:S2:13944:4	O
Administration	DUAVEE.xml:S2:13949:14	O
.	DUAVEE.xml:S2:13963:1	O

This	DUAVEE.xml:S2:13969:4	O
product	DUAVEE.xml:S2:13974:7	O
's	DUAVEE.xml:S2:13981:2	O
label	DUAVEE.xml:S2:13984:5	O
may	DUAVEE.xml:S2:13990:3	O
have	DUAVEE.xml:S2:13994:4	O
been	DUAVEE.xml:S2:13999:4	O
updated	DUAVEE.xml:S2:14004:7	O
.	DUAVEE.xml:S2:14011:1	O

For	DUAVEE.xml:S2:14013:3	O
current	DUAVEE.xml:S2:14017:7	O
full	DUAVEE.xml:S2:14025:4	O
prescribing	DUAVEE.xml:S2:14030:11	O
information	DUAVEE.xml:S2:14042:11	O
,	DUAVEE.xml:S2:14053:1	O
please	DUAVEE.xml:S2:14055:6	O
visit	DUAVEE.xml:S2:14062:5	O
www	DUAVEE.xml:S2:14068:3	O
.	DUAVEE.xml:S2:14071:1	O
pfizer	DUAVEE.xml:S2:14072:6	O
.	DUAVEE.xml:S2:14078:1	O
com	DUAVEE.xml:S2:14079:3	O
.	DUAVEE.xml:S2:14082:1	O

LAB	DUAVEE.xml:S2:14093:3	O
-	DUAVEE.xml:S2:14096:1	O
0583	DUAVEE.xml:S2:14097:4	O
-	DUAVEE.xml:S2:14101:1	O
1.0	DUAVEE.xml:S2:14102:3	O
\n\n\n\n	DUAVEE.xml:S2:14105:4	O
October	DUAVEE.xml:S2:14110:7	O
2013	DUAVEE.xml:S2:14118:4	O
\n	DUAVEE.xml:S2:14122:1	O
5	DUAVEE.xml:S3:4:1	O
WARNINGS	DUAVEE.xml:S3:6:8	O
AND	DUAVEE.xml:S3:15:3	O
PRECAUTIONS	DUAVEE.xml:S3:19:11	O

EXCERPT	DUAVEE.xml:S3:37:7	O
:	DUAVEE.xml:S3:44:1	O
Women	DUAVEE.xml:S3:52:5	O
taking	DUAVEE.xml:S3:58:6	O
DUAVEE	DUAVEE.xml:S3:65:6	O
should	DUAVEE.xml:S3:72:6	O
not	DUAVEE.xml:S3:79:3	O
take	DUAVEE.xml:S3:83:4	O
progestins	DUAVEE.xml:S3:88:10	O
,	DUAVEE.xml:S3:98:1	O
additional	DUAVEE.xml:S3:100:10	O
estrogens	DUAVEE.xml:S3:111:9	O
or	DUAVEE.xml:S3:121:2	O
additional	DUAVEE.xml:S3:124:10	O
estrogen	DUAVEE.xml:S3:135:8	O
agonist	DUAVEE.xml:S3:144:7	O
antagonists	DUAVEE.xml:S3:152:11	O
(	DUAVEE.xml:S3:164:1	O
5.1	DUAVEE.xml:S3:167:3	O
)	DUAVEE.xml:S3:172:1	O

Cardiovascular	DUAVEE.xml:S3:179:14	B-AdverseReaction
disorders	DUAVEE.xml:S3:194:9	I-AdverseReaction
,	DUAVEE.xml:S3:203:1	O
including	DUAVEE.xml:S3:205:9	O
venous	DUAVEE.xml:S3:215:6	B-AdverseReaction
thromboembolism	DUAVEE.xml:S3:222:15	I-AdverseReaction
,	DUAVEE.xml:S3:237:1	O
pulmonary	DUAVEE.xml:S3:239:9	B-AdverseReaction
embolism	DUAVEE.xml:S3:249:8	I-AdverseReaction
,	DUAVEE.xml:S3:257:1	O
stroke	DUAVEE.xml:S3:259:6	B-AdverseReaction
,	DUAVEE.xml:S3:265:1	O
and	DUAVEE.xml:S3:267:3	O
retinal	DUAVEE.xml:S3:271:7	B-AdverseReaction
vascular	DUAVEE.xml:S3:279:8	I-AdverseReaction
thrombosis	DUAVEE.xml:S3:288:10	I-AdverseReaction
(	DUAVEE.xml:S3:299:1	O
5.2	DUAVEE.xml:S3:302:3	O
,	DUAVEE.xml:S3:307:1	O
5.6	DUAVEE.xml:S3:310:3	O
)	DUAVEE.xml:S3:315:1	O

Malignant	DUAVEE.xml:S3:322:9	B-AdverseReaction
neoplasms	DUAVEE.xml:S3:332:9	I-AdverseReaction
,	DUAVEE.xml:S3:341:1	O
including	DUAVEE.xml:S3:343:9	O
endometrial	DUAVEE.xml:S3:353:11	B-AdverseReaction
cancer	DUAVEE.xml:S3:365:6	I-AdverseReaction
,	DUAVEE.xml:S3:371:1	O
breast	DUAVEE.xml:S3:373:6	B-AdverseReaction
cancer	DUAVEE.xml:S3:380:6	I-AdverseReaction
,	DUAVEE.xml:S3:386:1	O
and	DUAVEE.xml:S3:388:3	O
ovarian	DUAVEE.xml:S3:392:7	B-AdverseReaction
cancer	DUAVEE.xml:S3:400:6	I-AdverseReaction
(	DUAVEE.xml:S3:407:1	O
5.3	DUAVEE.xml:S3:410:3	O
)	DUAVEE.xml:S3:415:1	O

Estrogens	DUAVEE.xml:S3:422:9	O
increase	DUAVEE.xml:S3:432:8	O
the	DUAVEE.xml:S3:441:3	O
risk	DUAVEE.xml:S3:445:4	B-Factor
of	DUAVEE.xml:S3:450:2	O
gallbladder	DUAVEE.xml:S3:453:11	B-AdverseReaction
disease	DUAVEE.xml:S3:465:7	I-AdverseReaction
(	DUAVEE.xml:S3:473:1	O
5.5	DUAVEE.xml:S3:476:3	O
)	DUAVEE.xml:S3:481:1	O

Discontinue	DUAVEE.xml:S3:488:11	O
estrogen	DUAVEE.xml:S3:500:8	O
if	DUAVEE.xml:S3:509:2	O
loss	DUAVEE.xml:S3:512:4	O
of	DUAVEE.xml:S3:517:2	O
vision	DUAVEE.xml:S3:520:6	O
,	DUAVEE.xml:S3:526:1	O
severe	DUAVEE.xml:S3:528:6	O
hypertriglyceridemia	DUAVEE.xml:S3:535:20	O
or	DUAVEE.xml:S3:556:2	O
cholestatic	DUAVEE.xml:S3:559:11	O
jaundice	DUAVEE.xml:S3:571:8	O
occurs	DUAVEE.xml:S3:580:6	O
(	DUAVEE.xml:S3:587:1	O
5.6	DUAVEE.xml:S3:590:3	O
,	DUAVEE.xml:S3:595:1	O
5.8	DUAVEE.xml:S3:598:3	O
,	DUAVEE.xml:S3:603:1	O
5.9	DUAVEE.xml:S3:606:3	O
)	DUAVEE.xml:S3:611:1	O

Monitor	DUAVEE.xml:S3:618:7	O
thyroid	DUAVEE.xml:S3:626:7	O
function	DUAVEE.xml:S3:634:8	O
in	DUAVEE.xml:S3:643:2	O
women	DUAVEE.xml:S3:646:5	O
on	DUAVEE.xml:S3:652:2	O
thyroid	DUAVEE.xml:S3:655:7	O
replacement	DUAVEE.xml:S3:663:11	O
therapy	DUAVEE.xml:S3:675:7	O
(	DUAVEE.xml:S3:683:1	O
5.10	DUAVEE.xml:S3:686:4	O
,	DUAVEE.xml:S3:692:1	O
5.17	DUAVEE.xml:S3:695:4	O
)	DUAVEE.xml:S3:701:1	O

5.1	DUAVEE.xml:S3:715:3	O

Drugs	DUAVEE.xml:S3:719:5	O

Containing	DUAVEE.xml:S3:725:10	O
Progestins	DUAVEE.xml:S3:736:10	O
,	DUAVEE.xml:S3:746:1	O
Estrogens	DUAVEE.xml:S3:748:9	O
or	DUAVEE.xml:S3:758:2	O
Estrogen	DUAVEE.xml:S3:761:8	O
Agonist	DUAVEE.xml:S3:770:7	O
Antagonists	DUAVEE.xml:S3:778:11	O

DUAVEE	DUAVEE.xml:S3:795:6	O
contains	DUAVEE.xml:S3:802:8	O
conjugated	DUAVEE.xml:S3:811:10	O
estrogens	DUAVEE.xml:S3:822:9	O
and	DUAVEE.xml:S3:832:3	O
bazedoxifene	DUAVEE.xml:S3:836:12	O
,	DUAVEE.xml:S3:848:1	O
an	DUAVEE.xml:S3:850:2	O
estrogen	DUAVEE.xml:S3:853:8	O
agonist	DUAVEE.xml:S3:862:7	O
antagonist	DUAVEE.xml:S3:870:10	O
.	DUAVEE.xml:S3:880:1	O

Women	DUAVEE.xml:S3:882:5	O
taking	DUAVEE.xml:S3:888:6	O
DUAVEE	DUAVEE.xml:S3:895:6	O
should	DUAVEE.xml:S3:902:6	O
not	DUAVEE.xml:S3:909:3	O
take	DUAVEE.xml:S3:913:4	O
progestins	DUAVEE.xml:S3:918:10	O
,	DUAVEE.xml:S3:928:1	O
additional	DUAVEE.xml:S3:930:10	O
estrogens	DUAVEE.xml:S3:941:9	O
or	DUAVEE.xml:S3:951:2	O
additional	DUAVEE.xml:S3:954:10	O
estrogen	DUAVEE.xml:S3:965:8	O
agonist	DUAVEE.xml:S3:974:7	O
antagonists	DUAVEE.xml:S3:982:11	O
.	DUAVEE.xml:S3:993:1	O

5.2	DUAVEE.xml:S3:1002:3	O
Cardiovascular	DUAVEE.xml:S3:1006:14	O
Disorders	DUAVEE.xml:S3:1021:9	O

Estrogen	DUAVEE.xml:S3:1036:8	O
agonist	DUAVEE.xml:S3:1045:7	O
antagonists	DUAVEE.xml:S3:1053:11	O
(	DUAVEE.xml:S3:1065:1	O
including	DUAVEE.xml:S3:1066:9	O
bazedoxifene	DUAVEE.xml:S3:1076:12	O
,	DUAVEE.xml:S3:1088:1	O
a	DUAVEE.xml:S3:1090:1	O
component	DUAVEE.xml:S3:1092:9	O
of	DUAVEE.xml:S3:1102:2	O
DUAVEE	DUAVEE.xml:S3:1105:6	O
)	DUAVEE.xml:S3:1111:1	O
and	DUAVEE.xml:S3:1113:3	O
estrogens	DUAVEE.xml:S3:1117:9	O
individually	DUAVEE.xml:S3:1127:12	O
are	DUAVEE.xml:S3:1140:3	O
known	DUAVEE.xml:S3:1144:5	O
to	DUAVEE.xml:S3:1150:2	O
increase	DUAVEE.xml:S3:1153:8	O
the	DUAVEE.xml:S3:1162:3	O
risk	DUAVEE.xml:S3:1166:4	B-Factor
of	DUAVEE.xml:S3:1171:2	O
VTE	DUAVEE.xml:S3:1174:3	B-AdverseReaction
.	DUAVEE.xml:S3:1177:1	O

An	DUAVEE.xml:S3:1183:2	O
increased	DUAVEE.xml:S3:1186:9	O
risk	DUAVEE.xml:S3:1196:4	O
of	DUAVEE.xml:S3:1201:2	O
stroke	DUAVEE.xml:S3:1204:6	B-AdverseReaction
and	DUAVEE.xml:S3:1211:3	O
DVT	DUAVEE.xml:S3:1215:3	B-AdverseReaction
has	DUAVEE.xml:S3:1219:3	O
been	DUAVEE.xml:S3:1223:4	O
reported	DUAVEE.xml:S3:1228:8	O
with	DUAVEE.xml:S3:1237:4	O
estrogen	DUAVEE.xml:S3:1242:8	B-DrugClass
-	DUAVEE.xml:S3:1250:1	O
alone	DUAVEE.xml:S3:1251:5	O
therapy	DUAVEE.xml:S3:1257:7	O
.	DUAVEE.xml:S3:1264:1	O

Should	DUAVEE.xml:S3:1266:6	O
any	DUAVEE.xml:S3:1273:3	O
of	DUAVEE.xml:S3:1277:2	O
these	DUAVEE.xml:S3:1280:5	O
occur	DUAVEE.xml:S3:1286:5	O
or	DUAVEE.xml:S3:1292:2	O
be	DUAVEE.xml:S3:1295:2	O
suspected	DUAVEE.xml:S3:1298:9	O
,	DUAVEE.xml:S3:1307:1	O
DUAVEE	DUAVEE.xml:S3:1309:6	O
should	DUAVEE.xml:S3:1316:6	O
be	DUAVEE.xml:S3:1323:2	O
discontinued	DUAVEE.xml:S3:1326:12	O
immediately	DUAVEE.xml:S3:1339:11	O
.	DUAVEE.xml:S3:1350:1	O

Risk	DUAVEE.xml:S3:1356:4	O
factors	DUAVEE.xml:S3:1361:7	O
for	DUAVEE.xml:S3:1369:3	O
arterial	DUAVEE.xml:S3:1373:8	O
vascular	DUAVEE.xml:S3:1382:8	O
disease	DUAVEE.xml:S3:1391:7	O
(	DUAVEE.xml:S3:1399:1	O
for	DUAVEE.xml:S3:1400:3	O
example	DUAVEE.xml:S3:1404:7	O
,	DUAVEE.xml:S3:1411:1	O
hypertension	DUAVEE.xml:S3:1413:12	O
,	DUAVEE.xml:S3:1425:1	O
diabetes	DUAVEE.xml:S3:1427:8	O
mellitus	DUAVEE.xml:S3:1436:8	O
,	DUAVEE.xml:S3:1444:1	O
tobacco	DUAVEE.xml:S3:1446:7	O
use	DUAVEE.xml:S3:1454:3	O
,	DUAVEE.xml:S3:1457:1	O
hypercholesterolemia	DUAVEE.xml:S3:1459:20	O
,	DUAVEE.xml:S3:1479:1	O
and	DUAVEE.xml:S3:1481:3	O
obesity	DUAVEE.xml:S3:1485:7	O
)	DUAVEE.xml:S3:1492:1	O
and	DUAVEE.xml:S3:1494:3	O
or	DUAVEE.xml:S3:1498:2	O
VTE	DUAVEE.xml:S3:1501:3	O
(	DUAVEE.xml:S3:1505:1	O
for	DUAVEE.xml:S3:1506:3	O
example	DUAVEE.xml:S3:1510:7	O
,	DUAVEE.xml:S3:1517:1	O
personal	DUAVEE.xml:S3:1519:8	O
history	DUAVEE.xml:S3:1528:7	O
or	DUAVEE.xml:S3:1536:2	O
family	DUAVEE.xml:S3:1539:6	O
history	DUAVEE.xml:S3:1546:7	O
of	DUAVEE.xml:S3:1554:2	O
VTE	DUAVEE.xml:S3:1557:3	O
,	DUAVEE.xml:S3:1560:1	O
obesity	DUAVEE.xml:S3:1562:7	O
,	DUAVEE.xml:S3:1569:1	O
and	DUAVEE.xml:S3:1571:3	O
systemic	DUAVEE.xml:S3:1575:8	O
lupus	DUAVEE.xml:S3:1584:5	O
erythematosus	DUAVEE.xml:S3:1590:13	O
)	DUAVEE.xml:S3:1603:1	O
should	DUAVEE.xml:S3:1605:6	O
be	DUAVEE.xml:S3:1612:2	O
managed	DUAVEE.xml:S3:1615:7	O
appropriately	DUAVEE.xml:S3:1623:13	O
.	DUAVEE.xml:S3:1636:1	O

Stroke	DUAVEE.xml:S3:1645:6	O

In	DUAVEE.xml:S3:1658:2	O
the	DUAVEE.xml:S3:1661:3	O
WHI	DUAVEE.xml:S3:1665:3	O
estrogen	DUAVEE.xml:S3:1669:8	O
-	DUAVEE.xml:S3:1677:1	O
alone	DUAVEE.xml:S3:1678:5	O
substudy	DUAVEE.xml:S3:1684:8	O
,	DUAVEE.xml:S3:1692:1	O
a	DUAVEE.xml:S3:1694:1	O
statistically	DUAVEE.xml:S3:1696:13	O
significant	DUAVEE.xml:S3:1710:11	O
increased	DUAVEE.xml:S3:1722:9	O
risk	DUAVEE.xml:S3:1732:4	O
of	DUAVEE.xml:S3:1737:2	O
stroke	DUAVEE.xml:S3:1740:6	B-AdverseReaction
was	DUAVEE.xml:S3:1747:3	O
reported	DUAVEE.xml:S3:1751:8	O
in	DUAVEE.xml:S3:1760:2	O
women	DUAVEE.xml:S3:1763:5	O
50	DUAVEE.xml:S3:1769:2	O
to	DUAVEE.xml:S3:1772:2	O
79	DUAVEE.xml:S3:1775:2	O
years	DUAVEE.xml:S3:1778:5	O
of	DUAVEE.xml:S3:1784:2	O
age	DUAVEE.xml:S3:1787:3	O
receiving	DUAVEE.xml:S3:1791:9	O
daily	DUAVEE.xml:S3:1801:5	O
conjugated	DUAVEE.xml:S3:1807:10	B-DrugClass
estrogens	DUAVEE.xml:S3:1818:9	I-DrugClass
(	DUAVEE.xml:S3:1828:1	O
CE	DUAVEE.xml:S3:1829:2	O
)	DUAVEE.xml:S3:1831:1	O
(	DUAVEE.xml:S3:1833:1	O
0.625	DUAVEE.xml:S3:1834:5	O
mg	DUAVEE.xml:S3:1840:2	O
)-	DUAVEE.xml:S3:1842:2	O
alone	DUAVEE.xml:S3:1844:5	O
compared	DUAVEE.xml:S3:1850:8	O
to	DUAVEE.xml:S3:1859:2	O
women	DUAVEE.xml:S3:1862:5	O
in	DUAVEE.xml:S3:1868:2	O
the	DUAVEE.xml:S3:1871:3	O
same	DUAVEE.xml:S3:1875:4	O
age	DUAVEE.xml:S3:1880:3	O
group	DUAVEE.xml:S3:1884:5	O
receiving	DUAVEE.xml:S3:1890:9	O
placebo	DUAVEE.xml:S3:1900:7	O
(	DUAVEE.xml:S3:1908:1	O
45	DUAVEE.xml:S3:1909:2	O
versus	DUAVEE.xml:S3:1912:6	O
33	DUAVEE.xml:S3:1919:2	O
per	DUAVEE.xml:S3:1922:3	O
10	DUAVEE.xml:S3:1926:2	O
,	DUAVEE.xml:S3:1928:1	O
000	DUAVEE.xml:S3:1929:3	O
women	DUAVEE.xml:S3:1933:5	O
-	DUAVEE.xml:S3:1938:1	O
years	DUAVEE.xml:S3:1939:5	O
)	DUAVEE.xml:S3:1944:1	O
.	DUAVEE.xml:S3:1945:1	O

The	DUAVEE.xml:S3:1947:3	O
increase	DUAVEE.xml:S3:1951:8	O
in	DUAVEE.xml:S3:1960:2	O
risk	DUAVEE.xml:S3:1963:4	O
was	DUAVEE.xml:S3:1968:3	O
demonstrated	DUAVEE.xml:S3:1972:12	O
in	DUAVEE.xml:S3:1985:2	O
year	DUAVEE.xml:S3:1988:4	O
1	DUAVEE.xml:S3:1993:1	O
and	DUAVEE.xml:S3:1995:3	O
persisted	DUAVEE.xml:S3:1999:9	O
[	DUAVEE.xml:S3:2009:1	O
see	DUAVEE.xml:S3:2010:3	O
Clinical	DUAVEE.xml:S3:2015:8	O
Studies	DUAVEE.xml:S3:2024:7	O
(	DUAVEE.xml:S3:2032:1	O
14.5	DUAVEE.xml:S3:2033:4	O
)	DUAVEE.xml:S3:2037:1	O
]	DUAVEE.xml:S3:2040:1	O
.	DUAVEE.xml:S3:2043:1	O

Subgroup	DUAVEE.xml:S3:2049:8	O
analyses	DUAVEE.xml:S3:2058:8	O
of	DUAVEE.xml:S3:2067:2	O
women	DUAVEE.xml:S3:2070:5	O
50	DUAVEE.xml:S3:2076:2	O
to	DUAVEE.xml:S3:2079:2	O
59	DUAVEE.xml:S3:2082:2	O
years	DUAVEE.xml:S3:2085:5	O
of	DUAVEE.xml:S3:2091:2	O
age	DUAVEE.xml:S3:2094:3	O
suggest	DUAVEE.xml:S3:2098:7	O
no	DUAVEE.xml:S3:2106:2	B-Negation
increased	DUAVEE.xml:S3:2109:9	O
risk	DUAVEE.xml:S3:2119:4	O
of	DUAVEE.xml:S3:2124:2	O
stroke	DUAVEE.xml:S3:2127:6	B-AdverseReaction
for	DUAVEE.xml:S3:2134:3	O
those	DUAVEE.xml:S3:2138:5	O
women	DUAVEE.xml:S3:2144:5	O
receiving	DUAVEE.xml:S3:2150:9	O
conjugated	DUAVEE.xml:S3:2160:10	B-DrugClass
estrogens	DUAVEE.xml:S3:2171:9	I-DrugClass
(	DUAVEE.xml:S3:2181:1	O
0.625	DUAVEE.xml:S3:2182:5	O
mg	DUAVEE.xml:S3:2188:2	O
)-	DUAVEE.xml:S3:2190:2	O
alone	DUAVEE.xml:S3:2192:5	O
versus	DUAVEE.xml:S3:2198:6	O
those	DUAVEE.xml:S3:2205:5	O
receiving	DUAVEE.xml:S3:2211:9	O
placebo	DUAVEE.xml:S3:2221:7	O
(	DUAVEE.xml:S3:2229:1	O
18	DUAVEE.xml:S3:2230:2	O
versus	DUAVEE.xml:S3:2233:6	O
21	DUAVEE.xml:S3:2240:2	O
per	DUAVEE.xml:S3:2243:3	O
10	DUAVEE.xml:S3:2247:2	O
,	DUAVEE.xml:S3:2249:1	O
000	DUAVEE.xml:S3:2250:3	O
women	DUAVEE.xml:S3:2254:5	O
-	DUAVEE.xml:S3:2259:1	O
years	DUAVEE.xml:S3:2260:5	O
)	DUAVEE.xml:S3:2265:1	O
.	DUAVEE.xml:S3:2266:1	O

Should	DUAVEE.xml:S3:2272:6	O
a	DUAVEE.xml:S3:2279:1	O
stroke	DUAVEE.xml:S3:2281:6	O
occur	DUAVEE.xml:S3:2288:5	O
or	DUAVEE.xml:S3:2294:2	O
be	DUAVEE.xml:S3:2297:2	O
suspected	DUAVEE.xml:S3:2300:9	O
,	DUAVEE.xml:S3:2309:1	O
DUAVEE	DUAVEE.xml:S3:2311:6	O
should	DUAVEE.xml:S3:2318:6	O
be	DUAVEE.xml:S3:2325:2	O
discontinued	DUAVEE.xml:S3:2328:12	O
immediately	DUAVEE.xml:S3:2341:11	O
[	DUAVEE.xml:S3:2353:1	O
see	DUAVEE.xml:S3:2354:3	O
Contraindications	DUAVEE.xml:S3:2359:17	O
(	DUAVEE.xml:S3:2377:1	O
4	DUAVEE.xml:S3:2378:1	O
)	DUAVEE.xml:S3:2379:1	O
]	DUAVEE.xml:S3:2382:1	O
.	DUAVEE.xml:S3:2383:1	O

Coronary	DUAVEE.xml:S3:2394:8	O
Heart	DUAVEE.xml:S3:2403:5	O
Disease	DUAVEE.xml:S3:2409:7	O

In	DUAVEE.xml:S3:2423:2	O
the	DUAVEE.xml:S3:2426:3	O
WHI	DUAVEE.xml:S3:2430:3	O
estrogen	DUAVEE.xml:S3:2434:8	O
-	DUAVEE.xml:S3:2442:1	O
alone	DUAVEE.xml:S3:2443:5	O
substudy	DUAVEE.xml:S3:2449:8	O
,	DUAVEE.xml:S3:2457:1	O
no	DUAVEE.xml:S3:2459:2	O
overall	DUAVEE.xml:S3:2462:7	O
effect	DUAVEE.xml:S3:2470:6	O
on	DUAVEE.xml:S3:2477:2	O
coronary	DUAVEE.xml:S3:2480:8	B-AdverseReaction
heart	DUAVEE.xml:S3:2489:5	I-AdverseReaction
disease	DUAVEE.xml:S3:2495:7	I-AdverseReaction
(	DUAVEE.xml:S3:2503:1	O
CHD	DUAVEE.xml:S3:2504:3	B-AdverseReaction
)	DUAVEE.xml:S3:2507:1	O
events	DUAVEE.xml:S3:2509:6	O
(	DUAVEE.xml:S3:2516:1	O
defined	DUAVEE.xml:S3:2517:7	O
as	DUAVEE.xml:S3:2525:2	O
nonfatal	DUAVEE.xml:S3:2528:8	B-Severity
myocardial	DUAVEE.xml:S3:2537:10	B-AdverseReaction
infarction	DUAVEE.xml:S3:2548:10	I-AdverseReaction
,	DUAVEE.xml:S3:2558:1	O
silent	DUAVEE.xml:S3:2560:6	B-AdverseReaction
myocardial	DUAVEE.xml:S3:2567:10	I-AdverseReaction
infarction	DUAVEE.xml:S3:2578:10	I-AdverseReaction
,	DUAVEE.xml:S3:2588:1	O
or	DUAVEE.xml:S3:2590:2	O
CHD	DUAVEE.xml:S3:2593:3	B-AdverseReaction
death	DUAVEE.xml:S3:2597:5	I-AdverseReaction
)	DUAVEE.xml:S3:2602:1	O
was	DUAVEE.xml:S3:2604:3	O
reported	DUAVEE.xml:S3:2608:8	O
in	DUAVEE.xml:S3:2617:2	O
women	DUAVEE.xml:S3:2620:5	O
receiving	DUAVEE.xml:S3:2626:9	O
estrogen	DUAVEE.xml:S3:2636:8	B-DrugClass
-	DUAVEE.xml:S3:2644:1	O
alone	DUAVEE.xml:S3:2645:5	O
compared	DUAVEE.xml:S3:2651:8	O
to	DUAVEE.xml:S3:2660:2	O
placebo	DUAVEE.xml:S3:2663:7	O
[	DUAVEE.xml:S3:2671:1	O
see	DUAVEE.xml:S3:2672:3	O
Clinical	DUAVEE.xml:S3:2677:8	O
Studies	DUAVEE.xml:S3:2686:7	O
(	DUAVEE.xml:S3:2694:1	O
14.5	DUAVEE.xml:S3:2695:4	O
)	DUAVEE.xml:S3:2699:1	O
]	DUAVEE.xml:S3:2702:1	O
.	DUAVEE.xml:S3:2705:1	O

Subgroup	DUAVEE.xml:S3:2711:8	O
analyses	DUAVEE.xml:S3:2720:8	O
of	DUAVEE.xml:S3:2729:2	O
women	DUAVEE.xml:S3:2732:5	O
50	DUAVEE.xml:S3:2738:2	O
to	DUAVEE.xml:S3:2741:2	O
59	DUAVEE.xml:S3:2744:2	O
years	DUAVEE.xml:S3:2747:5	O
of	DUAVEE.xml:S3:2753:2	O
age	DUAVEE.xml:S3:2756:3	O
suggest	DUAVEE.xml:S3:2760:7	O
a	DUAVEE.xml:S3:2768:1	O
statistically	DUAVEE.xml:S3:2770:13	O
non	DUAVEE.xml:S3:2784:3	O
-	DUAVEE.xml:S3:2787:1	O
significant	DUAVEE.xml:S3:2788:11	O
reduction	DUAVEE.xml:S3:2800:9	B-Negation
in	DUAVEE.xml:S3:2810:2	O
CHD	DUAVEE.xml:S3:2813:3	B-AdverseReaction
events	DUAVEE.xml:S3:2817:6	O
(	DUAVEE.xml:S3:2824:1	O
CE	DUAVEE.xml:S3:2825:2	O
[	DUAVEE.xml:S3:2828:1	O
0.625	DUAVEE.xml:S3:2829:5	O
mg	DUAVEE.xml:S3:2835:2	O
]-	DUAVEE.xml:S3:2837:2	O
alone	DUAVEE.xml:S3:2839:5	O
compared	DUAVEE.xml:S3:2845:8	O
to	DUAVEE.xml:S3:2854:2	O
placebo	DUAVEE.xml:S3:2857:7	O
)	DUAVEE.xml:S3:2864:1	O
in	DUAVEE.xml:S3:2866:2	O
women	DUAVEE.xml:S3:2869:5	O
with	DUAVEE.xml:S3:2875:4	O
less	DUAVEE.xml:S3:2880:4	O
than	DUAVEE.xml:S3:2885:4	O
10	DUAVEE.xml:S3:2890:2	O
years	DUAVEE.xml:S3:2893:5	O
since	DUAVEE.xml:S3:2899:5	O
menopause	DUAVEE.xml:S3:2905:9	O
(	DUAVEE.xml:S3:2915:1	O
8	DUAVEE.xml:S3:2916:1	O
versus	DUAVEE.xml:S3:2918:6	O
16	DUAVEE.xml:S3:2925:2	O
per	DUAVEE.xml:S3:2928:3	O
10	DUAVEE.xml:S3:2932:2	O
,	DUAVEE.xml:S3:2934:1	O
000	DUAVEE.xml:S3:2935:3	O
women	DUAVEE.xml:S3:2939:5	O
-	DUAVEE.xml:S3:2944:1	O
years	DUAVEE.xml:S3:2945:5	O
)	DUAVEE.xml:S3:2950:1	O
.	DUAVEE.xml:S3:2951:1	O

Venous	DUAVEE.xml:S3:2960:6	O
Thromboembolism	DUAVEE.xml:S3:2967:15	O
(	DUAVEE.xml:S3:2983:1	O
VTE	DUAVEE.xml:S3:2984:3	O
)	DUAVEE.xml:S3:2987:1	O

In	DUAVEE.xml:S3:2995:2	O
the	DUAVEE.xml:S3:2998:3	O
WHI	DUAVEE.xml:S3:3002:3	O
estrogen	DUAVEE.xml:S3:3006:8	O
-	DUAVEE.xml:S3:3014:1	O
alone	DUAVEE.xml:S3:3015:5	O
substudy	DUAVEE.xml:S3:3021:8	O
,	DUAVEE.xml:S3:3029:1	O
the	DUAVEE.xml:S3:3031:3	O
risk	DUAVEE.xml:S3:3035:4	O
of	DUAVEE.xml:S3:3040:2	O
VTE	DUAVEE.xml:S3:3043:3	B-AdverseReaction
[	DUAVEE.xml:S3:3047:1	O
DVT	DUAVEE.xml:S3:3048:3	B-AdverseReaction
and	DUAVEE.xml:S3:3052:3	O
pulmonary	DUAVEE.xml:S3:3056:9	B-AdverseReaction
embolism	DUAVEE.xml:S3:3066:8	I-AdverseReaction
(	DUAVEE.xml:S3:3075:1	O
PE	DUAVEE.xml:S3:3076:2	B-AdverseReaction
)]	DUAVEE.xml:S3:3078:2	O
was	DUAVEE.xml:S3:3081:3	O
increased	DUAVEE.xml:S3:3085:9	O
for	DUAVEE.xml:S3:3095:3	O
women	DUAVEE.xml:S3:3099:5	O
receiving	DUAVEE.xml:S3:3105:9	O
daily	DUAVEE.xml:S3:3115:5	O
conjugated	DUAVEE.xml:S3:3121:10	B-DrugClass
estrogens	DUAVEE.xml:S3:3132:9	I-DrugClass
(	DUAVEE.xml:S3:3142:1	O
0.625	DUAVEE.xml:S3:3143:5	O
mg	DUAVEE.xml:S3:3149:2	O
)-	DUAVEE.xml:S3:3151:2	O
alone	DUAVEE.xml:S3:3153:5	O
compared	DUAVEE.xml:S3:3159:8	O
to	DUAVEE.xml:S3:3168:2	O
placebo	DUAVEE.xml:S3:3171:7	O
(	DUAVEE.xml:S3:3179:1	O
30	DUAVEE.xml:S3:3180:2	O
versus	DUAVEE.xml:S3:3183:6	O
22	DUAVEE.xml:S3:3190:2	O
per	DUAVEE.xml:S3:3193:3	O
10	DUAVEE.xml:S3:3197:2	O
,	DUAVEE.xml:S3:3199:1	O
000	DUAVEE.xml:S3:3200:3	O
women	DUAVEE.xml:S3:3204:5	O
-	DUAVEE.xml:S3:3209:1	O
years	DUAVEE.xml:S3:3210:5	O
)	DUAVEE.xml:S3:3215:1	O
,	DUAVEE.xml:S3:3216:1	O
although	DUAVEE.xml:S3:3218:8	O
only	DUAVEE.xml:S3:3227:4	O
the	DUAVEE.xml:S3:3232:3	O
increased	DUAVEE.xml:S3:3236:9	O
risk	DUAVEE.xml:S3:3246:4	O
of	DUAVEE.xml:S3:3251:2	O
DVT	DUAVEE.xml:S3:3254:3	B-AdverseReaction
reached	DUAVEE.xml:S3:3258:7	O
statistical	DUAVEE.xml:S3:3266:11	O
significance	DUAVEE.xml:S3:3278:12	O
(	DUAVEE.xml:S3:3291:1	O
23	DUAVEE.xml:S3:3292:2	O
versus	DUAVEE.xml:S3:3295:6	O
15	DUAVEE.xml:S3:3302:2	O
per	DUAVEE.xml:S3:3305:3	O
10	DUAVEE.xml:S3:3309:2	O
,	DUAVEE.xml:S3:3311:1	O
000	DUAVEE.xml:S3:3312:3	O
women	DUAVEE.xml:S3:3316:5	O
-	DUAVEE.xml:S3:3321:1	O
years	DUAVEE.xml:S3:3322:5	O
)	DUAVEE.xml:S3:3327:1	O
.	DUAVEE.xml:S3:3328:1	O

The	DUAVEE.xml:S3:3330:3	O
increase	DUAVEE.xml:S3:3334:8	O
in	DUAVEE.xml:S3:3343:2	O
VTE	DUAVEE.xml:S3:3346:3	B-AdverseReaction
risk	DUAVEE.xml:S3:3350:4	B-Factor
was	DUAVEE.xml:S3:3355:3	O
demonstrated	DUAVEE.xml:S3:3359:12	O
during	DUAVEE.xml:S3:3372:6	O
the	DUAVEE.xml:S3:3379:3	O
first	DUAVEE.xml:S3:3383:5	O
2	DUAVEE.xml:S3:3389:1	O
years	DUAVEE.xml:S3:3391:5	O
[	DUAVEE.xml:S3:3397:1	O
see	DUAVEE.xml:S3:3398:3	O
Clinical	DUAVEE.xml:S3:3403:8	O
Studies	DUAVEE.xml:S3:3412:7	O
(	DUAVEE.xml:S3:3420:1	O
14.5	DUAVEE.xml:S3:3421:4	O
)	DUAVEE.xml:S3:3425:1	O
]	DUAVEE.xml:S3:3428:1	O
.	DUAVEE.xml:S3:3431:1	O

If	DUAVEE.xml:S3:3437:2	O
feasible	DUAVEE.xml:S3:3440:8	O
,	DUAVEE.xml:S3:3448:1	O
DUAVEE	DUAVEE.xml:S3:3450:6	O
should	DUAVEE.xml:S3:3457:6	O
be	DUAVEE.xml:S3:3464:2	O
discontinued	DUAVEE.xml:S3:3467:12	O
at	DUAVEE.xml:S3:3480:2	O
least	DUAVEE.xml:S3:3483:5	O
4	DUAVEE.xml:S3:3489:1	O
to	DUAVEE.xml:S3:3491:2	O
6	DUAVEE.xml:S3:3494:1	O
weeks	DUAVEE.xml:S3:3496:5	O
before	DUAVEE.xml:S3:3502:6	O
surgery	DUAVEE.xml:S3:3509:7	O
of	DUAVEE.xml:S3:3517:2	O
the	DUAVEE.xml:S3:3520:3	O
type	DUAVEE.xml:S3:3524:4	O
associated	DUAVEE.xml:S3:3529:10	O
with	DUAVEE.xml:S3:3540:4	O
an	DUAVEE.xml:S3:3545:2	O
increased	DUAVEE.xml:S3:3548:9	O
risk	DUAVEE.xml:S3:3558:4	O
of	DUAVEE.xml:S3:3563:2	O
thromboembolism	DUAVEE.xml:S3:3566:15	O
,	DUAVEE.xml:S3:3581:1	O
or	DUAVEE.xml:S3:3583:2	O
during	DUAVEE.xml:S3:3586:6	O
periods	DUAVEE.xml:S3:3593:7	O
of	DUAVEE.xml:S3:3601:2	O
prolonged	DUAVEE.xml:S3:3604:9	O
immobilization	DUAVEE.xml:S3:3614:14	O
.	DUAVEE.xml:S3:3628:1	O

Because	DUAVEE.xml:S3:3630:7	O
immobilization	DUAVEE.xml:S3:3638:14	O
increases	DUAVEE.xml:S3:3653:9	O
the	DUAVEE.xml:S3:3663:3	O
risk	DUAVEE.xml:S3:3667:4	O
for	DUAVEE.xml:S3:3672:3	O
venous	DUAVEE.xml:S3:3676:6	O
thromboembolic	DUAVEE.xml:S3:3683:14	O
events	DUAVEE.xml:S3:3698:6	O
independent	DUAVEE.xml:S3:3705:11	O
of	DUAVEE.xml:S3:3717:2	O
therapy	DUAVEE.xml:S3:3720:7	O
,	DUAVEE.xml:S3:3727:1	O
DUAVEE	DUAVEE.xml:S3:3729:6	O
should	DUAVEE.xml:S3:3736:6	O
be	DUAVEE.xml:S3:3743:2	O
discontinued	DUAVEE.xml:S3:3746:12	O
prior	DUAVEE.xml:S3:3759:5	O
to	DUAVEE.xml:S3:3765:2	O
and	DUAVEE.xml:S3:3768:3	O
during	DUAVEE.xml:S3:3772:6	O
prolonged	DUAVEE.xml:S3:3779:9	O
immobilization	DUAVEE.xml:S3:3789:14	O
(	DUAVEE.xml:S3:3804:1	O
e	DUAVEE.xml:S3:3805:1	O
.	DUAVEE.xml:S3:3806:1	O
g	DUAVEE.xml:S3:3807:1	O
.	DUAVEE.xml:S3:3808:1	O
,	DUAVEE.xml:S3:3809:1	O
post	DUAVEE.xml:S3:3811:4	O
-	DUAVEE.xml:S3:3815:1	O
surgical	DUAVEE.xml:S3:3816:8	O
recovery	DUAVEE.xml:S3:3825:8	O
,	DUAVEE.xml:S3:3833:1	O
prolonged	DUAVEE.xml:S3:3835:9	O
bed	DUAVEE.xml:S3:3845:3	O
rest	DUAVEE.xml:S3:3849:4	O
)	DUAVEE.xml:S3:3853:1	O
and	DUAVEE.xml:S3:3855:3	O
DUAVEE	DUAVEE.xml:S3:3859:6	O
therapy	DUAVEE.xml:S3:3866:7	O
should	DUAVEE.xml:S3:3874:6	O
be	DUAVEE.xml:S3:3881:2	O
resumed	DUAVEE.xml:S3:3884:7	O
only	DUAVEE.xml:S3:3892:4	O
after	DUAVEE.xml:S3:3897:5	O
the	DUAVEE.xml:S3:3903:3	O
patient	DUAVEE.xml:S3:3907:7	O
is	DUAVEE.xml:S3:3915:2	O
fully	DUAVEE.xml:S3:3918:5	O
ambulatory	DUAVEE.xml:S3:3924:10	O
.	DUAVEE.xml:S3:3934:1	O

In	DUAVEE.xml:S3:3936:2	O
addition	DUAVEE.xml:S3:3939:8	O
,	DUAVEE.xml:S3:3947:1	O
women	DUAVEE.xml:S3:3949:5	O
taking	DUAVEE.xml:S3:3955:6	O
DUAVEE	DUAVEE.xml:S3:3962:6	O
should	DUAVEE.xml:S3:3969:6	O
be	DUAVEE.xml:S3:3976:2	O
advised	DUAVEE.xml:S3:3979:7	O
to	DUAVEE.xml:S3:3987:2	O
move	DUAVEE.xml:S3:3990:4	O
about	DUAVEE.xml:S3:3995:5	O
periodically	DUAVEE.xml:S3:4001:12	O
during	DUAVEE.xml:S3:4014:6	O
travel	DUAVEE.xml:S3:4021:6	O
involving	DUAVEE.xml:S3:4028:9	O
prolonged	DUAVEE.xml:S3:4038:9	O
immobilization	DUAVEE.xml:S3:4048:14	O
.	DUAVEE.xml:S3:4062:1	O

5.3	DUAVEE.xml:S3:4071:3	O
Malignant	DUAVEE.xml:S3:4075:9	O
Neoplasms	DUAVEE.xml:S3:4085:9	O

Endometrial	DUAVEE.xml:S3:4101:11	O
Cancer	DUAVEE.xml:S3:4113:6	O

An	DUAVEE.xml:S3:4126:2	O
increased	DUAVEE.xml:S3:4129:9	O
risk	DUAVEE.xml:S3:4139:4	O
of	DUAVEE.xml:S3:4144:2	O
endometrial	DUAVEE.xml:S3:4147:11	B-AdverseReaction
cancer	DUAVEE.xml:S3:4159:6	I-AdverseReaction
has	DUAVEE.xml:S3:4166:3	O
been	DUAVEE.xml:S3:4170:4	O
reported	DUAVEE.xml:S3:4175:8	O
with	DUAVEE.xml:S3:4184:4	O
the	DUAVEE.xml:S3:4189:3	O
use	DUAVEE.xml:S3:4193:3	O
of	DUAVEE.xml:S3:4197:2	O
unopposed	DUAVEE.xml:S3:4200:9	O
estrogen	DUAVEE.xml:S3:4210:8	B-DrugClass
therapy	DUAVEE.xml:S3:4219:7	O
in	DUAVEE.xml:S3:4227:2	O
women	DUAVEE.xml:S3:4230:5	O
with	DUAVEE.xml:S3:4236:4	O
a	DUAVEE.xml:S3:4241:1	O
uterus	DUAVEE.xml:S3:4243:6	O
.	DUAVEE.xml:S3:4249:1	O

The	DUAVEE.xml:S3:4251:3	O
reported	DUAVEE.xml:S3:4255:8	O
endometrial	DUAVEE.xml:S3:4264:11	B-AdverseReaction
cancer	DUAVEE.xml:S3:4276:6	I-AdverseReaction
risk	DUAVEE.xml:S3:4283:4	O
among	DUAVEE.xml:S3:4288:5	O
unopposed	DUAVEE.xml:S3:4294:9	O
estrogen	DUAVEE.xml:S3:4304:8	B-DrugClass
users	DUAVEE.xml:S3:4313:5	O
is	DUAVEE.xml:S3:4319:2	O
about	DUAVEE.xml:S3:4322:5	O
2	DUAVEE.xml:S3:4328:1	O
to	DUAVEE.xml:S3:4330:2	O
12	DUAVEE.xml:S3:4333:2	O
times	DUAVEE.xml:S3:4336:5	O
greater	DUAVEE.xml:S3:4342:7	O
than	DUAVEE.xml:S3:4350:4	O
in	DUAVEE.xml:S3:4355:2	O
non	DUAVEE.xml:S3:4358:3	O
-	DUAVEE.xml:S3:4361:1	O
users	DUAVEE.xml:S3:4362:5	O
,	DUAVEE.xml:S3:4367:1	O
and	DUAVEE.xml:S3:4369:3	O
appears	DUAVEE.xml:S3:4373:7	O
dependent	DUAVEE.xml:S3:4381:9	O
on	DUAVEE.xml:S3:4391:2	O
duration	DUAVEE.xml:S3:4394:8	O
of	DUAVEE.xml:S3:4403:2	O
treatment	DUAVEE.xml:S3:4406:9	O
and	DUAVEE.xml:S3:4416:3	O
on	DUAVEE.xml:S3:4420:2	O
estrogen	DUAVEE.xml:S3:4423:8	O
dose	DUAVEE.xml:S3:4432:4	O
.	DUAVEE.xml:S3:4436:1	O

Most	DUAVEE.xml:S3:4438:4	O
studies	DUAVEE.xml:S3:4443:7	O
show	DUAVEE.xml:S3:4451:4	O
no	DUAVEE.xml:S3:4456:2	O
significant	DUAVEE.xml:S3:4459:11	O
increased	DUAVEE.xml:S3:4471:9	O
risk	DUAVEE.xml:S3:4481:4	O
associated	DUAVEE.xml:S3:4486:10	O
with	DUAVEE.xml:S3:4497:4	O
use	DUAVEE.xml:S3:4502:3	O
of	DUAVEE.xml:S3:4506:2	O
estrogens	DUAVEE.xml:S3:4509:9	O
for	DUAVEE.xml:S3:4519:3	O
less	DUAVEE.xml:S3:4523:4	O
than	DUAVEE.xml:S3:4528:4	O
1	DUAVEE.xml:S3:4533:1	O
year	DUAVEE.xml:S3:4535:4	O
.	DUAVEE.xml:S3:4539:1	O

The	DUAVEE.xml:S3:4541:3	O
greatest	DUAVEE.xml:S3:4545:8	O
risk	DUAVEE.xml:S3:4554:4	O
appears	DUAVEE.xml:S3:4559:7	O
associated	DUAVEE.xml:S3:4567:10	O
with	DUAVEE.xml:S3:4578:4	O
prolonged	DUAVEE.xml:S3:4583:9	O
use	DUAVEE.xml:S3:4593:3	O
,	DUAVEE.xml:S3:4596:1	O
with	DUAVEE.xml:S3:4598:4	O
increased	DUAVEE.xml:S3:4603:9	O
risks	DUAVEE.xml:S3:4613:5	O
of	DUAVEE.xml:S3:4619:2	O
15	DUAVEE.xml:S3:4622:2	O
-	DUAVEE.xml:S3:4624:1	O
to	DUAVEE.xml:S3:4626:2	O
24	DUAVEE.xml:S3:4629:2	O
-	DUAVEE.xml:S3:4631:1	O
fold	DUAVEE.xml:S3:4632:4	O
for	DUAVEE.xml:S3:4637:3	O
5	DUAVEE.xml:S3:4641:1	O
to	DUAVEE.xml:S3:4643:2	O
10	DUAVEE.xml:S3:4646:2	O
years	DUAVEE.xml:S3:4649:5	O
or	DUAVEE.xml:S3:4655:2	O
more	DUAVEE.xml:S3:4658:4	O
of	DUAVEE.xml:S3:4663:2	O
treatment	DUAVEE.xml:S3:4666:9	O
.	DUAVEE.xml:S3:4675:1	O

This	DUAVEE.xml:S3:4677:4	O
risk	DUAVEE.xml:S3:4682:4	O
has	DUAVEE.xml:S3:4687:3	O
been	DUAVEE.xml:S3:4691:4	O
shown	DUAVEE.xml:S3:4696:5	O
to	DUAVEE.xml:S3:4702:2	O
persist	DUAVEE.xml:S3:4705:7	O
for	DUAVEE.xml:S3:4713:3	O
at	DUAVEE.xml:S3:4717:2	O
least	DUAVEE.xml:S3:4720:5	O
8	DUAVEE.xml:S3:4726:1	O
to	DUAVEE.xml:S3:4728:2	O
15	DUAVEE.xml:S3:4731:2	O
years	DUAVEE.xml:S3:4734:5	O
after	DUAVEE.xml:S3:4740:5	O
estrogen	DUAVEE.xml:S3:4746:8	O
therapy	DUAVEE.xml:S3:4755:7	O
is	DUAVEE.xml:S3:4763:2	O
discontinued	DUAVEE.xml:S3:4766:12	O
.	DUAVEE.xml:S3:4778:1	O

DUAVEE	DUAVEE.xml:S3:4784:6	O
contains	DUAVEE.xml:S3:4791:8	O
an	DUAVEE.xml:S3:4800:2	O
estrogen	DUAVEE.xml:S3:4803:8	O
agonist	DUAVEE.xml:S3:4812:7	O
antagonist	DUAVEE.xml:S3:4820:10	O
.	DUAVEE.xml:S3:4830:1	O

This	DUAVEE.xml:S3:4832:4	O
component	DUAVEE.xml:S3:4837:9	O
reduces	DUAVEE.xml:S3:4847:7	O
the	DUAVEE.xml:S3:4855:3	O
risk	DUAVEE.xml:S3:4859:4	O
of	DUAVEE.xml:S3:4864:2	O
endometrial	DUAVEE.xml:S3:4867:11	O
hyperplasia	DUAVEE.xml:S3:4879:11	O
that	DUAVEE.xml:S3:4891:4	O
can	DUAVEE.xml:S3:4896:3	O
occur	DUAVEE.xml:S3:4900:5	O
with	DUAVEE.xml:S3:4906:4	O
the	DUAVEE.xml:S3:4911:3	O
conjugated	DUAVEE.xml:S3:4915:10	O
estrogens	DUAVEE.xml:S3:4926:9	O
component	DUAVEE.xml:S3:4936:9	O
.	DUAVEE.xml:S3:4945:1	O

Endometrial	DUAVEE.xml:S3:4947:11	O
hyperplasia	DUAVEE.xml:S3:4959:11	O
may	DUAVEE.xml:S3:4971:3	O
be	DUAVEE.xml:S3:4975:2	O
a	DUAVEE.xml:S3:4978:1	O
precursor	DUAVEE.xml:S3:4980:9	O
to	DUAVEE.xml:S3:4990:2	O
endometrial	DUAVEE.xml:S3:4993:11	O
cancer	DUAVEE.xml:S3:5005:6	O
.	DUAVEE.xml:S3:5011:1	O

Women	DUAVEE.xml:S3:5013:5	O
taking	DUAVEE.xml:S3:5019:6	O
DUAVEE	DUAVEE.xml:S3:5026:6	O
should	DUAVEE.xml:S3:5033:6	O
not	DUAVEE.xml:S3:5040:3	O
take	DUAVEE.xml:S3:5044:4	O
additional	DUAVEE.xml:S3:5049:10	O
estrogens	DUAVEE.xml:S3:5060:9	O
as	DUAVEE.xml:S3:5070:2	O
this	DUAVEE.xml:S3:5073:4	O
may	DUAVEE.xml:S3:5078:3	O
increase	DUAVEE.xml:S3:5082:8	O
the	DUAVEE.xml:S3:5091:3	O
risk	DUAVEE.xml:S3:5095:4	O
of	DUAVEE.xml:S3:5100:2	O
endometrial	DUAVEE.xml:S3:5103:11	O
hyperplasia	DUAVEE.xml:S3:5115:11	O
.	DUAVEE.xml:S3:5126:1	O

Clinical	DUAVEE.xml:S3:5132:8	O
surveillance	DUAVEE.xml:S3:5141:12	O
of	DUAVEE.xml:S3:5154:2	O
all	DUAVEE.xml:S3:5157:3	O
women	DUAVEE.xml:S3:5161:5	O
taking	DUAVEE.xml:S3:5167:6	O
DUAVEE	DUAVEE.xml:S3:5174:6	O
is	DUAVEE.xml:S3:5181:2	O
important	DUAVEE.xml:S3:5184:9	O
.	DUAVEE.xml:S3:5193:1	O

Adequate	DUAVEE.xml:S3:5195:8	O
diagnostic	DUAVEE.xml:S3:5204:10	O
measures	DUAVEE.xml:S3:5215:8	O
,	DUAVEE.xml:S3:5223:1	O
including	DUAVEE.xml:S3:5225:9	O
directed	DUAVEE.xml:S3:5235:8	O
or	DUAVEE.xml:S3:5244:2	O
random	DUAVEE.xml:S3:5247:6	O
endometrial	DUAVEE.xml:S3:5254:11	O
sampling	DUAVEE.xml:S3:5266:8	O
when	DUAVEE.xml:S3:5275:4	O
indicated	DUAVEE.xml:S3:5280:9	O
,	DUAVEE.xml:S3:5289:1	O
should	DUAVEE.xml:S3:5291:6	O
be	DUAVEE.xml:S3:5298:2	O
undertaken	DUAVEE.xml:S3:5301:10	O
to	DUAVEE.xml:S3:5312:2	O
rule	DUAVEE.xml:S3:5315:4	O
out	DUAVEE.xml:S3:5320:3	O
malignancy	DUAVEE.xml:S3:5324:10	O
in	DUAVEE.xml:S3:5335:2	O
postmenopausal	DUAVEE.xml:S3:5338:14	O
women	DUAVEE.xml:S3:5353:5	O
with	DUAVEE.xml:S3:5359:4	O
undiagnosed	DUAVEE.xml:S3:5364:11	O
persistent	DUAVEE.xml:S3:5376:10	O
or	DUAVEE.xml:S3:5387:2	O
recurring	DUAVEE.xml:S3:5390:9	O
abnormal	DUAVEE.xml:S3:5400:8	O
genital	DUAVEE.xml:S3:5409:7	O
bleeding	DUAVEE.xml:S3:5417:8	O
.	DUAVEE.xml:S3:5425:1	O

Breast	DUAVEE.xml:S3:5434:6	O
Cancer	DUAVEE.xml:S3:5441:6	O

The	DUAVEE.xml:S3:5454:3	O
most	DUAVEE.xml:S3:5458:4	O
important	DUAVEE.xml:S3:5463:9	O
randomized	DUAVEE.xml:S3:5473:10	O
clinical	DUAVEE.xml:S3:5484:8	O
study	DUAVEE.xml:S3:5493:5	O
providing	DUAVEE.xml:S3:5499:9	O
information	DUAVEE.xml:S3:5509:11	O
about	DUAVEE.xml:S3:5521:5	O
breast	DUAVEE.xml:S3:5527:6	O
cancer	DUAVEE.xml:S3:5534:6	O
in	DUAVEE.xml:S3:5541:2	O
estrogen	DUAVEE.xml:S3:5544:8	O
-	DUAVEE.xml:S3:5552:1	O
alone	DUAVEE.xml:S3:5553:5	O
users	DUAVEE.xml:S3:5559:5	O
is	DUAVEE.xml:S3:5565:2	O
the	DUAVEE.xml:S3:5568:3	O
WHI	DUAVEE.xml:S3:5572:3	O
substudy	DUAVEE.xml:S3:5576:8	O
of	DUAVEE.xml:S3:5585:2	O
daily	DUAVEE.xml:S3:5588:5	O
conjugated	DUAVEE.xml:S3:5594:10	O
estrogens	DUAVEE.xml:S3:5605:9	O
(	DUAVEE.xml:S3:5615:1	O
0.625	DUAVEE.xml:S3:5616:5	O
mg	DUAVEE.xml:S3:5622:2	O
)-	DUAVEE.xml:S3:5624:2	O
alone	DUAVEE.xml:S3:5626:5	O
.	DUAVEE.xml:S3:5631:1	O

In	DUAVEE.xml:S3:5633:2	O
the	DUAVEE.xml:S3:5636:3	O
WHI	DUAVEE.xml:S3:5640:3	O
estrogen	DUAVEE.xml:S3:5644:8	O
-	DUAVEE.xml:S3:5652:1	O
alone	DUAVEE.xml:S3:5653:5	O
substudy	DUAVEE.xml:S3:5659:8	O
,	DUAVEE.xml:S3:5667:1	O
after	DUAVEE.xml:S3:5669:5	O
an	DUAVEE.xml:S3:5675:2	O
average	DUAVEE.xml:S3:5678:7	O
follow	DUAVEE.xml:S3:5686:6	O
-	DUAVEE.xml:S3:5692:1	O
up	DUAVEE.xml:S3:5693:2	O
of	DUAVEE.xml:S3:5696:2	O
7.1	DUAVEE.xml:S3:5699:3	O
years	DUAVEE.xml:S3:5703:5	O
,	DUAVEE.xml:S3:5708:1	O
daily	DUAVEE.xml:S3:5710:5	O
conjugated	DUAVEE.xml:S3:5716:10	B-DrugClass
estrogen	DUAVEE.xml:S3:5727:8	I-DrugClass
(	DUAVEE.xml:S3:5736:1	O
0.625	DUAVEE.xml:S3:5737:5	O
mg	DUAVEE.xml:S3:5743:2	O
)-	DUAVEE.xml:S3:5745:2	O
alone	DUAVEE.xml:S3:5747:5	O
was	DUAVEE.xml:S3:5753:3	O
not	DUAVEE.xml:S3:5757:3	O
associated	DUAVEE.xml:S3:5761:10	O
with	DUAVEE.xml:S3:5772:4	O
an	DUAVEE.xml:S3:5777:2	O
increased	DUAVEE.xml:S3:5780:9	O
risk	DUAVEE.xml:S3:5790:4	O
of	DUAVEE.xml:S3:5795:2	O
invasive	DUAVEE.xml:S3:5798:8	B-AdverseReaction
breast	DUAVEE.xml:S3:5807:6	I-AdverseReaction
cancer	DUAVEE.xml:S3:5814:6	I-AdverseReaction
(	DUAVEE.xml:S3:5821:1	O
relative	DUAVEE.xml:S3:5822:8	O
risk	DUAVEE.xml:S3:5831:4	O
[	DUAVEE.xml:S3:5836:1	O
RR	DUAVEE.xml:S3:5837:2	O
]	DUAVEE.xml:S3:5839:1	O
0.80	DUAVEE.xml:S3:5841:4	O
)	DUAVEE.xml:S3:5845:1	O
.	DUAVEE.xml:S3:5846:1	O

The	DUAVEE.xml:S3:5852:3	O
use	DUAVEE.xml:S3:5856:3	O
of	DUAVEE.xml:S3:5860:2	O
estrogen	DUAVEE.xml:S3:5863:8	O
-	DUAVEE.xml:S3:5871:1	O
alone	DUAVEE.xml:S3:5872:5	O
has	DUAVEE.xml:S3:5878:3	O
been	DUAVEE.xml:S3:5882:4	O
reported	DUAVEE.xml:S3:5887:8	O
to	DUAVEE.xml:S3:5896:2	O
result	DUAVEE.xml:S3:5899:6	O
in	DUAVEE.xml:S3:5906:2	O
an	DUAVEE.xml:S3:5909:2	O
increase	DUAVEE.xml:S3:5912:8	O
in	DUAVEE.xml:S3:5921:2	O
abnormal	DUAVEE.xml:S3:5924:8	O
mammograms	DUAVEE.xml:S3:5933:10	O
requiring	DUAVEE.xml:S3:5944:9	O
further	DUAVEE.xml:S3:5954:7	O
evaluation	DUAVEE.xml:S3:5962:10	O
.	DUAVEE.xml:S3:5972:1	O

The	DUAVEE.xml:S3:5974:3	O
effect	DUAVEE.xml:S3:5978:6	O
of	DUAVEE.xml:S3:5985:2	O
treatment	DUAVEE.xml:S3:5988:9	O
with	DUAVEE.xml:S3:5998:4	O
DUAVEE	DUAVEE.xml:S3:6003:6	O
on	DUAVEE.xml:S3:6010:2	O
the	DUAVEE.xml:S3:6013:3	O
risk	DUAVEE.xml:S3:6017:4	O
of	DUAVEE.xml:S3:6022:2	O
breast	DUAVEE.xml:S3:6025:6	O
cancer	DUAVEE.xml:S3:6032:6	O
is	DUAVEE.xml:S3:6039:2	O
unknown	DUAVEE.xml:S3:6042:7	O
.	DUAVEE.xml:S3:6049:1	O

All	DUAVEE.xml:S3:6055:3	O
women	DUAVEE.xml:S3:6059:5	O
should	DUAVEE.xml:S3:6065:6	O
receive	DUAVEE.xml:S3:6072:7	O
yearly	DUAVEE.xml:S3:6080:6	O
breast	DUAVEE.xml:S3:6087:6	O
examinations	DUAVEE.xml:S3:6094:12	O
by	DUAVEE.xml:S3:6107:2	O
a	DUAVEE.xml:S3:6110:1	O
healthcare	DUAVEE.xml:S3:6112:10	O
provider	DUAVEE.xml:S3:6123:8	O
and	DUAVEE.xml:S3:6132:3	O
perform	DUAVEE.xml:S3:6136:7	O
monthly	DUAVEE.xml:S3:6144:7	O
breast	DUAVEE.xml:S3:6152:6	O
self	DUAVEE.xml:S3:6159:4	O
-	DUAVEE.xml:S3:6163:1	O
examinations	DUAVEE.xml:S3:6164:12	O
.	DUAVEE.xml:S3:6176:1	O

In	DUAVEE.xml:S3:6178:2	O
addition	DUAVEE.xml:S3:6181:8	O
,	DUAVEE.xml:S3:6189:1	O
mammography	DUAVEE.xml:S3:6191:11	O
examinations	DUAVEE.xml:S3:6203:12	O
should	DUAVEE.xml:S3:6216:6	O
be	DUAVEE.xml:S3:6223:2	O
scheduled	DUAVEE.xml:S3:6226:9	O
based	DUAVEE.xml:S3:6236:5	O
on	DUAVEE.xml:S3:6242:2	O
patient	DUAVEE.xml:S3:6245:7	O
age	DUAVEE.xml:S3:6253:3	O
,	DUAVEE.xml:S3:6256:1	O
risk	DUAVEE.xml:S3:6258:4	O
factors	DUAVEE.xml:S3:6263:7	O
,	DUAVEE.xml:S3:6270:1	O
and	DUAVEE.xml:S3:6272:3	O
prior	DUAVEE.xml:S3:6276:5	O
mammogram	DUAVEE.xml:S3:6282:9	O
results	DUAVEE.xml:S3:6292:7	O
.	DUAVEE.xml:S3:6299:1	O

Ovarian	DUAVEE.xml:S3:6308:7	O
Cancer	DUAVEE.xml:S3:6316:6	O

In	DUAVEE.xml:S3:6329:2	O
some	DUAVEE.xml:S3:6332:4	O
epidemiological	DUAVEE.xml:S3:6337:15	O
studies	DUAVEE.xml:S3:6353:7	O
,	DUAVEE.xml:S3:6360:1	O
the	DUAVEE.xml:S3:6362:3	O
use	DUAVEE.xml:S3:6366:3	O
of	DUAVEE.xml:S3:6370:2	O
estrogen	DUAVEE.xml:S3:6373:8	B-DrugClass
-	DUAVEE.xml:S3:6381:1	O
only	DUAVEE.xml:S3:6382:4	O
products	DUAVEE.xml:S3:6387:8	O
,	DUAVEE.xml:S3:6395:1	O
in	DUAVEE.xml:S3:6397:2	O
particular	DUAVEE.xml:S3:6400:10	O
for	DUAVEE.xml:S3:6411:3	O
5	DUAVEE.xml:S3:6415:1	O
or	DUAVEE.xml:S3:6417:2	O
more	DUAVEE.xml:S3:6420:4	O
years	DUAVEE.xml:S3:6425:5	O
,	DUAVEE.xml:S3:6430:1	O
has	DUAVEE.xml:S3:6432:3	O
been	DUAVEE.xml:S3:6436:4	O
associated	DUAVEE.xml:S3:6441:10	O
with	DUAVEE.xml:S3:6452:4	O
an	DUAVEE.xml:S3:6457:2	O
increased	DUAVEE.xml:S3:6460:9	O
risk	DUAVEE.xml:S3:6470:4	O
of	DUAVEE.xml:S3:6475:2	O
ovarian	DUAVEE.xml:S3:6478:7	B-AdverseReaction
cancer	DUAVEE.xml:S3:6486:6	I-AdverseReaction
.	DUAVEE.xml:S3:6492:1	O

However	DUAVEE.xml:S3:6494:7	O
,	DUAVEE.xml:S3:6501:1	O
the	DUAVEE.xml:S3:6503:3	O
duration	DUAVEE.xml:S3:6507:8	O
of	DUAVEE.xml:S3:6516:2	O
exposure	DUAVEE.xml:S3:6519:8	O
associated	DUAVEE.xml:S3:6528:10	O
with	DUAVEE.xml:S3:6539:4	O
increased	DUAVEE.xml:S3:6544:9	O
risk	DUAVEE.xml:S3:6554:4	O
is	DUAVEE.xml:S3:6559:2	O
not	DUAVEE.xml:S3:6562:3	O
consistent	DUAVEE.xml:S3:6566:10	O
across	DUAVEE.xml:S3:6577:6	O
all	DUAVEE.xml:S3:6584:3	O
epidemiologic	DUAVEE.xml:S3:6588:13	O
studies	DUAVEE.xml:S3:6602:7	O
,	DUAVEE.xml:S3:6609:1	O
and	DUAVEE.xml:S3:6611:3	O
some	DUAVEE.xml:S3:6615:4	O
report	DUAVEE.xml:S3:6620:6	O
no	DUAVEE.xml:S3:6627:2	O
association	DUAVEE.xml:S3:6630:11	O
.	DUAVEE.xml:S3:6641:1	O

The	DUAVEE.xml:S3:6643:3	O
effect	DUAVEE.xml:S3:6647:6	O
of	DUAVEE.xml:S3:6654:2	O
treatment	DUAVEE.xml:S3:6657:9	O
with	DUAVEE.xml:S3:6667:4	O
DUAVEE	DUAVEE.xml:S3:6672:6	O
on	DUAVEE.xml:S3:6679:2	O
the	DUAVEE.xml:S3:6682:3	O
risk	DUAVEE.xml:S3:6686:4	O
of	DUAVEE.xml:S3:6691:2	O
ovarian	DUAVEE.xml:S3:6694:7	O
cancer	DUAVEE.xml:S3:6702:6	O
is	DUAVEE.xml:S3:6709:2	O
unknown	DUAVEE.xml:S3:6712:7	O
.	DUAVEE.xml:S3:6719:1	O

5.4	DUAVEE.xml:S3:6728:3	O
Probable	DUAVEE.xml:S3:6732:8	O
Dementia	DUAVEE.xml:S3:6741:8	O

In	DUAVEE.xml:S3:6755:2	O
the	DUAVEE.xml:S3:6758:3	O
WHIMS	DUAVEE.xml:S3:6762:5	O
estrogen	DUAVEE.xml:S3:6768:8	O
-	DUAVEE.xml:S3:6776:1	O
alone	DUAVEE.xml:S3:6777:5	O
ancillary	DUAVEE.xml:S3:6783:9	O
study	DUAVEE.xml:S3:6793:5	O
of	DUAVEE.xml:S3:6799:2	O
WHI	DUAVEE.xml:S3:6802:3	O
,	DUAVEE.xml:S3:6805:1	O
a	DUAVEE.xml:S3:6807:1	O
population	DUAVEE.xml:S3:6809:10	O
of	DUAVEE.xml:S3:6820:2	O
2	DUAVEE.xml:S3:6823:1	O
,	DUAVEE.xml:S3:6824:1	O
947	DUAVEE.xml:S3:6825:3	O
hysterectomized	DUAVEE.xml:S3:6829:15	O
women	DUAVEE.xml:S3:6845:5	O
65	DUAVEE.xml:S3:6851:2	O
to	DUAVEE.xml:S3:6854:2	O
79	DUAVEE.xml:S3:6857:2	O
years	DUAVEE.xml:S3:6860:5	O
of	DUAVEE.xml:S3:6866:2	O
age	DUAVEE.xml:S3:6869:3	O
was	DUAVEE.xml:S3:6873:3	O
randomized	DUAVEE.xml:S3:6877:10	O
to	DUAVEE.xml:S3:6888:2	O
daily	DUAVEE.xml:S3:6891:5	O
CE	DUAVEE.xml:S3:6897:2	O
(	DUAVEE.xml:S3:6900:1	O
0.625	DUAVEE.xml:S3:6901:5	O
mg	DUAVEE.xml:S3:6907:2	O
)-	DUAVEE.xml:S3:6909:2	O
alone	DUAVEE.xml:S3:6911:5	O
or	DUAVEE.xml:S3:6917:2	O
placebo	DUAVEE.xml:S3:6920:7	O
.	DUAVEE.xml:S3:6927:1	O

After	DUAVEE.xml:S3:6933:5	O
an	DUAVEE.xml:S3:6939:2	O
average	DUAVEE.xml:S3:6942:7	O
follow	DUAVEE.xml:S3:6950:6	O
-	DUAVEE.xml:S3:6956:1	O
up	DUAVEE.xml:S3:6957:2	O
of	DUAVEE.xml:S3:6960:2	O
5.2	DUAVEE.xml:S3:6963:3	O
years	DUAVEE.xml:S3:6967:5	O
,	DUAVEE.xml:S3:6972:1	O
28	DUAVEE.xml:S3:6974:2	O
women	DUAVEE.xml:S3:6977:5	O
in	DUAVEE.xml:S3:6983:2	O
the	DUAVEE.xml:S3:6986:3	O
estrogen	DUAVEE.xml:S3:6990:8	B-DrugClass
-	DUAVEE.xml:S3:6998:1	O
alone	DUAVEE.xml:S3:6999:5	O
group	DUAVEE.xml:S3:7005:5	O
and	DUAVEE.xml:S3:7011:3	O
19	DUAVEE.xml:S3:7015:2	O
women	DUAVEE.xml:S3:7018:5	O
in	DUAVEE.xml:S3:7024:2	O
the	DUAVEE.xml:S3:7027:3	O
placebo	DUAVEE.xml:S3:7031:7	O
group	DUAVEE.xml:S3:7039:5	O
were	DUAVEE.xml:S3:7045:4	O
diagnosed	DUAVEE.xml:S3:7050:9	O
with	DUAVEE.xml:S3:7060:4	O
probable	DUAVEE.xml:S3:7065:8	O
dementia	DUAVEE.xml:S3:7074:8	B-AdverseReaction
.	DUAVEE.xml:S3:7082:1	O

The	DUAVEE.xml:S3:7084:3	O
relative	DUAVEE.xml:S3:7088:8	O
risk	DUAVEE.xml:S3:7097:4	O
of	DUAVEE.xml:S3:7102:2	O
probable	DUAVEE.xml:S3:7105:8	O
dementia	DUAVEE.xml:S3:7114:8	B-AdverseReaction
for	DUAVEE.xml:S3:7123:3	O
CE	DUAVEE.xml:S3:7127:2	B-DrugClass
-	DUAVEE.xml:S3:7129:1	O
alone	DUAVEE.xml:S3:7130:5	O
versus	DUAVEE.xml:S3:7136:6	O
placebo	DUAVEE.xml:S3:7143:7	O
was	DUAVEE.xml:S3:7151:3	O
1.49	DUAVEE.xml:S3:7155:4	O
(	DUAVEE.xml:S3:7160:1	O
95	DUAVEE.xml:S3:7161:2	O
percent	DUAVEE.xml:S3:7164:7	O
CI	DUAVEE.xml:S3:7172:2	O
,	DUAVEE.xml:S3:7174:1	O
0.83	DUAVEE.xml:S3:7176:4	O
-	DUAVEE.xml:S3:7180:1	O
2.66	DUAVEE.xml:S3:7181:4	O
)	DUAVEE.xml:S3:7185:1	O
.	DUAVEE.xml:S3:7186:1	O

The	DUAVEE.xml:S3:7188:3	O
absolute	DUAVEE.xml:S3:7192:8	O
risk	DUAVEE.xml:S3:7201:4	O
of	DUAVEE.xml:S3:7206:2	O
probable	DUAVEE.xml:S3:7209:8	O
dementia	DUAVEE.xml:S3:7218:8	B-AdverseReaction
for	DUAVEE.xml:S3:7227:3	O
CE	DUAVEE.xml:S3:7231:2	B-DrugClass
-	DUAVEE.xml:S3:7233:1	O
alone	DUAVEE.xml:S3:7234:5	O
versus	DUAVEE.xml:S3:7240:6	O
placebo	DUAVEE.xml:S3:7247:7	O
was	DUAVEE.xml:S3:7255:3	O
37	DUAVEE.xml:S3:7259:2	O
versus	DUAVEE.xml:S3:7262:6	O
25	DUAVEE.xml:S3:7269:2	O
cases	DUAVEE.xml:S3:7272:5	O
per	DUAVEE.xml:S3:7278:3	O
10	DUAVEE.xml:S3:7282:2	O
,	DUAVEE.xml:S3:7284:1	O
000	DUAVEE.xml:S3:7285:3	O
women	DUAVEE.xml:S3:7289:5	O
-	DUAVEE.xml:S3:7294:1	O
years	DUAVEE.xml:S3:7295:5	O
[	DUAVEE.xml:S3:7301:1	O
see	DUAVEE.xml:S3:7302:3	O
Use	DUAVEE.xml:S3:7307:3	O
in	DUAVEE.xml:S3:7311:2	O
Specific	DUAVEE.xml:S3:7314:8	O
Populations	DUAVEE.xml:S3:7323:11	O
(	DUAVEE.xml:S3:7335:1	O
8.5	DUAVEE.xml:S3:7336:3	O
)	DUAVEE.xml:S3:7339:1	O
and	DUAVEE.xml:S3:7342:3	O
Clinical	DUAVEE.xml:S3:7347:8	O
Studies	DUAVEE.xml:S3:7356:7	O
(	DUAVEE.xml:S3:7364:1	O
14.6	DUAVEE.xml:S3:7365:4	O
)	DUAVEE.xml:S3:7369:1	O
]	DUAVEE.xml:S3:7372:1	O
.	DUAVEE.xml:S3:7375:1	O

5.5	DUAVEE.xml:S3:7384:3	O
Gallbladder	DUAVEE.xml:S3:7388:11	O
Disease	DUAVEE.xml:S3:7400:7	O

A	DUAVEE.xml:S3:7413:1	O
2	DUAVEE.xml:S3:7415:1	O
-	DUAVEE.xml:S3:7416:1	O
to	DUAVEE.xml:S3:7418:2	O
4	DUAVEE.xml:S3:7421:1	O
-	DUAVEE.xml:S3:7422:1	O
fold	DUAVEE.xml:S3:7423:4	O
increase	DUAVEE.xml:S3:7428:8	O
in	DUAVEE.xml:S3:7437:2	O
the	DUAVEE.xml:S3:7440:3	O
risk	DUAVEE.xml:S3:7444:4	B-Factor
of	DUAVEE.xml:S3:7449:2	O
gallbladder	DUAVEE.xml:S3:7452:11	B-AdverseReaction
disease	DUAVEE.xml:S3:7464:7	I-AdverseReaction
requiring	DUAVEE.xml:S3:7472:9	O
surgery	DUAVEE.xml:S3:7482:7	O
in	DUAVEE.xml:S3:7490:2	O
postmenopausal	DUAVEE.xml:S3:7493:14	O
women	DUAVEE.xml:S3:7508:5	O
receiving	DUAVEE.xml:S3:7514:9	O
estrogens	DUAVEE.xml:S3:7524:9	O
has	DUAVEE.xml:S3:7534:3	O
been	DUAVEE.xml:S3:7538:4	O
reported	DUAVEE.xml:S3:7543:8	O
.	DUAVEE.xml:S3:7551:1	O

5.6	DUAVEE.xml:S3:7560:3	O
Visual	DUAVEE.xml:S3:7564:6	O
Abnormalities	DUAVEE.xml:S3:7571:13	O

Retinal	DUAVEE.xml:S3:7590:7	B-AdverseReaction
vascular	DUAVEE.xml:S3:7598:8	I-AdverseReaction
thrombosis	DUAVEE.xml:S3:7607:10	I-AdverseReaction
has	DUAVEE.xml:S3:7618:3	O
been	DUAVEE.xml:S3:7622:4	O
reported	DUAVEE.xml:S3:7627:8	O
in	DUAVEE.xml:S3:7636:2	O
patients	DUAVEE.xml:S3:7639:8	O
receiving	DUAVEE.xml:S3:7648:9	O
estrogens	DUAVEE.xml:S3:7658:9	O
.	DUAVEE.xml:S3:7667:1	O

Discontinue	DUAVEE.xml:S3:7669:11	O
medication	DUAVEE.xml:S3:7681:10	O
pending	DUAVEE.xml:S3:7692:7	O
examination	DUAVEE.xml:S3:7700:11	O
if	DUAVEE.xml:S3:7712:2	O
there	DUAVEE.xml:S3:7715:5	O
is	DUAVEE.xml:S3:7721:2	O
sudden	DUAVEE.xml:S3:7724:6	O
partial	DUAVEE.xml:S3:7731:7	O
or	DUAVEE.xml:S3:7739:2	O
complete	DUAVEE.xml:S3:7742:8	O
loss	DUAVEE.xml:S3:7751:4	O
of	DUAVEE.xml:S3:7756:2	O
vision	DUAVEE.xml:S3:7759:6	O
,	DUAVEE.xml:S3:7765:1	O
or	DUAVEE.xml:S3:7767:2	O
a	DUAVEE.xml:S3:7770:1	O
sudden	DUAVEE.xml:S3:7772:6	O
onset	DUAVEE.xml:S3:7779:5	O
of	DUAVEE.xml:S3:7785:2	O
proptosis	DUAVEE.xml:S3:7788:9	O
,	DUAVEE.xml:S3:7797:1	O
diplopia	DUAVEE.xml:S3:7799:8	O
,	DUAVEE.xml:S3:7807:1	O
or	DUAVEE.xml:S3:7809:2	O
migraine	DUAVEE.xml:S3:7812:8	O
.	DUAVEE.xml:S3:7820:1	O

If	DUAVEE.xml:S3:7822:2	O
examination	DUAVEE.xml:S3:7825:11	O
reveals	DUAVEE.xml:S3:7837:7	O
papilledema	DUAVEE.xml:S3:7845:11	O
or	DUAVEE.xml:S3:7857:2	O
retinal	DUAVEE.xml:S3:7860:7	O
vascular	DUAVEE.xml:S3:7868:8	O
lesions	DUAVEE.xml:S3:7877:7	O
,	DUAVEE.xml:S3:7884:1	O
DUAVEE	DUAVEE.xml:S3:7886:6	O
should	DUAVEE.xml:S3:7893:6	O
be	DUAVEE.xml:S3:7900:2	O
permanently	DUAVEE.xml:S3:7903:11	O
discontinued	DUAVEE.xml:S3:7915:12	O
.	DUAVEE.xml:S3:7927:1	O

5.7	DUAVEE.xml:S3:7936:3	O
Elevated	DUAVEE.xml:S3:7940:8	O
Blood	DUAVEE.xml:S3:7949:5	O
Pressure	DUAVEE.xml:S3:7955:8	O

In	DUAVEE.xml:S3:7969:2	O
a	DUAVEE.xml:S3:7972:1	O
small	DUAVEE.xml:S3:7974:5	O
number	DUAVEE.xml:S3:7980:6	O
of	DUAVEE.xml:S3:7987:2	O
case	DUAVEE.xml:S3:7990:4	O
reports	DUAVEE.xml:S3:7995:7	O
in	DUAVEE.xml:S3:8003:2	O
women	DUAVEE.xml:S3:8006:5	O
receiving	DUAVEE.xml:S3:8012:9	O
estrogens	DUAVEE.xml:S3:8022:9	O
,	DUAVEE.xml:S3:8031:1	O
substantial	DUAVEE.xml:S3:8033:11	B-Severity
increases	DUAVEE.xml:S3:8045:9	B-AdverseReaction
in	DUAVEE.xml:S3:8055:2	I-AdverseReaction
blood	DUAVEE.xml:S3:8058:5	I-AdverseReaction
pressure	DUAVEE.xml:S3:8064:8	I-AdverseReaction
have	DUAVEE.xml:S3:8073:4	O
been	DUAVEE.xml:S3:8078:4	O
attributed	DUAVEE.xml:S3:8083:10	O
to	DUAVEE.xml:S3:8094:2	O
idiosyncratic	DUAVEE.xml:S3:8097:13	O
reactions	DUAVEE.xml:S3:8111:9	O
to	DUAVEE.xml:S3:8121:2	O
estrogens	DUAVEE.xml:S3:8124:9	O
.	DUAVEE.xml:S3:8133:1	O

In	DUAVEE.xml:S3:8135:2	O
a	DUAVEE.xml:S3:8138:1	O
large	DUAVEE.xml:S3:8140:5	O
,	DUAVEE.xml:S3:8145:1	O
randomized	DUAVEE.xml:S3:8147:10	O
,	DUAVEE.xml:S3:8157:1	O
placebo	DUAVEE.xml:S3:8159:7	O
-	DUAVEE.xml:S3:8166:1	O
controlled	DUAVEE.xml:S3:8167:10	O
clinical	DUAVEE.xml:S3:8178:8	O
study	DUAVEE.xml:S3:8187:5	O
,	DUAVEE.xml:S3:8192:1	O
a	DUAVEE.xml:S3:8194:1	O
generalized	DUAVEE.xml:S3:8196:11	O
effect	DUAVEE.xml:S3:8208:6	B-AdverseReaction
of	DUAVEE.xml:S3:8215:2	O
estrogens	DUAVEE.xml:S3:8218:9	O
on	DUAVEE.xml:S3:8228:2	I-AdverseReaction
blood	DUAVEE.xml:S3:8231:5	I-AdverseReaction
pressure	DUAVEE.xml:S3:8237:8	I-AdverseReaction
was	DUAVEE.xml:S3:8246:3	O
not	DUAVEE.xml:S3:8250:3	B-Negation
seen	DUAVEE.xml:S3:8254:4	O
.	DUAVEE.xml:S3:8258:1	O

5.8	DUAVEE.xml:S3:8267:3	O
Hypertriglyceridemia	DUAVEE.xml:S3:8271:20	O

In	DUAVEE.xml:S3:8297:2	O
women	DUAVEE.xml:S3:8300:5	O
with	DUAVEE.xml:S3:8306:4	O
pre	DUAVEE.xml:S3:8311:3	O
-	DUAVEE.xml:S3:8314:1	O
existing	DUAVEE.xml:S3:8315:8	O
hypertriglyceridemia	DUAVEE.xml:S3:8324:20	O
,	DUAVEE.xml:S3:8344:1	O
treatment	DUAVEE.xml:S3:8346:9	O
with	DUAVEE.xml:S3:8356:4	O
estrogens	DUAVEE.xml:S3:8361:9	O
may	DUAVEE.xml:S3:8371:3	B-Factor
be	DUAVEE.xml:S3:8375:2	O
associated	DUAVEE.xml:S3:8378:10	O
with	DUAVEE.xml:S3:8389:4	O
elevations	DUAVEE.xml:S3:8394:10	B-AdverseReaction
of	DUAVEE.xml:S3:8405:2	I-AdverseReaction
plasma	DUAVEE.xml:S3:8408:6	I-AdverseReaction
triglycerides	DUAVEE.xml:S3:8415:13	I-AdverseReaction
leading	DUAVEE.xml:S3:8429:7	O
to	DUAVEE.xml:S3:8437:2	O
pancreatitis	DUAVEE.xml:S3:8440:12	B-AdverseReaction
.	DUAVEE.xml:S3:8452:1	O

Consider	DUAVEE.xml:S3:8454:8	O
discontinuation	DUAVEE.xml:S3:8463:15	O
of	DUAVEE.xml:S3:8479:2	O
DUAVEE	DUAVEE.xml:S3:8482:6	O
if	DUAVEE.xml:S3:8489:2	O
pancreatitis	DUAVEE.xml:S3:8492:12	O
occurs	DUAVEE.xml:S3:8505:6	O
.	DUAVEE.xml:S3:8511:1	O

5.9	DUAVEE.xml:S3:8520:3	O
Hepatic	DUAVEE.xml:S3:8524:7	O
Impairment	DUAVEE.xml:S3:8532:10	O
and	DUAVEE.xml:S3:8543:3	O
Past	DUAVEE.xml:S3:8547:4	O
History	DUAVEE.xml:S3:8552:7	O
of	DUAVEE.xml:S3:8560:2	O
Cholestatic	DUAVEE.xml:S3:8563:11	O
Jaundice	DUAVEE.xml:S3:8575:8	O

DUAVEE	DUAVEE.xml:S3:8589:6	O
has	DUAVEE.xml:S3:8596:3	O
not	DUAVEE.xml:S3:8600:3	O
been	DUAVEE.xml:S3:8604:4	O
studied	DUAVEE.xml:S3:8609:7	O
in	DUAVEE.xml:S3:8617:2	O
women	DUAVEE.xml:S3:8620:5	O
with	DUAVEE.xml:S3:8626:4	O
impaired	DUAVEE.xml:S3:8631:8	O
liver	DUAVEE.xml:S3:8640:5	O
function	DUAVEE.xml:S3:8646:8	O
or	DUAVEE.xml:S3:8655:2	O
past	DUAVEE.xml:S3:8658:4	O
history	DUAVEE.xml:S3:8663:7	O
of	DUAVEE.xml:S3:8671:2	O
cholestatic	DUAVEE.xml:S3:8674:11	O
jaundice	DUAVEE.xml:S3:8686:8	O
.	DUAVEE.xml:S3:8694:1	O

Estrogens	DUAVEE.xml:S3:8700:9	O
may	DUAVEE.xml:S3:8710:3	O
be	DUAVEE.xml:S3:8714:2	O
poorly	DUAVEE.xml:S3:8717:6	O
metabolized	DUAVEE.xml:S3:8724:11	O
in	DUAVEE.xml:S3:8736:2	O
women	DUAVEE.xml:S3:8739:5	O
with	DUAVEE.xml:S3:8745:4	O
impaired	DUAVEE.xml:S3:8750:8	O
liver	DUAVEE.xml:S3:8759:5	O
function	DUAVEE.xml:S3:8765:8	O
.	DUAVEE.xml:S3:8773:1	O

On	DUAVEE.xml:S3:8779:2	O
average	DUAVEE.xml:S3:8782:7	O
,	DUAVEE.xml:S3:8789:1	O
women	DUAVEE.xml:S3:8791:5	O
with	DUAVEE.xml:S3:8797:4	O
hepatic	DUAVEE.xml:S3:8802:7	O
impairment	DUAVEE.xml:S3:8810:10	O
treated	DUAVEE.xml:S3:8821:7	O
with	DUAVEE.xml:S3:8829:4	O
bazedoxifene	DUAVEE.xml:S3:8834:12	O
alone	DUAVEE.xml:S3:8847:5	O
showed	DUAVEE.xml:S3:8853:6	O
a	DUAVEE.xml:S3:8860:1	O
4.3	DUAVEE.xml:S3:8862:3	O
-	DUAVEE.xml:S3:8865:1	O
fold	DUAVEE.xml:S3:8866:4	O
increase	DUAVEE.xml:S3:8871:8	O
in	DUAVEE.xml:S3:8880:2	O
overall	DUAVEE.xml:S3:8883:7	O
exposures	DUAVEE.xml:S3:8891:9	O
compared	DUAVEE.xml:S3:8901:8	O
with	DUAVEE.xml:S3:8910:4	O
controls	DUAVEE.xml:S3:8915:8	O
[	DUAVEE.xml:S3:8924:1	O
see	DUAVEE.xml:S3:8925:3	O
Use	DUAVEE.xml:S3:8930:3	O
in	DUAVEE.xml:S3:8934:2	O
Specific	DUAVEE.xml:S3:8937:8	O
Populations	DUAVEE.xml:S3:8946:11	O
(	DUAVEE.xml:S3:8958:1	O
8.7	DUAVEE.xml:S3:8959:3	O
)	DUAVEE.xml:S3:8962:1	O
and	DUAVEE.xml:S3:8965:3	O
Clinical	DUAVEE.xml:S3:8970:8	O
Pharmacology	DUAVEE.xml:S3:8979:12	O
(	DUAVEE.xml:S3:8992:1	O
12.3	DUAVEE.xml:S3:8993:4	O
)	DUAVEE.xml:S3:8997:1	O
]	DUAVEE.xml:S3:9000:1	O
.	DUAVEE.xml:S3:9003:1	O

For	DUAVEE.xml:S3:9009:3	O
women	DUAVEE.xml:S3:9013:5	O
with	DUAVEE.xml:S3:9019:4	O
a	DUAVEE.xml:S3:9024:1	O
history	DUAVEE.xml:S3:9026:7	O
of	DUAVEE.xml:S3:9034:2	O
cholestatic	DUAVEE.xml:S3:9037:11	O
jaundice	DUAVEE.xml:S3:9049:8	O
associated	DUAVEE.xml:S3:9058:10	O
with	DUAVEE.xml:S3:9069:4	O
past	DUAVEE.xml:S3:9074:4	O
estrogen	DUAVEE.xml:S3:9079:8	O
use	DUAVEE.xml:S3:9088:3	O
or	DUAVEE.xml:S3:9092:2	O
with	DUAVEE.xml:S3:9095:4	O
pregnancy	DUAVEE.xml:S3:9100:9	O
,	DUAVEE.xml:S3:9109:1	O
caution	DUAVEE.xml:S3:9111:7	O
should	DUAVEE.xml:S3:9119:6	O
be	DUAVEE.xml:S3:9126:2	O
exercised	DUAVEE.xml:S3:9129:9	O
;	DUAVEE.xml:S3:9138:1	O
and	DUAVEE.xml:S3:9140:3	O
in	DUAVEE.xml:S3:9144:2	O
the	DUAVEE.xml:S3:9147:3	O
case	DUAVEE.xml:S3:9151:4	O
of	DUAVEE.xml:S3:9156:2	O
recurrence	DUAVEE.xml:S3:9159:10	O
,	DUAVEE.xml:S3:9169:1	O
DUAVEE	DUAVEE.xml:S3:9171:6	O
should	DUAVEE.xml:S3:9178:6	O
be	DUAVEE.xml:S3:9185:2	O
discontinued	DUAVEE.xml:S3:9188:12	O
.	DUAVEE.xml:S3:9200:1	O

Use	DUAVEE.xml:S3:9202:3	O
of	DUAVEE.xml:S3:9206:2	O
DUAVEE	DUAVEE.xml:S3:9209:6	O
in	DUAVEE.xml:S3:9216:2	O
patients	DUAVEE.xml:S3:9219:8	O
with	DUAVEE.xml:S3:9228:4	O
hepatic	DUAVEE.xml:S3:9233:7	O
impairment	DUAVEE.xml:S3:9241:10	O
is	DUAVEE.xml:S3:9252:2	O
contraindicated	DUAVEE.xml:S3:9255:15	O
[	DUAVEE.xml:S3:9271:1	O
see	DUAVEE.xml:S3:9272:3	O
Contraindications	DUAVEE.xml:S3:9277:17	O
(	DUAVEE.xml:S3:9295:1	O
4	DUAVEE.xml:S3:9296:1	O
)	DUAVEE.xml:S3:9297:1	O
]	DUAVEE.xml:S3:9300:1	O
.	DUAVEE.xml:S3:9303:1	O

5.10	DUAVEE.xml:S3:9312:4	O
Hypothyroidism	DUAVEE.xml:S3:9317:14	O

Estrogen	DUAVEE.xml:S3:9337:8	O
administration	DUAVEE.xml:S3:9346:14	O
leads	DUAVEE.xml:S3:9361:5	O
to	DUAVEE.xml:S3:9367:2	O
increased	DUAVEE.xml:S3:9370:9	B-AdverseReaction
thyroid	DUAVEE.xml:S3:9380:7	I-AdverseReaction
-	DUAVEE.xml:S3:9387:1	I-AdverseReaction
binding	DUAVEE.xml:S3:9388:7	I-AdverseReaction
globulin	DUAVEE.xml:S3:9396:8	I-AdverseReaction
(	DUAVEE.xml:S3:9405:1	O
TBG	DUAVEE.xml:S3:9406:3	I-AdverseReaction
)	DUAVEE.xml:S3:9409:1	O
levels	DUAVEE.xml:S3:9411:6	I-AdverseReaction
.	DUAVEE.xml:S3:9417:1	O

Women	DUAVEE.xml:S3:9419:5	O
with	DUAVEE.xml:S3:9425:4	O
normal	DUAVEE.xml:S3:9430:6	O
thyroid	DUAVEE.xml:S3:9437:7	O
function	DUAVEE.xml:S3:9445:8	O
can	DUAVEE.xml:S3:9454:3	O
compensate	DUAVEE.xml:S3:9458:10	O
for	DUAVEE.xml:S3:9469:3	O
the	DUAVEE.xml:S3:9473:3	O
increased	DUAVEE.xml:S3:9477:9	B-AdverseReaction
TBG	DUAVEE.xml:S3:9487:3	I-AdverseReaction
by	DUAVEE.xml:S3:9491:2	O
making	DUAVEE.xml:S3:9494:6	O
more	DUAVEE.xml:S3:9501:4	O
thyroid	DUAVEE.xml:S3:9506:7	O
hormone	DUAVEE.xml:S3:9514:7	O
,	DUAVEE.xml:S3:9521:1	O
thus	DUAVEE.xml:S3:9523:4	O
maintaining	DUAVEE.xml:S3:9528:11	O
free	DUAVEE.xml:S3:9540:4	O
T4	DUAVEE.xml:S3:9545:2	O
and	DUAVEE.xml:S3:9548:3	O
T3	DUAVEE.xml:S3:9552:2	O
serum	DUAVEE.xml:S3:9555:5	O
concentrations	DUAVEE.xml:S3:9561:14	O
in	DUAVEE.xml:S3:9576:2	O
the	DUAVEE.xml:S3:9579:3	O
normal	DUAVEE.xml:S3:9583:6	O
range	DUAVEE.xml:S3:9590:5	O
.	DUAVEE.xml:S3:9595:1	O

Women	DUAVEE.xml:S3:9597:5	O
dependent	DUAVEE.xml:S3:9603:9	O
on	DUAVEE.xml:S3:9613:2	O
thyroid	DUAVEE.xml:S3:9616:7	O
hormone	DUAVEE.xml:S3:9624:7	O
replacement	DUAVEE.xml:S3:9632:11	O
therapy	DUAVEE.xml:S3:9644:7	O
who	DUAVEE.xml:S3:9652:3	O
are	DUAVEE.xml:S3:9656:3	O
also	DUAVEE.xml:S3:9660:4	O
receiving	DUAVEE.xml:S3:9665:9	O
estrogens	DUAVEE.xml:S3:9675:9	O
may	DUAVEE.xml:S3:9685:3	O
require	DUAVEE.xml:S3:9689:7	O
increased	DUAVEE.xml:S3:9697:9	O
doses	DUAVEE.xml:S3:9707:5	O
of	DUAVEE.xml:S3:9713:2	O
their	DUAVEE.xml:S3:9716:5	O
thyroid	DUAVEE.xml:S3:9722:7	O
replacement	DUAVEE.xml:S3:9730:11	O
therapy	DUAVEE.xml:S3:9742:7	O
.	DUAVEE.xml:S3:9749:1	O

These	DUAVEE.xml:S3:9751:5	O
women	DUAVEE.xml:S3:9757:5	O
should	DUAVEE.xml:S3:9763:6	O
have	DUAVEE.xml:S3:9770:4	O
their	DUAVEE.xml:S3:9775:5	O
thyroid	DUAVEE.xml:S3:9781:7	O
function	DUAVEE.xml:S3:9789:8	O
monitored	DUAVEE.xml:S3:9798:9	O
in	DUAVEE.xml:S3:9808:2	O
order	DUAVEE.xml:S3:9811:5	O
to	DUAVEE.xml:S3:9817:2	O
maintain	DUAVEE.xml:S3:9820:8	O
their	DUAVEE.xml:S3:9829:5	O
free	DUAVEE.xml:S3:9835:4	O
thyroid	DUAVEE.xml:S3:9840:7	O
hormone	DUAVEE.xml:S3:9848:7	O
levels	DUAVEE.xml:S3:9856:6	O
in	DUAVEE.xml:S3:9863:2	O
an	DUAVEE.xml:S3:9866:2	O
acceptable	DUAVEE.xml:S3:9869:10	O
range	DUAVEE.xml:S3:9880:5	O
.	DUAVEE.xml:S3:9885:1	O

5.11	DUAVEE.xml:S3:9894:4	O
Fluid	DUAVEE.xml:S3:9899:5	O
Retention	DUAVEE.xml:S3:9905:9	O

Estrogens	DUAVEE.xml:S3:9920:9	O
may	DUAVEE.xml:S3:9930:3	B-Factor
cause	DUAVEE.xml:S3:9934:5	O
some	DUAVEE.xml:S3:9940:4	O
degree	DUAVEE.xml:S3:9945:6	O
of	DUAVEE.xml:S3:9952:2	O
fluid	DUAVEE.xml:S3:9955:5	B-AdverseReaction
retention	DUAVEE.xml:S3:9961:9	I-AdverseReaction
.	DUAVEE.xml:S3:9970:1	O

Because	DUAVEE.xml:S3:9972:7	O
of	DUAVEE.xml:S3:9980:2	O
this	DUAVEE.xml:S3:9983:4	O
,	DUAVEE.xml:S3:9987:1	O
patients	DUAVEE.xml:S3:9989:8	O
who	DUAVEE.xml:S3:9998:3	O
have	DUAVEE.xml:S3:10002:4	O
conditions	DUAVEE.xml:S3:10007:10	O
that	DUAVEE.xml:S3:10018:4	O
might	DUAVEE.xml:S3:10023:5	O
be	DUAVEE.xml:S3:10029:2	O
influenced	DUAVEE.xml:S3:10032:10	O
by	DUAVEE.xml:S3:10043:2	O
this	DUAVEE.xml:S3:10046:4	O
factor	DUAVEE.xml:S3:10051:6	O
,	DUAVEE.xml:S3:10057:1	O
such	DUAVEE.xml:S3:10059:4	O
as	DUAVEE.xml:S3:10064:2	O
cardiac	DUAVEE.xml:S3:10067:7	O
dysfunction	DUAVEE.xml:S3:10075:11	O
or	DUAVEE.xml:S3:10087:2	O
renal	DUAVEE.xml:S3:10090:5	O
impairment	DUAVEE.xml:S3:10096:10	O
,	DUAVEE.xml:S3:10106:1	O
warrant	DUAVEE.xml:S3:10108:7	O
careful	DUAVEE.xml:S3:10116:7	O
observation	DUAVEE.xml:S3:10124:11	O
when	DUAVEE.xml:S3:10136:4	O
estrogens	DUAVEE.xml:S3:10141:9	O
are	DUAVEE.xml:S3:10151:3	O
prescribed	DUAVEE.xml:S3:10155:10	O
.	DUAVEE.xml:S3:10165:1	O

Use	DUAVEE.xml:S3:10167:3	O
of	DUAVEE.xml:S3:10171:2	O
DUAVEE	DUAVEE.xml:S3:10174:6	O
in	DUAVEE.xml:S3:10181:2	O
patients	DUAVEE.xml:S3:10184:8	O
with	DUAVEE.xml:S3:10193:4	O
renal	DUAVEE.xml:S3:10198:5	O
impairment	DUAVEE.xml:S3:10204:10	O
is	DUAVEE.xml:S3:10215:2	O
not	DUAVEE.xml:S3:10218:3	O
recommended	DUAVEE.xml:S3:10222:11	O
[	DUAVEE.xml:S3:10234:1	O
see	DUAVEE.xml:S3:10235:3	O
Use	DUAVEE.xml:S3:10240:3	O
in	DUAVEE.xml:S3:10244:2	O
Specific	DUAVEE.xml:S3:10247:8	O
Populations	DUAVEE.xml:S3:10256:11	O
(	DUAVEE.xml:S3:10268:1	O
8.6	DUAVEE.xml:S3:10269:3	O
)	DUAVEE.xml:S3:10272:1	O
]	DUAVEE.xml:S3:10275:1	O
.	DUAVEE.xml:S3:10278:1	O

5.12	DUAVEE.xml:S3:10287:4	O
Hypocalcemia	DUAVEE.xml:S3:10292:12	O

Estrogen	DUAVEE.xml:S3:10310:8	O
therapy	DUAVEE.xml:S3:10319:7	O
should	DUAVEE.xml:S3:10327:6	O
be	DUAVEE.xml:S3:10334:2	O
used	DUAVEE.xml:S3:10337:4	O
with	DUAVEE.xml:S3:10342:4	O
caution	DUAVEE.xml:S3:10347:7	O
in	DUAVEE.xml:S3:10355:2	O
women	DUAVEE.xml:S3:10358:5	O
with	DUAVEE.xml:S3:10364:4	O
hypoparathyroidism	DUAVEE.xml:S3:10369:18	O
as	DUAVEE.xml:S3:10388:2	O
estrogen	DUAVEE.xml:S3:10391:8	O
-	DUAVEE.xml:S3:10399:1	O
induced	DUAVEE.xml:S3:10400:7	O
hypocalcemia	DUAVEE.xml:S3:10408:12	O
may	DUAVEE.xml:S3:10421:3	O
occur	DUAVEE.xml:S3:10425:5	O
.	DUAVEE.xml:S3:10430:1	O

5.13	DUAVEE.xml:S3:10439:4	O
Hereditary	DUAVEE.xml:S3:10444:10	O
Angioedema	DUAVEE.xml:S3:10455:10	O

Exogenous	DUAVEE.xml:S3:10471:9	O
estrogens	DUAVEE.xml:S3:10481:9	O
may	DUAVEE.xml:S3:10491:3	B-Factor
exacerbate	DUAVEE.xml:S3:10495:10	B-AdverseReaction
symptoms	DUAVEE.xml:S3:10506:8	O
of	DUAVEE.xml:S3:10515:2	O
angioedema	DUAVEE.xml:S3:10518:10	I-AdverseReaction
in	DUAVEE.xml:S3:10529:2	O
women	DUAVEE.xml:S3:10532:5	O
with	DUAVEE.xml:S3:10538:4	O
hereditary	DUAVEE.xml:S3:10543:10	O
angioedema	DUAVEE.xml:S3:10554:10	O
.	DUAVEE.xml:S3:10564:1	O

5.14	DUAVEE.xml:S3:10573:4	O
Exacerbation	DUAVEE.xml:S3:10578:12	O
of	DUAVEE.xml:S3:10591:2	O
Other	DUAVEE.xml:S3:10594:5	O
Conditions	DUAVEE.xml:S3:10600:10	O

Estrogens	DUAVEE.xml:S3:10616:9	O
may	DUAVEE.xml:S3:10626:3	O
cause	DUAVEE.xml:S3:10630:5	O
an	DUAVEE.xml:S3:10636:2	O
exacerbation	DUAVEE.xml:S3:10639:12	O
of	DUAVEE.xml:S3:10652:2	O
asthma	DUAVEE.xml:S3:10655:6	O
,	DUAVEE.xml:S3:10661:1	O
diabetes	DUAVEE.xml:S3:10663:8	O
mellitus	DUAVEE.xml:S3:10672:8	O
,	DUAVEE.xml:S3:10680:1	O
epilepsy	DUAVEE.xml:S3:10682:8	O
,	DUAVEE.xml:S3:10690:1	O
migraine	DUAVEE.xml:S3:10692:8	O
or	DUAVEE.xml:S3:10701:2	O
porphyria	DUAVEE.xml:S3:10704:9	O
,	DUAVEE.xml:S3:10713:1	O
systemic	DUAVEE.xml:S3:10715:8	O
lupus	DUAVEE.xml:S3:10724:5	O
erythematosus	DUAVEE.xml:S3:10730:13	O
,	DUAVEE.xml:S3:10743:1	O
and	DUAVEE.xml:S3:10745:3	O
hepatic	DUAVEE.xml:S3:10749:7	O
hemangiomas	DUAVEE.xml:S3:10757:11	O
and	DUAVEE.xml:S3:10769:3	O
should	DUAVEE.xml:S3:10773:6	O
be	DUAVEE.xml:S3:10780:2	O
used	DUAVEE.xml:S3:10783:4	O
with	DUAVEE.xml:S3:10788:4	O
caution	DUAVEE.xml:S3:10793:7	O
in	DUAVEE.xml:S3:10801:2	O
women	DUAVEE.xml:S3:10804:5	O
with	DUAVEE.xml:S3:10810:4	O
these	DUAVEE.xml:S3:10815:5	O
conditions	DUAVEE.xml:S3:10821:10	O
.	DUAVEE.xml:S3:10831:1	O

5.15	DUAVEE.xml:S3:10840:4	O
Premenopausal	DUAVEE.xml:S3:10845:13	O
Women	DUAVEE.xml:S3:10859:5	O

There	DUAVEE.xml:S3:10870:5	O
is	DUAVEE.xml:S3:10876:2	O
no	DUAVEE.xml:S3:10879:2	O
indication	DUAVEE.xml:S3:10882:10	O
for	DUAVEE.xml:S3:10893:3	O
premenopausal	DUAVEE.xml:S3:10897:13	O
use	DUAVEE.xml:S3:10911:3	O
of	DUAVEE.xml:S3:10915:2	O
DUAVEE	DUAVEE.xml:S3:10918:6	O
.	DUAVEE.xml:S3:10924:1	O

The	DUAVEE.xml:S3:10926:3	O
efficacy	DUAVEE.xml:S3:10930:8	O
and	DUAVEE.xml:S3:10939:3	O
safety	DUAVEE.xml:S3:10943:6	O
of	DUAVEE.xml:S3:10950:2	O
DUAVEE	DUAVEE.xml:S3:10953:6	O
in	DUAVEE.xml:S3:10960:2	O
premenopausal	DUAVEE.xml:S3:10963:13	O
women	DUAVEE.xml:S3:10977:5	O
have	DUAVEE.xml:S3:10983:4	O
not	DUAVEE.xml:S3:10988:3	O
been	DUAVEE.xml:S3:10992:4	O
established	DUAVEE.xml:S3:10997:11	O
,	DUAVEE.xml:S3:11008:1	O
and	DUAVEE.xml:S3:11010:3	O
its	DUAVEE.xml:S3:11014:3	O
use	DUAVEE.xml:S3:11018:3	O
is	DUAVEE.xml:S3:11022:2	O
not	DUAVEE.xml:S3:11025:3	O
recommended	DUAVEE.xml:S3:11029:11	O
.	DUAVEE.xml:S3:11040:1	O

5.16	DUAVEE.xml:S3:11049:4	O
Laboratory	DUAVEE.xml:S3:11054:10	O
Tests	DUAVEE.xml:S3:11065:5	O

Serum	DUAVEE.xml:S3:11076:5	O
follicle	DUAVEE.xml:S3:11082:8	O
stimulating	DUAVEE.xml:S3:11091:11	O
hormone	DUAVEE.xml:S3:11103:7	O
(	DUAVEE.xml:S3:11111:1	O
FSH	DUAVEE.xml:S3:11112:3	O
)	DUAVEE.xml:S3:11115:1	O
and	DUAVEE.xml:S3:11117:3	O
estradiol	DUAVEE.xml:S3:11121:9	O
levels	DUAVEE.xml:S3:11131:6	O
have	DUAVEE.xml:S3:11138:4	O
not	DUAVEE.xml:S3:11143:3	O
been	DUAVEE.xml:S3:11147:4	O
shown	DUAVEE.xml:S3:11152:5	O
to	DUAVEE.xml:S3:11158:2	O
be	DUAVEE.xml:S3:11161:2	O
useful	DUAVEE.xml:S3:11164:6	O
in	DUAVEE.xml:S3:11171:2	O
the	DUAVEE.xml:S3:11174:3	O
management	DUAVEE.xml:S3:11178:10	O
of	DUAVEE.xml:S3:11189:2	O
moderate	DUAVEE.xml:S3:11192:8	O
to	DUAVEE.xml:S3:11201:2	O
severe	DUAVEE.xml:S3:11204:6	O
vasomotor	DUAVEE.xml:S3:11211:9	O
symptoms	DUAVEE.xml:S3:11221:8	O
.	DUAVEE.xml:S3:11229:1	O

5.17	DUAVEE.xml:S3:11238:4	O
Drug	DUAVEE.xml:S3:11243:4	O
-	DUAVEE.xml:S3:11247:1	O
Laboratory	DUAVEE.xml:S3:11248:10	O
Test	DUAVEE.xml:S3:11259:4	O
Interactions	DUAVEE.xml:S3:11264:12	O

Accelerated	DUAVEE.xml:S3:11282:11	B-AdverseReaction
prothrombin	DUAVEE.xml:S3:11294:11	I-AdverseReaction
time	DUAVEE.xml:S3:11306:4	I-AdverseReaction
,	DUAVEE.xml:S3:11310:1	O
partial	DUAVEE.xml:S3:11312:7	I-AdverseReaction
thromboplastin	DUAVEE.xml:S3:11320:14	I-AdverseReaction
time	DUAVEE.xml:S3:11335:4	I-AdverseReaction
,	DUAVEE.xml:S3:11339:1	O
and	DUAVEE.xml:S3:11341:3	O
platelet	DUAVEE.xml:S3:11345:8	I-AdverseReaction
aggregation	DUAVEE.xml:S3:11354:11	I-AdverseReaction
time	DUAVEE.xml:S3:11366:4	I-AdverseReaction
;	DUAVEE.xml:S3:11370:1	O
increased	DUAVEE.xml:S3:11372:9	B-AdverseReaction
platelet	DUAVEE.xml:S3:11382:8	I-AdverseReaction
count	DUAVEE.xml:S3:11391:5	I-AdverseReaction
;	DUAVEE.xml:S3:11396:1	O
increased	DUAVEE.xml:S3:11398:9	B-AdverseReaction
factors	DUAVEE.xml:S3:11408:7	I-AdverseReaction
II	DUAVEE.xml:S3:11416:2	I-AdverseReaction
,	DUAVEE.xml:S3:11418:1	O
VII	DUAVEE.xml:S3:11420:3	I-AdverseReaction
antigen	DUAVEE.xml:S3:11424:7	I-AdverseReaction
,	DUAVEE.xml:S3:11431:1	O
VIII	DUAVEE.xml:S3:11433:4	I-AdverseReaction
antigen	DUAVEE.xml:S3:11438:7	I-AdverseReaction
,	DUAVEE.xml:S3:11445:1	O
VIII	DUAVEE.xml:S3:11447:4	I-AdverseReaction
coagulant	DUAVEE.xml:S3:11452:9	I-AdverseReaction
activity	DUAVEE.xml:S3:11462:8	I-AdverseReaction
,	DUAVEE.xml:S3:11470:1	O
IX	DUAVEE.xml:S3:11472:2	I-AdverseReaction
,	DUAVEE.xml:S3:11474:1	O
X	DUAVEE.xml:S3:11476:1	I-AdverseReaction
,	DUAVEE.xml:S3:11477:1	O
XII	DUAVEE.xml:S3:11479:3	I-AdverseReaction
,	DUAVEE.xml:S3:11482:1	O
VII	DUAVEE.xml:S3:11484:3	I-AdverseReaction
-	DUAVEE.xml:S3:11487:1	I-AdverseReaction
X	DUAVEE.xml:S3:11488:1	I-AdverseReaction
complex	DUAVEE.xml:S3:11490:7	I-AdverseReaction
,	DUAVEE.xml:S3:11497:1	O
II	DUAVEE.xml:S3:11499:2	I-AdverseReaction
-	DUAVEE.xml:S3:11501:1	I-AdverseReaction
VII	DUAVEE.xml:S3:11502:3	I-AdverseReaction
-	DUAVEE.xml:S3:11505:1	I-AdverseReaction
X	DUAVEE.xml:S3:11506:1	I-AdverseReaction
complex	DUAVEE.xml:S3:11508:7	I-AdverseReaction
,	DUAVEE.xml:S3:11515:1	O
and	DUAVEE.xml:S3:11517:3	O
beta	DUAVEE.xml:S3:11521:4	I-AdverseReaction
-	DUAVEE.xml:S3:11525:1	I-AdverseReaction
thromboglobulin	DUAVEE.xml:S3:11526:15	I-AdverseReaction
;	DUAVEE.xml:S3:11541:1	O
decreased	DUAVEE.xml:S3:11543:9	B-AdverseReaction
levels	DUAVEE.xml:S3:11553:6	I-AdverseReaction
of	DUAVEE.xml:S3:11560:2	I-AdverseReaction
antifactor	DUAVEE.xml:S3:11563:10	I-AdverseReaction
Xa	DUAVEE.xml:S3:11574:2	I-AdverseReaction
and	DUAVEE.xml:S3:11577:3	O
antithrombin	DUAVEE.xml:S3:11581:12	I-AdverseReaction
III	DUAVEE.xml:S3:11594:3	I-AdverseReaction
,	DUAVEE.xml:S3:11597:1	O
decreased	DUAVEE.xml:S3:11599:9	B-AdverseReaction
antithrombin	DUAVEE.xml:S3:11609:12	I-AdverseReaction
III	DUAVEE.xml:S3:11622:3	I-AdverseReaction
activity	DUAVEE.xml:S3:11626:8	I-AdverseReaction
;	DUAVEE.xml:S3:11634:1	O
increased	DUAVEE.xml:S3:11636:9	B-AdverseReaction
levels	DUAVEE.xml:S3:11646:6	I-AdverseReaction
of	DUAVEE.xml:S3:11653:2	I-AdverseReaction
fibrinogen	DUAVEE.xml:S3:11656:10	I-AdverseReaction
and	DUAVEE.xml:S3:11667:3	O
fibrinogen	DUAVEE.xml:S3:11671:10	I-AdverseReaction
activity	DUAVEE.xml:S3:11682:8	I-AdverseReaction
;	DUAVEE.xml:S3:11690:1	O
increased	DUAVEE.xml:S3:11692:9	B-AdverseReaction
plasminogen	DUAVEE.xml:S3:11702:11	I-AdverseReaction
antigen	DUAVEE.xml:S3:11714:7	I-AdverseReaction
and	DUAVEE.xml:S3:11722:3	O
activity	DUAVEE.xml:S3:11726:8	I-AdverseReaction
.	DUAVEE.xml:S3:11734:1	O

Increased	DUAVEE.xml:S3:11740:9	B-AdverseReaction
thyroid	DUAVEE.xml:S3:11750:7	I-AdverseReaction
-	DUAVEE.xml:S3:11757:1	I-AdverseReaction
binding	DUAVEE.xml:S3:11758:7	I-AdverseReaction
globulin	DUAVEE.xml:S3:11766:8	I-AdverseReaction
(	DUAVEE.xml:S3:11775:1	O
TBG	DUAVEE.xml:S3:11776:3	I-AdverseReaction
)	DUAVEE.xml:S3:11779:1	O
leading	DUAVEE.xml:S3:11781:7	O
to	DUAVEE.xml:S3:11789:2	O
increased	DUAVEE.xml:S3:11792:9	B-AdverseReaction
circulating	DUAVEE.xml:S3:11802:11	I-AdverseReaction
total	DUAVEE.xml:S3:11814:5	I-AdverseReaction
thyroid	DUAVEE.xml:S3:11820:7	I-AdverseReaction
hormone	DUAVEE.xml:S3:11828:7	I-AdverseReaction
,	DUAVEE.xml:S3:11835:1	O
as	DUAVEE.xml:S3:11837:2	O
measured	DUAVEE.xml:S3:11840:8	O
by	DUAVEE.xml:S3:11849:2	O
protein	DUAVEE.xml:S3:11852:7	O
-	DUAVEE.xml:S3:11859:1	O
bound	DUAVEE.xml:S3:11860:5	O
iodine	DUAVEE.xml:S3:11866:6	O
(	DUAVEE.xml:S3:11873:1	O
PBI	DUAVEE.xml:S3:11874:3	O
)	DUAVEE.xml:S3:11877:1	O
,	DUAVEE.xml:S3:11878:1	O
T4	DUAVEE.xml:S3:11880:2	I-AdverseReaction
levels	DUAVEE.xml:S3:11883:6	I-AdverseReaction
(	DUAVEE.xml:S3:11890:1	O
by	DUAVEE.xml:S3:11891:2	O
column	DUAVEE.xml:S3:11894:6	O
or	DUAVEE.xml:S3:11901:2	O
by	DUAVEE.xml:S3:11904:2	O
radioimmunoassay	DUAVEE.xml:S3:11907:16	O
)	DUAVEE.xml:S3:11923:1	O
,	DUAVEE.xml:S3:11924:1	O
or	DUAVEE.xml:S3:11926:2	O
T3	DUAVEE.xml:S3:11929:2	I-AdverseReaction
levels	DUAVEE.xml:S3:11932:6	I-AdverseReaction
by	DUAVEE.xml:S3:11939:2	O
radioimmunoassay	DUAVEE.xml:S3:11942:16	O
.	DUAVEE.xml:S3:11958:1	O

T3	DUAVEE.xml:S3:11960:2	B-AdverseReaction
resin	DUAVEE.xml:S3:11963:5	I-AdverseReaction
uptake	DUAVEE.xml:S3:11969:6	I-AdverseReaction
is	DUAVEE.xml:S3:11976:2	O
decreased	DUAVEE.xml:S3:11979:9	I-AdverseReaction
,	DUAVEE.xml:S3:11988:1	O
reflecting	DUAVEE.xml:S3:11990:10	O
the	DUAVEE.xml:S3:12001:3	O
elevated	DUAVEE.xml:S3:12005:8	B-AdverseReaction
TBG	DUAVEE.xml:S3:12014:3	I-AdverseReaction
.	DUAVEE.xml:S3:12017:1	O

Free	DUAVEE.xml:S3:12019:4	O
T4	DUAVEE.xml:S3:12024:2	O
and	DUAVEE.xml:S3:12027:3	O
free	DUAVEE.xml:S3:12031:4	O
T3	DUAVEE.xml:S3:12036:2	O
concentrations	DUAVEE.xml:S3:12039:14	O
are	DUAVEE.xml:S3:12054:3	O
unaltered	DUAVEE.xml:S3:12058:9	O
.	DUAVEE.xml:S3:12067:1	O

Women	DUAVEE.xml:S3:12069:5	O
on	DUAVEE.xml:S3:12075:2	O
thyroid	DUAVEE.xml:S3:12078:7	O
replacement	DUAVEE.xml:S3:12086:11	O
therapy	DUAVEE.xml:S3:12098:7	O
may	DUAVEE.xml:S3:12106:3	O
require	DUAVEE.xml:S3:12110:7	O
higher	DUAVEE.xml:S3:12118:6	O
doses	DUAVEE.xml:S3:12125:5	O
of	DUAVEE.xml:S3:12131:2	O
thyroid	DUAVEE.xml:S3:12134:7	O
hormone	DUAVEE.xml:S3:12142:7	O
.	DUAVEE.xml:S3:12149:1	O

Other	DUAVEE.xml:S3:12155:5	O
binding	DUAVEE.xml:S3:12161:7	O
proteins	DUAVEE.xml:S3:12169:8	O
may	DUAVEE.xml:S3:12178:3	B-Factor
be	DUAVEE.xml:S3:12182:2	O
elevated	DUAVEE.xml:S3:12185:8	B-AdverseReaction
in	DUAVEE.xml:S3:12194:2	O
serum	DUAVEE.xml:S3:12197:5	O
,	DUAVEE.xml:S3:12202:1	O
for	DUAVEE.xml:S3:12204:3	O
example	DUAVEE.xml:S3:12208:7	O
,	DUAVEE.xml:S3:12215:1	O
corticosteroid	DUAVEE.xml:S3:12217:14	I-AdverseReaction
binding	DUAVEE.xml:S3:12232:7	I-AdverseReaction
globulin	DUAVEE.xml:S3:12240:8	I-AdverseReaction
(	DUAVEE.xml:S3:12249:1	O
CBG	DUAVEE.xml:S3:12250:3	I-AdverseReaction
)	DUAVEE.xml:S3:12253:1	O
,	DUAVEE.xml:S3:12254:1	O
sex	DUAVEE.xml:S3:12256:3	I-AdverseReaction
hormone	DUAVEE.xml:S3:12260:7	I-AdverseReaction
-	DUAVEE.xml:S3:12267:1	I-AdverseReaction
binding	DUAVEE.xml:S3:12268:7	I-AdverseReaction
globulin	DUAVEE.xml:S3:12276:8	I-AdverseReaction
(	DUAVEE.xml:S3:12285:1	O
SHBG	DUAVEE.xml:S3:12286:4	I-AdverseReaction
)	DUAVEE.xml:S3:12290:1	O
,	DUAVEE.xml:S3:12291:1	O
leading	DUAVEE.xml:S3:12293:7	O
to	DUAVEE.xml:S3:12301:2	O
increased	DUAVEE.xml:S3:12304:9	B-AdverseReaction
total	DUAVEE.xml:S3:12314:5	I-AdverseReaction
circulating	DUAVEE.xml:S3:12320:11	I-AdverseReaction
corticosteroids	DUAVEE.xml:S3:12332:15	I-AdverseReaction
and	DUAVEE.xml:S3:12348:3	O
sex	DUAVEE.xml:S3:12352:3	I-AdverseReaction
steroids	DUAVEE.xml:S3:12356:8	I-AdverseReaction
,	DUAVEE.xml:S3:12364:1	O
respectively	DUAVEE.xml:S3:12366:12	O
.	DUAVEE.xml:S3:12378:1	O

Free	DUAVEE.xml:S3:12380:4	B-AdverseReaction
hormone	DUAVEE.xml:S3:12385:7	I-AdverseReaction
concentrations	DUAVEE.xml:S3:12393:14	I-AdverseReaction
,	DUAVEE.xml:S3:12407:1	O
such	DUAVEE.xml:S3:12409:4	O
as	DUAVEE.xml:S3:12414:2	O
testosterone	DUAVEE.xml:S3:12417:12	B-AdverseReaction
and	DUAVEE.xml:S3:12430:3	O
estradiol	DUAVEE.xml:S3:12434:9	B-AdverseReaction
,	DUAVEE.xml:S3:12443:1	O
may	DUAVEE.xml:S3:12445:3	B-Factor
be	DUAVEE.xml:S3:12449:2	O
decreased	DUAVEE.xml:S3:12452:9	I-AdverseReaction
.	DUAVEE.xml:S3:12461:1	O

Other	DUAVEE.xml:S3:12463:5	O
plasma	DUAVEE.xml:S3:12469:6	B-AdverseReaction
proteins	DUAVEE.xml:S3:12476:8	I-AdverseReaction
may	DUAVEE.xml:S3:12485:3	B-Factor
be	DUAVEE.xml:S3:12489:2	O
increased	DUAVEE.xml:S3:12492:9	I-AdverseReaction
(	DUAVEE.xml:S3:12502:1	O
angiotensinogen	DUAVEE.xml:S3:12503:15	I-AdverseReaction
renin	DUAVEE.xml:S3:12519:5	I-AdverseReaction
substrate	DUAVEE.xml:S3:12525:9	I-AdverseReaction
,	DUAVEE.xml:S3:12534:1	O
alpha	DUAVEE.xml:S3:12536:5	I-AdverseReaction
-	DUAVEE.xml:S3:12541:1	I-AdverseReaction
1	DUAVEE.xml:S3:12542:1	I-AdverseReaction
-	DUAVEE.xml:S3:12543:1	I-AdverseReaction
antitrypsin	DUAVEE.xml:S3:12544:11	I-AdverseReaction
,	DUAVEE.xml:S3:12555:1	O
ceruloplasmin	DUAVEE.xml:S3:12557:13	I-AdverseReaction
)	DUAVEE.xml:S3:12570:1	O
.	DUAVEE.xml:S3:12571:1	O

Increased	DUAVEE.xml:S3:12577:9	B-AdverseReaction
plasma	DUAVEE.xml:S3:12587:6	I-AdverseReaction
high	DUAVEE.xml:S3:12594:4	I-AdverseReaction
-	DUAVEE.xml:S3:12598:1	I-AdverseReaction
density	DUAVEE.xml:S3:12599:7	I-AdverseReaction
lipoprotein	DUAVEE.xml:S3:12607:11	I-AdverseReaction
(	DUAVEE.xml:S3:12619:1	O
HDL	DUAVEE.xml:S3:12620:3	I-AdverseReaction
)	DUAVEE.xml:S3:12623:1	O
and	DUAVEE.xml:S3:12625:3	O
HDL2	DUAVEE.xml:S3:12629:4	I-AdverseReaction
cholesterol	DUAVEE.xml:S3:12634:11	I-AdverseReaction
subfraction	DUAVEE.xml:S3:12646:11	I-AdverseReaction
concentrations	DUAVEE.xml:S3:12658:14	I-AdverseReaction
,	DUAVEE.xml:S3:12672:1	O
reduced	DUAVEE.xml:S3:12674:7	B-AdverseReaction
low	DUAVEE.xml:S3:12682:3	I-AdverseReaction
-	DUAVEE.xml:S3:12685:1	I-AdverseReaction
density	DUAVEE.xml:S3:12686:7	I-AdverseReaction
lipoprotein	DUAVEE.xml:S3:12694:11	I-AdverseReaction
(	DUAVEE.xml:S3:12706:1	O
LDL	DUAVEE.xml:S3:12707:3	I-AdverseReaction
)	DUAVEE.xml:S3:12710:1	O
cholesterol	DUAVEE.xml:S3:12712:11	I-AdverseReaction
concentrations	DUAVEE.xml:S3:12724:14	I-AdverseReaction
,	DUAVEE.xml:S3:12738:1	O
increased	DUAVEE.xml:S3:12740:9	B-AdverseReaction
triglyceride	DUAVEE.xml:S3:12750:12	I-AdverseReaction
levels	DUAVEE.xml:S3:12763:6	I-AdverseReaction
.	DUAVEE.xml:S3:12769:1	O

Impaired	DUAVEE.xml:S3:12775:8	B-AdverseReaction
glucose	DUAVEE.xml:S3:12784:7	I-AdverseReaction
tolerance	DUAVEE.xml:S3:12792:9	I-AdverseReaction
.	DUAVEE.xml:S3:12801:1	O
